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Summary 
The airway epithelium is the first point of contact in the lung for inhaled material, 
including infectious pathogens and particulate matter, and protects against toxicity from 
these substances by trapping and clearance via the mucociliary escalator, presence of a 
protective barrier with tight junctions and initiation of a local inflammatory response. 
The inflammatory response involves recruitment of phagocytic cells to neutralise and 
remove and invading materials and is oftern modelled using rodents. However, 
development of valid in vitro airway epithelial models is of great importance due to the 
restrictions on animal studies for cosmetic compound testing implicit in the 7
th
 
amendment to the European Union Cosmetics Directive. Further, rodent innate immune 
responses have fundamental differences to human. Pulmonary endothelial cells and 
leukocytes are also involved in the innate response initiated during pulmonary 
inflammation.  Co-culture models of the airways, in particular where epithelial cells are 
cultured at air liquid interface with the presence of tight junctions and differentiated 
mucociliary cells, offer a solution to this problem. Ideally validated models will allow 
for detection of early biomarkers of response to exposure and investigation into 
inflammatory response during exposure. This thesis describes the approaches taken 
towards developing an in vitro epithelial/endothelial cell model of the human airways 
and identification biomarkers of response to exposure to xenobiotics. The model 
comprised normal human primary microvascular endothelial cells and the bronchial 
epithelial cell line BEAS-2B or normal human bronchial epithelial cells. BEAS-2B 
were chosen as their characterisation at air liquid interface is limited but they are robust 
in culture, thereby predicted to provide a more reliable test system. Proteomics analysis 
was undertaken on challenged cells to investigate biomarkers of exposure.   
BEAS-2B morphology was characterised at air liquid interface compared with normal 
human bronchial epithelial cells.  The results indicate that BEAS-2B cells at an air 
liquid interface form tight junctions as shown by expression of the tight junction protein 
zonula occludens-1. To this author’s knowledge this is the first time this result has been 
reported. The inflammatory response of BEAS-2B (measured as secretion of the 
inflammatory mediators interleukin-8 and -6) air liquid interface mono-cultures to 
Escherichia coli lipopolysaccharide or particulate matter (fine and ultrafine titanium 
dioxide) was comparable to published data for epithelial cells.  Cells were also exposed 
to polymers of “commercial interest” which were in the nanoparticle range (and 
referred to particles hereafter). BEAS-2B mono-cultures showed an increased secretion 
of inflammatory mediators after challenge. Inclusion of microvascular endothelial cells 
resulted in protection against LPS- and particle- induced epithelial toxicity, measured as 
cell viability and inflammatory response, indicating the importance of co-cultures for 
investigations into toxicity. Two-dimensional proteomic analysis of lysates from 
particle-challenged cells failed to identify biomarkers of toxicity due to assay 
interference and experimental variability. Separately, decreased plasma concentrations 
of serine protease inhibitors, and the negative acute phase proteins transthyretin, 
histidine-rich glycoprotein and alpha2-HS glycoprotein were identified as potential 
biomarkers of methyl methacrylate/ethyl methacrylate/butylacrylate treatment in rats.  
Key words Co-culture, air-liquid interface, lipopolysaccharide, titanium dioxide and 
proteomics 
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ZO   Zonnula Occludens 
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Chapter 1. Introduction 
Host defences against foreign materials, such as pathogens, toxic chemicals and 
particulates are achieved by a range of innate physicochemical, humoral and cell 
mediated mechanisms. In mammals, the mucosal and epithelial surfaces are the first 
point of contact of exposures and are therefore often specialised to defend against insult 
and are able to initiate an immune response after noxious exposure.  
The airway epithelium secretes antimicrobial peptides and mucus which work with cilia 
to protect the airways from pathogenic invasion (Tortora and Graboswki, 1993). 
Airway epithelial cells are anchored to a basement membrane that is enriched in 
extracellular matrix proteins, termed the extracellular matrix (ECM), which supports 
epithelial cell attachment, survival and morphology. Comprised of adhesive 
glycoproteins (including fibronectin and laminin), structural proteins (including 
collagen and elastin) and proteins involved in ECM homeostasis (for example 
hyaluronan) (Schulz & Wysocki, 2009) the ECM also functions in epithelial cell wound 
repair. ECM-mediated epithelial wound repair is aided by the ability of the ECM to 
sequester growth factors including fibroblast growth factor (FGF)-2 and vascular 
endothelial growth factor (VEGF) (Schulz & Wysocki, 2009)  and other mediators such 
as cytokines including tumour necrosis factor (TNF)-α (Vaday & Lider, 2000). The 
growth factor hepatocyte growth factor (HGF) is also sequestered by the ECM and 
fucntions in epithelial cells proliferation and differentiation (Ito et al., 2005) and has 
anti-inflammatory properties (Skibinski et al., 2007). 
 
Ambient air contains noxious material such as pathogens and particulates from several 
sources including; endotoxins such as LPS which is shed from gram negative bacteria, 
combustion particulates and particulates liberated from cleaning products and cosmetic 
products. Endotoxin levels emitted from humidifiers alone are up to 0.39µg/m
3
, and it is 
estimated that cleaning products contribute to >32 tonnes volatile organic particulates 
worldwide per day (Nazaroff & Weschler, 2004).  Further, the UK acceptable air 
pollution levels of respirable PM with a mean diameter of 10µm (PM10) is 50µg/m
3
 
(DEFRA). The average adult respires 12,000 litres of air per day (Rogers, 2007), 
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protective mechanisms in the airways are therefore required to prevent airways damage 
after inhalation exposure.  
 
1.1. Structure of the respiratory system 
The respiratory system comprises of a conducting portion and a respiratory portion. The 
conducting portion includes the trachea, bronchi and terminal bronchioles and transfers 
inspired air into the alveolar region of the lungs. The trachea divides into the primary 
bronchi which enter the lung and further divide into smaller secondary bronchi, which 
again divide into smaller (tertiary) bronchi and then bronchioles (Tortora & Grabowski, 
1993). This division continues and is termed the bronchial tree; the last “branches” are 
the terminal bronchioles. The respiratory portion includes the bronchioles, alveolar 
ducts and alveoli, and is where gas exchange occurs (Tortora & Grabowski, 1993). 
Structurally the trachea is composed of hyaline cartilage, smooth muscle fibres and 
elastic connective tissue which provide firm support to prevent collapse. The supportive 
incomplete rings of cartilage become cartilage sheets in the bronchi which are replaced 
entirely by smooth muscle in the bronchioles.  The terminal bronchioles further divide 
into the respiratory bronchioles and alveolar ducts (Tortora & Grabowski, 1993). A 
protective epithelial cell layer lines the entire respiratory tract, the morphology of the 
epithelial layers changes throughout the respiratory tract and reflects a change in 
function. 
 
1.1.1 Airway epithelium 
The tracheal and bronchial epithelium is formed of pseudostratified differentiated 
muco-ciliary epithelial cells (Tortora & Grabowski, 1993), anchored to the basement 
membrane by a basal epithelial cell layer. The basal epithelial cells also act as cell 
progenitors which are able to differentiate and replace muco-ciliary epithelial cells 
during injury (Erjefalt et al., 2007; Lazard et al., 2009; Plopper et al., 1992). The 
morphology of the epithelium alters throughout the respiratory tract (Figure 1.1), 
secretory and ciliated epithelial cells predominate the upper airways and are absent in 
the bronchioles. Goblet cells synthesise, store and secrete mucin granules which absorb 
water to form the mucus layer covering the upper respiratory tract. This mucus is 
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cleared by the beating action of cilia from ciliated cells (Fahy & Dickey, 2010). 
Submucosal glands are also present in the upper airways and contains serous and mucus 
secreting cells. The serous cells secrete antimicrobial proteins (Reviewed in Fahy & 
Dickey, 2010). Simple cuboidal epithelial cells and secretory Clara cells are present in 
the bronchioles (Tortora & Grabowski, 1993). Clara cells are also secretory cells and 
function to detoxify xenobiotics and produce surfactant (a fluid layer comprising 
phospholipids and apoproteins covering epithelium of bronchioles and alveoli) 
(Jefferey, 1997). The morphology of the airways epithelium again changes as the 
bronchioles descend into the alveoli, where Type 1 pneumocytes are abundant with few 
Type 2 pneumocytes  (Tortora & Grabowski, 1993).  
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Figure 1.1: The morphology of the epithelium alters throughout the respiratory tract. (A) 
The upper respiratory tract is lined with differentiated pseudostratified columnar muco-ciliary 
epithelial cells attached to the basement membrane by a layer of basal epithelial cells. (B) 
Excess mucous production within the upper respiratory tract is a consequence of either mucous 
cell hypersecretion or mucous cell metaplasia (Rogers, 2007).(C) simple cuboidal epithelial 
cells of the (D) Type 1 squamous epithelial cells predominate the epithelium of the alveoli.
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The differentiation state of epithelial cells can be characterised by their expression of 
cytokeratins. The epithelium of the upper airways is the first point of contact for inhaled 
material, and protects the lungs against noxious insult. The morphology of the muco-
ciliary epithelium represents this role, allowing for a muco-ciliary escalator to clear 
inhaled material from the lungs (Mills et al., 2009) (see below). The differentiated 
epithelium also forms tight junctions, which prevent access of xenobiotics to the 
underlying tissue (Niessen, 2007).  
 
1.1.2 Cytokeratin profiles of airways epithelium 
Epithelial cells can be characterised by expression of discrete epithelial cell-specific 
markers, cytokeratins (Iyonaga et al., 1997; Moll et al., 1982; Purkis et al., 1990).  
Cytokeratins are intermediate cytoskeleton filaments which serve to provide physical 
support for the cells. The expression profile in both normal and tumorous epithelia was 
characterised by Moll et al., (1982) who described cytokeratins 1-6 as large basic 
cytokeratins that are expressed in stratified epithelia, cytokeratins 7 and 8 as having 
intermediate size and charge, and are typical of simple epithelia within the trachea. 
Cytokeratins 9-12 are described as acidic with intermediate or large size, with 
cytokeratin 12 expression in the cornea and 9-11 in epidermis. Cytokeratins 13-17 are 
small acidic cytokeratins expressed in trachea and some glands and cytokeratin 19 (a 
small acidic cytokeratin) is expressed in simple and stratified epithelia (Moll et al., 
1982).  
 
In vitro, primary airway epithelial cells cultured at air-liquid interface (ALI) form 
multiple cell layers, with the lower cell layer showing positive staining for cytokeratins 
1, 5, 10 and 14 (Endres et al., 2005). Further, Pohl et al., (2009) characterised basal cell 
populations of NHBE in cells cultured at ALI by expression of cytokeratin 14. The 
airways epithelium in vivo can be described as containing pseudo-columnar 
differentiated cells with a cytokeratin expression pattern of 7, 8, 13 and 19 with 
cytokeratin 5 and 14 expressed in the basal population (Iyonaga et al., 1997).  
Cytokeratin expression patterns therefore form a useful tool for identifying the 
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differentiation status of epithelial cells in in vitro culture, where the aim is to culture 
populations of epithelial cells that have morphologies representative in vivo cells. 
 
1.1.3 Tight junctions 
Areas of fused membranes between adjoining epithelial cells have been observed in a 
number of epithelial cell types including toad bladder epithelium (Choi, 1961). 
Farquhar and Palade, (1963) using rodent epithelial models, were the first authors to 
identify these junctions as “tight junctions” and as the most apical of the three epithelial 
cell junction complexes (tight junctions, adherens junctions and desmosomes).  
Farquhar and Palade, (1963) observed that these junctions fused the membranes on 
neighbouring epithelial cells and restrict the passage of proteins solutions through 
epithelial cell monolayers. As a consequence the tight junctions were given the Latin 
term “Zonula Occludens” translating to “closing belt”. Freeze-fracture studies of these 
junctions have led to the identification of structural proteins within these junctions. The 
first tight junction protein to be identified by this method was termed Zonula 
Occludens-1 (ZO-1) (Stevenson et al., 1986).  
 
The structure (Figure 1.2) and function of tight junctions has since been intensively 
studied and reviewed. ZO- proteins act as scaffolding proteins which provide an anchor 
between actin and the tight junction proteins claudin and occludin (Niessen, 2007). 
Occludin was the first transmembrane protein identified within the tight junction 
(Furuse et al., 1993) and has been suggested to have a role in tight junction 
permeability (Steed et al., 2010).  Claudin, a tight junction transmembrane protein, 
regulates the “tightness” of epithelial cell tight junctions (Furuse et al., 2001). 
Junctional adhesion molecules (JAMs) play a role in cell migration (Niessen, 2007) for 
example, leukocyte diapedesis.  
 
Aside from their role in maintaining a physical protective barrier, tight junctions serve 
to maintain airway homeostasis. Electrolytes such as sodium (Na
+
) and chloride (Cl
-
) 
pass through epithelial tight junctions to the airway surface liquid and mucus layers 
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(Welsh, 1987). These ions have roles in maintaining a hydrated mucus layer. Impaired 
ion transport (by both the paracellular and transcellular pathways) may lead to thick 
dehydrated mucus which limits muco-ciliary beat, thereby decreasing mucus clearance 
(Tarran, 2004) and increasing pathogenic colonisation and inflammation. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: The structure of epithelial tight junctions. The epithelial tight junction is 
composed of the transmembrane proteins occludin, claudin (involved in size selectivity of the 
tight junction), and ZO which provides structural support between cytoskeletal and 
transmembrane proteins.  
 
1.1.4 Mucin 
Synthesised and secreted by goblet cells, mucins are high molecular weight 
glycoproteins which form a thick mucus film over the epithelium, serving to trap any 
inhaled particulates and pathogens. Twenty mucin (Muc) proteins have been identified, 
of which Muc2, Muc5AC, Muc5b and Muc6 encoded by MUC2, MUC5AC, MUC5B 
and MUC6 genes are gel-forming mucins found in airway epithelial cells  (Davis, 2002; 
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Kim et al., 2007; Mills et al., 1999; Rogers, 2007; Williams et al., 2006). Muc19 has 
also recently been identified to be a gel forming mucin of the human airway (Williams 
et al., 2006). The mucus layer serves to trap invading particulates and pathogens, 
thereby protecting the epithelium. Trapped material is cleared by the beating action of 
the cilia protruding from the ciliated cells in a process termed the muco-ciliary escalator 
(Mills et al., 1999).  Mucin traps bacteria by adhesion between mucin glycoproteins and 
bacterial ligands. For example the respiratory pathogen Pseudomonas aeruginosa (P. 
aeruginosa) strain PAO1 flagellin protein fLID binds to mucin carbohydrate moieties 
(Scharfman et al., 2001). Once trapped in the mucin, pathogenic material can be cleared 
by the muco-ciliary escalator.  
 
1.2 Inflammation 
If pathogens/irritants breach mucosal surfaces the innate immune system provokes an 
inflammatory response at the site of insult in order to neutralise and remove the “non-
self” material (Smith, 1994). During microbial invasion, pattern recognition receptors 
(PRR) on host cells, such as Toll-like receptors (TLR) on epithelial cells, recognise 
pathogen associated molecular patterns (PAMPs) on the microbe. Circulating dendritic 
cells and resident macrophages also express PRR (Barton, 2008). Pattern recognition 
triggers inflammatory mediator secretion by the affected cells/tissue to promote 
recruitment of innate immune cells such as neutrophils and monocytes (which 
differentiate into macrophages upon activation). B and T lymphocytes are also recruited 
by epithelial derived cytokines (Riffo-Vasquez & Spina, 2002). Recruitment of 
macrophages and neutrophils promotes removal of pathogenic material by phagocytosis 
(Reviewed in Parihar et al., 2010) and is therefore desirable. However, failure to 
resolve inflammation can lead to airways damage and can contribute to airways 
pathologies such as asthma (Murphey & O’Byrne, 2010) and chronic obstructive 
pulmonary disease (COPD) (Barnes, 2009).  
 
1.2.1 Inflammatory respiratory diseases  
Symptoms of respiratory illnesses such as asthma, COPD and cystic fibrosis (CF) are 
often worsened by chronic inflammation which results in airways tissue damage. As 
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many as 5.4 million individuals in the UK suffers from asthma (www.asthma.org) and 
symptoms include breathlessness, wheezing and coughing. There are two principle 
forms of asthma, allergic (where asthma attacks are induced after allergen exposure e.g. 
pollen, and non-allergic. T-helper cells infiltrate the airways in abundance and induce 
inflammation by secretion of chemokines and cytokines. These proinflammatory 
molecules promote migration and activation of inflammatory cells including 
eosinophils, mast cells, basophils and leukocytes (Reviewed in Murphey & O’Byrne, 
2010). Like asthma, inflammation is observed in COPD which is estimated to affect up 
to 19% of the adult population aged over 40 years, and is characterised by restricted 
airflow that is progressive and non-reversible (Ling & van Eeden, 2009). In COPD 
infiltration of inflammatory cells such as macrophages and neutrophils enhance 
inflammation impaired respiratory symptoms and fibrosis (Barnes, 2009). Occupational 
exposures ranging from asphalt workers to domestic cleaning have been associated with 
increased risk of both asthma and COPD (Medina-Raman et al., 2005; Randem et al., 
2004).  
 
Idiopathic pulmonary fibrosis (IPF) is a fatal airways disorder which involves 
remodelling of the vasculature (Strieter et al., 2007) and airway inflammation 
(Yamauchi et al., 2010). Epithelial-to-mesenchymal transition (EMT), a process 
whereby epithelial cells de-differentiate into mesenchymal myofibroblasts is associated 
with fibrosis (Guarino et al., 2009; Yamauchi et al., 2010). Damaged epithelial cells 
down-regulate epithelial cell markers such as E-cadherin, ZO-1 and cytokeratin and up-
regulate mesenchymal proteins including alpha-smooth muscle actin, vimentin and 
fibroblast specific protein-1 (FSP1) (Guarino et al., 2009). Transforming growth factor 
(TGF)-β induces EMT in vitro (Guarino et al., 2009; Yamauchi et al., 2010); further, 
TGF-β induced EMT is enhanced by the pro-inflammatory mediator TNFα, indicating 
that lung inflammation may drive airway remodelling observed in airway pathologies. 
In all of the above conditions there is excess inflammatory mediator secretion resulting 
in immune cell recruitment. Cysteinyl leukotrienes are lipid mediators secreted from 
many inflammatory cells including eosinophils, neutrophils and macrophages 
(Monstuschi, 2010). Cysteinyl leukotrienes contribute to airway remodelling 
(Monstuschi, 2010) and COPD (Drakatos et al., 2009) by promoting fibroblast 
proliferation and collagen deposition, and smooth muscle proliferation leading to 
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thickening of the airway wall (Monstuchi, 2010). Leukotriene B4 also leads to 
worsening of airway inflammation by acting as a chemoattractant for T cells and 
neutrophils (Drakatos et al., 2009). 
 
Cystic fibrosis (CF) is a genetic disorder affecting 9000 individuals in the UK 
(www.cftrust.org.uk).  The most common genetic mutation in CF is the loss of 
phenylalanine in position 508 (ΔF508) in the cystic fibrosis transmembrane 
conductance regulator (CFTR) protein leading to abnormal chlorine conductance. The 
respiratory consequences of the mutated CFTR protein is dehydrated airway surface 
leading to cilia collapse and subsequent build-up of a thick mucus layer. This provides 
an environment for bacterial colonisation and results in chronic inflammation due to 
persistent activation of the immune response (Ratjen, 2009).  
 
 1.2.2 Role of airways epithelium in innate immune response 
As well as providing a protective barrier and muco-ciliary escalator, airway epithelial 
cells protect against pathogenic colonisation by orchestrating an immune response by 
secretion of a range of pro-inflammatory mediators (Table 1.1) such as chemokines 
(interleukin (IL)-8, regulated upon activation, normal T cell expressed and secreted 
(RANTES) and granulocyte macrophage colony-stimulating factor (GM-CSF)), and 
cytokines (IL-6 and IL-1β).  Signalling molecules and cytotoxic (such as reactive 
oxygen species (ROS) and reactive nitrogen species (RNS)) and antimicrobial factors 
such as β-defensin, lysozyme and lactoferrin are also secreted by epithelial cells during 
innate immune response (Bals & Hiemstra, 2004; Polito and Proud, 1998; Thompson et 
al., 1995). The pro-inflammatory mediators IL-8 and IL-6 are increased in 
bronchial/bronchio-alveolar lavage (BAL) and induced sputum from asthma, COPD 
and bronchitis sufferers (Garcia-Rio et al., 2010; Jatakanon et al., 1999; Riise et al., 
1995) and in asthmatic serum (Fitzpatrick et al., 2010), again indicating a link between 
excessive inflammatory responses and airway pathology. 
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Table 1.1: Airway epithelial cell inflammatory mediator secretion. The airways epithelium 
can secrete a number of inflammatory mediators including colony stimulating factors which 
promote the differentiation and survival of immune cells, chemotactic cytokines which attract 
immune cells and multifunctional cytokines and signalling molecules (Bals & Hiemstra, 2004; 
Polito & Proud, 1998;  Thompson et al., 1995). M-CSF; macrophage colony-stimulating factor, 
MCP; monocyte chemotactic species, SP, surfactant protein, SIgA; secretory immunoglobulin 
A. 
During inflammation epithelial cell-derived cytokines such as IL-1β induce a 
conformational change and up-regulation of adhesion molecules on endothelial cells to 
facilitate recruitment by chemotaxis of circulating leukocytes to clear the pathogenic 
insult (Rafiee et al., 2003; Yan et al., 2010).  
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1.2.3 Role of the endothelium in the innate immune response 
As well as its role in blood supply the endothelium has a role in inflammatory cell 
trafficking (Danese et al., 2007). Activation of endothelial cells results in increased 
expression of adhesion molecules which allow for attachment and extravasation of 
circulating leukocytes to sites of infection and inflammation (Langer & Chavakis, 2009; 
Rao et al., 2007). Endothelial cell adhesion molecules capable of interacting with 
leukocytes include selectins (E-selectin and P-selectin) and major integrin ligands 
(VCAM-1 and ICAM) (Danese et al., 2007). Leukocytes adhere to the endothelium by 
a tethering and rolling process. Binding first occurs via adherence of the leukocyte 
carbohydrates to endothelial selectins. Rolling leukocytes form firm attachments to the 
endothelial cells (Langer & Chavakis, 2009) and then migrate through the endothelial 
cell layer via interactions between leukocyte integrins and endothelial junctional 
adhesion molecules (JAM) (Langer & Chavakis, 2009). 
 
Further, in the event of endothelial challenge endothelial cells themselves secrete 
inflammatory mediators (Danese et al., 2007). Adherence of platelets to the 
endothelium, via the endothelial cell specific molecule Von Willebrand factor (VWF) 
for instance, may also occur during endothelial cells insult. The platelets allow 
leukocyte adherence to the endothelium through binding of P-selectin on the platelet 
surface to P-selectin glycoprotein ligand 1 on the leukocytes (Danese et al., 2007). 
 
 1.2.4 Role of leukocytes in the innate immune response 
Leukocytes, including monocytes, macrophages and neutrophils, play pivotal roles in 
elimination of “non-self” xenobiotic materials such as pathogens.  Upon activation by 
colony stimulating factors such as GM-CSF, circulating monocytes differentiate into 
macrophages which phagocytose the infective substances (reviewed in Parihar et al., 
2010). Neutrophils, whilst integral in the innate immune response are able to activate 
the adaptive immune response via release of cytokines and chemokines (for example 
IL-8) which activate and induce differentiation of B- and T lymphocytes (reviewed in 
Coscao et al., 2009). 
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  1.2.4.1 Neutrophils and the innate immune response 
Daily, the adult human bone marrow produces 10
11
 neutrophils which comprise up to 
60% of the total circulating leukocytes (Smith, 1994), and remain in circulation for up 
to 18 hours before removal by apoptosis. This removal maintains a balance in 
neutrophil numbers and homeostasis. Circulating neutrophils act as immune surveyors 
and roll along endothelial cell monolayers allowing for rapid migration into infected 
areas upon activation (Coscao et al., 2009). Upon activation, rolling neutrophils adhere 
to endothelium via binding between endothelial ICAM-1 and neutrophil β2-integrin, 
such as LFA-1 (CD11b/CD18). Neutrophils then move through the endothelial cell 
layer by a process termed diapedesis (Figure 1.3), which involves binding between 
neutrophil PECAM-1 and endothelial PECAM-1 and neutrophil LFA-1 and endothelial 
JAM in tight junctions (reviewed in Coscao et al., 2009).  
 
Neutrophils eliminate pathogens via phagocytosis which triggers the neutrophil 
respiratory burst and degranulation principally into the phagosome. Phagocytosis occurs 
via binding between Ig-opsonised material and Fcγ neutrophil receptors or via binding 
between complement C3bi opsonised material and neutrophil CD11b/CD18 (Coscao et 
al., 2009). The respiratory burst is initiated upon neutrophil activation and involves the 
formation of NADPH oxidase/cytochrome b558 which transfers electrons from 
NADPH to oxygen forming superoxide anion radicals (Coscao et al., 2009). 
Cytochrome b558 is formed by the translocation of the p47
phox
 , p67
phox
 and p40
phox
 
heterotrimer, along with rac-GTP from the cytosol to the plasma membrane where it 
binds gp91
phox
 and p22
phox
 to form the cytochrome (Rosario & Fonseca, 2009; Wientjes 
& Segal, 2005). 
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Figure 1.3: Role of neutrophils in the innate immune response. Upon activation neutrophils extravasate through the endothelium to the site of 
infection. Neutrophils aid to resolve infection by elimination of the pathogen by phagocytosis. 
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1.3 LPS and PM induce innate immune response in airways epithelium 
 1.3.1 LPS 
LPS is a virulence factor located on the outermost layer of Gram-negative bacterial 
membranes, and induces an inflammatory response in a broad range of cells including 
epithelial cells (Rietschel et al., 1994).   
  1.3.1.1 General structure 
LPS has 3 components (Figure 1.4); lipid A, a core region and a polysaccharide region 
referred to as o-antigen (Haeffner-Cavaillon et al., 1998; Rietschel et al., 1994). Lipid 
A is composed of fatty acids attached to an N-acetylglucosamine dimer, and is the part 
of LPS responsible for antigenicity (Rietschel et al., 1994). The core oligosaccharide 
contains a 2-keto-deoxyoctonic acid (Kdo) domain, a sugar specific to LPS, which 
attached to lipid A. The o-antigen of LPS is composed of repeating oligosaccharides 
(each comprising 3-7 sugars) and is responsible for the variation of LPS structure 
between bacterial serotypes and species (Rietschel et al., 1994).   
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Figure 1.4: Structure of LPS. LPS contains 3 major domains, a Lipid A domain which is responsible for the biological activity of LPS, a core 
domain which is connected to Lipid A via a Kdo domain, and a polysaccharide usually referred to as O-antigen or O-polysaccharide. The 
structure of o-polysaccharide varies between bacterial species and serotypes. Image adapted from Tobias et al., (1999).
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1.3.1.2 LPS/TLR signalling 
TLR’s are PRR which bind PAMPs such as LPS (which is recognised mainly by TLR 
4). During LPS recognition LPS is bound by LPS-binding protein (LBP) and transferred 
to CD14 and MD-2. (Lu et al., 2008). After LPS recognition by TLR-4, signalling 
occurs via 2 pathways; the myeloid differentiation primary response gene 88 (MyD88)-
dependent pathway or the MyD88-independent pathway (Figure 1.5). Signalling via the 
MyD88-dependent pathway results in up-regulation of pro-inflammatory cytokine 
secretion via a number of transcription factor signalling pathways,  including  the p38 
mitogen-activated protein kinase (MAPK) pathway, which induces activator protein 
(AP)-1 nuclear translocation (Dunston & Griffiths, 2010). Activation of nuclear factor-
κB (NF-κB) is also a result of LPS/TLR4 binding. NF-κB is a dimer of RelA (p65) and 
p50, in un-activated cells NF-κB is held in the cytoplasm by inhibitory IκB proteins 
which cover nuclear localisation signalling domains (Dunston & Griffiths, 2010). 
Activation results in degradation of the inhibitory proteins and nuclear translocation of 
NF-kB.  The MyD88-independent pathway involves up-regulation of Type I inteferons 
which aid in clearance of viral and bacrterial pathogens (Perry et al., 2005).  
 
 1.3.2 Particles 
PM with a diameter of <10µm deposit within the respiratory tract and can elicit airway 
epithelium inflammation and cytotoxicity if ineffectively cleared (Heyder, 2004). 
Inhalation exposure to particulates may occur from a number of sources including 
diesel exhaust particulates (DEP) and other combustion derived particulates (Duffin et 
al., 2007) to particles from workplace exposure such as coal dust particles (Schims and 
Borm, 1999) or particulates for commercial products such as fine titanium dioxide 
(TiO2).   
 
1.3.3: PM induced-ROS and inflammatory signalling  
During inflammation, ROS are liberated by epithelial and endothelial cells as mediators 
of cell signalling (Bals & Hiemstra, 2004 & Polito & Proud, 1998) and by leukocytes 
during phagocytosis (Coscao et al., 2009). Furthermore, inhaled xenobiotics have the 
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potential to produce ROS; for example transition metal-containing particulates result in 
ROS formation by via the Fenton reaction (Carter et al., 1997). PM also induce cellular 
ROS induction by impairment of mitcochondrial electron transfer (Zhao et al., 2009).  
  1.3.4: Glutathione and redox homeostasis 
The tri-peptide thiol glutathione (GSH) protects against excess ROS in the airways and 
is present in airway surface lining fluid (Biswas & Rahman, 2009). GSH exists both in 
the reduced (GSH) and oxidised form (GSSG, also known as glutathione disulphide), 
with reduced GSH accounting for 99% of total cellular glutathione levels. Glutathione 
peroxidase and peroxiredoxin 6 catalyse the conversion of H2O2 to water, resulting in 
GSH oxidation (GSSG) (Forman et al., 2009). GSSG is reduced to GSH, a reaction 
catalysed by glutathione reductase, at the expense of NADPH (Harvey et al., 2009). 
GSH replenishment also occurs via de novo synthesis from glutamate, cysteine and 
glycine. Catalysed by glutamate cysteine ligase (also known as a γ-glutamylcysteine 
synthetase), the first stage in GSH de novo synthesis involves a reaction between 
cysteine and glutamate to produce γ-glutamylcysteine. Glycine is then added to γ-
glutamylcysteine to form GSH, a reaction catalysed by glutathione synthetase (Forman 
et al., 2009). Up-regulation of glutamate cysteine ligase and other GSH related enzymes 
by nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) also contributes to GSH de 
novo synthesis. ROS and RNS induce liberation of Nrf2 from Keap1 and translocation 
of Nrf2 to the nucleus. Nrf2 interacts with target genes through antioxidant response 
elements (AREs) (Harvey et al., 2009). Nrf2-regulated genes include glutamate 
cysteine ligase, and other GSH-regulation genes. Nrf2 also has a negative-regulatory 
role on inflammatory events during LPS induced septaceamia. NADPH oxidase 
dependant ROS (liberated during the neutrophil respiratory burst during pathogenic 
clearance) increased TLR4 inflammatory signalling in NRF2
-/-
 macrophages (Kong et 
al., 2010).  
 
Excessive ROS production leads to depletion of cellular GSH resulting in a redox 
imbalance and increased levels of GSSG. GSSG induces ubiquitination and 
phospohorylation of IKK leading to activation of NF-κB, GSSG also activates AP-1, 
leading to inflammatory gene up-regulation (Rahman & MacNee, 2000). Furthemore, 
mitochondrial ROS induces pro-inflammatory signalling via activation of p38 MAPK 
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signalling cascades (West et al., 2011), NF-κB and the transcription factor 
CCAAT/enhancer binding protein beta (C/EBPβ) (Zhao et al., 2009) (Figure 1.5). Pro-
inflammatory cytokines containing AP-1, NF-κB or C/EBPβ response elements are 
therefore potentially induced by LPS or PM exposure. The IL-8 gene promoter region 
contains a NF-κB element, an AP-1 element and a C/EBP-element and therefore up-
regulation of IL-8 gene expression can result from a number of stimuli (Hoffmann et 
al., 2002). IL-6 is up-regulated by mitochondrial ROS induced C/EBPβ activation after 
PM exposure (Zhao et al., 2009), and is also up-regulated by p38 MAPK pathways 
(Heinrich et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Inflammatory signalling induced by LPS and PM. LPS binding to the TLR4 
receptor induces pro-inflammatory mediator up-regulation via transcription factors NF-κB and 
AP-1. PM exposure results in mitochondrial ROS production which activates C/EBPβ, NF-κB 
and p38 MAPK signalling. Image adapted from Lu et al., (2008). Blue arrows represent the 
MyD88-independent pathway, red arrows represent the MyD88-dependent pathway and green 
arrows represent PM induced inflammatory signalling.  
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1.4 IL-8 and IL-6 in airway pathologies 
Yoshimura et al., (1987) first identified a neutrophil chemotactic mediator in 
conditioned media of Escherichia coli (E. coli) LPS stimulated human blood 
mononuclear cells, termed monocyte-derived neutrophil chemotactic factor (MDNCF). 
MDNCF is now known as IL-8 (Baggiolini et al., 1989) and has since been extensively 
studied. After cleavage of the 20 amino acid residue signal sequence from the 99 
amino-acid IL-8 precursor, the principal IL-8 variant of 72 amino acids is secreted from 
immune cells such as neutrophils, whilst non-immune cells such as epithelial cells 
secrete IL-8-77 (Mikolajczyk-Powlinska et al., 1998).  Variants with lengths of 79, 71, 
70 and 69 amino acids have also been reported (Nourshargh et al., 1992). IL-8 secretion 
is observed from a number of different cell types including fibroblasts, epithelial cells 
and endothelial cells, and induces neutrophil migration, release of storage proteins and 
respiratory burst (Baggiolini & Clarke-Lewis, 1992).  
 
Kishimoto & Ishizaka, (1973) identified that activated T cells secreted a mediator 
capable of inducing B cell growth and differentiation. Later, the cDNA of this mediator 
was identified and the mediator was termed B-cell stimulatory factor (BSF-2) (Hirano 
et al., 1986). BSF-2 was also independently identified as a hepatocyte stimulating factor 
(Andus et al., 1987). BSF-2, now known as IL-6, (Kishimoto, 2010) has pro-
inflammatory mediator properties including activation of leukocytes (Jones, 2005). IL-6 
is also suggested to play a role in leukocyte chemotaxis (Jones, 2005).  
 
Increased secretion of IL-8 and IL-6 contributes to the persistent inflammation in 
asthma, COPD and bronchitis (Fitzpatrick et al., 2010; Garcia-Rio et al., 2010; 
Jatakanon et al., 1999; Riise et al., 1995). In a large scale study of COPD (324 COPD 
sufferers and 110 control individuals) serum levels of IL-8 were found to be 
significantly greater in COPD subjects than control (after adjustment for age, gender 
and BMI) whilst serum levels of IL-6 was significantly greater in subjects with severe 
COPD compared to those with mild COPD (Garcia-Rio et al., 2010). Further IL-8 
levels are increased in BAL of chronic bronchitis sufferers compared with control 
(Riise et al., 1995) and severe asthmatic adults compared to both mild asthmatic adults 
 43 
and normal control adults (Jatakanon et al., 1999). Increased numbers of neutrophils 
were also observed in BAL from severe asthmatic compared to control and mild 
asthmatic adults (Jatakanon et al., 1999) indicating the role of increased IL-8 secretion 
in asthma. Increased IL-6 is also observed in BAL of asthmatic subjects compared to 
control (Fitzpatrick et al., 2010). PM exposure has also been linked to decreased 
respiratory function in asthmatic children (Barraza-Villarreal et al., 2008; Holguin et 
al., 2007) and increased cardiovascular disease (Nascimento et al., 2001).  
 
1.5 PM and airway pathologies and links to cardiovascular disease 
As described above PM induce ROS that in turn promote inflammatory signalling via 
MAPK and NF-κB. Exposure to PM in individuals with respiratory illness may 
therefore worsen disease state by increased inflammation. Significant correlations 
between impaired respiratory function (measured by forced expiratory volume in one 
second (FEV1)) and increased ambient PM2.5 (PM with a mean diameter of <2.5µm) 
levels have been observed in asthmatic children (Barraza-Villarreal et al., 2008; 
Holguin et al., 2007). Further, increased ambient PM2.5 levels correlated significantly 
with increased IL-8 in nasal lavage in both asthmatic and non-asthmatic children 
(Barraza-Villarreal et al., 2008). PM also induce epidermal growth factor signalling 
(EGF) in bronchial epithelial cells which also induces epithelial cell proliferation 
(Sydlick et al., 2006; Tamaoki et al., 2004); it is likely that excessive signalling could 
potentially lead to airway remodelling and narrowing of the airways.    
 
Inhaled PM have been shown to translocate into the blood stream (Nenmar et al., 2002) 
and may therefore result in vascular inflammation and pathology. Indeed, PM exposure 
results in increased microvascular ROS production and impaired vasoldilation in 
coronary arterioles in rats (LeBlank et al., 2010), increased platelet activation (O’Tool 
et al., 2010), reduced NO synthase levels, increased inflammatory gene expression and 
endothelial cell death (Yamawaki et al., 2006) in humans. Plasma inflammatory marker 
concentrations (IL-6, soluble P-selectin and C-reactive protein) in elderly coronary 
artery disease patients (Delfino et al., 2008) and CVD related hospital patient 
admissions correlated significantly with ambient PM levels.  
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Due to the potential for tissue damage, airway remodelling and decreased lung function 
during airway inflammation, and CVD complications, valid models of airways 
inflammation are required to help identify mechanisms and inducers inflammatory 
events and potential inhibitory treatments. Rodent models can be used widely to study 
inflammatory responses to LPS (Schwartz et al., 2001) and PM (Bermudez et al., 2004) 
exposure.  
 
1.6 Animal models of respiratory pathologies 
Mouse models of asthma often use ovalbumin as a stimulator of pulmonary 
inflammation, which induces eosinophil infiltration of the lungs and airway remodelling 
(Nials & Uddins, 2008). House dust mite extract, (which is a more relevant stimulus as 
it can induce asthmatic symptoms in humans), also induces eosinophil recruitment to 
the lungs of challenged mice and airway inflammation (Johnson et al., 2004). Rodent 
models are used to study PM toxicity. Inhalation exposure of hamsters, rats and mice to 
ultrafine titanium dioxide (UFTiO2) (variable doses for 6 hours a day, 5 days a week for 
13 weeks) induced increasing numbers of macrophages, neutrophils and lymphocytes in 
BAL of rats and mice indicating the inflammatory potential of this particle in vivo 
(Bermudez et al., 2004). Lung burdens of particles observed after treatment declined 
during recovery periods for animals. Further, increased burdens in lymph nodes for rats 
were observed during recovery (Bermudez et al., 2004) indicating clearance of 
particles. Murine models of CF are also utilised, however, mice bearing CF mutations 
do not develop spontaneous airway disease (Sheth et al., 2008), possibly due to 
differences between human and murine immune responses. 
 
1.6.1 Immunological variance between human and animal lung immunity 
Whilst animal models are useful to study the effect of a toxicant on multiple organs, and 
the cross-talk between multiple cell types, the physiology is not entirely representative 
of humans. For instance, approximately 60% total circulating leukocytes are neutrophils 
in humans (Smith, 1994), 10-20% in mice (Mestos & Hughes, 2004) and 10-20% in rats 
(Haley, 2003). Mice also have different TLR2, 3, 9 and 10 expression and activation 
patterns. For example TLR3 is expressed on both dendritic cells and macrophages in 
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mice and is activated by LPS, in humans however, TLR3 is expressed on dendritic cells 
only and is non-responsive to LPS.  Mice also do not express the immune mediators 
caspase 10 (an important mediator in initiation of apoptosis) (Mestos and Hughes, 
2004). Rodents do not express the IL-8 gene, the equivalent keratinocyte-derived 
chemokine (KC) is found in mice and cytokine-induced neutrophil chemoattractants 
(CINC) are present in rats (Tarrant, 2010). The difference in immune systems between 
rodents and humans may be important when evaluating the toxicity potential of certain 
compounds, for example drugs or cosmetics. Further European Regulation (7
th
 
Amendment of the European Union Cosmetic Directive, 2003) governing the use of 
animals in cosmetic studies is now limiting their use for the safety assessment of 
cosmetic ingredients. The Cosmetic Directive now rules that animal repeat dose testing 
for cosmetic ingredients will be banned after 2013 (7
th
 Amendment of the European 
Union Cosmetic Directive, 2003). Due to the differences in human and rodent 
physiology regarding the immune response and limitations placed on animal testing, 
valid and robust in vitro cell models are required for evaluating toxicity, in particular 
cosmetic compound toxicity, testing. 
 
1.7 Epithelial cell models 
Culture of human primary airway epithelial cells (NHBE) on Transwell
®
 inserts at ALI 
allows for culture of multiple cell layers (as observed in vivo). NHBE cells cultured at 
ALI regain cilia formation, have cytokeratin profiles consistent with airway epithelial 
cells in vivo (de Jong et al., 1993; de Jong et al., 2004), and secrete mucin, lysozyme, 
lactoferrin and SLP1 (Gray et al., 1996). The trans-epithelial electrical resistance (TER) 
of NHBE cells at ALI is high (>800 Ωxcm2, Gray et al., 1996) and tight junctions are 
formed between neighbouring cells, as determined by immunohistochemical straining 
of ZO-1 (Coyne et al., 2002). TER measures ion flow throughout the paracellular 
pathway (Tang & Goodenough, 2003) which is governed by the particular properties of 
the cells tight junctions.  These data indicate that primary airway epithelial cells 
cultured at ALI are representative of the airway epithelial cells in vivo. TER 
measurements of different epithelial cell lines have shown that electrical resistance, and 
thus tight junction “tightness”, is variable. For example, values of 700-1000 Ω x cm2 
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are reached by the airway epithelial cell line Calu-3 (Grainger et al., 2006) and 300-
1200 Ω x cm2 are achieved by 16HBE14o- cells (Wan et al., 2000).  
 
Investigations into the transcriptome and apical secretions from primary bronchial 
epithelial cells cultured at ALI have further shown these cells to be a representative 
model of the airways epithelium in vivo by their expression of mucociliary genes and 
secretion of mucins (Dvorak et al., 2010; Kesimer et al., 2009). In a study comparing 
EpiAirway (MatTek) ALI models of airway epithelial cells from healthy non-smoking 
donors to primary airway epithelial cells obtained from bronchoscopy Dvorak et al., 
(2011) investigated the transcriptome of both models in relation to ciliary, secretory and 
basal epithelial cell genes. Expression of cilia-related genes were significantly increased 
in brushed cell cultures whilst basal cell-related genes showed significantly increased 
expression in ALI cultures. This is in agreement with histological findings which show 
that more ciliated cells and fewer basal are found in cells obtained by bronchoscopy. 
However, both models contained ciliated, secretory and basal cells. Furthermore, over 
80% of the genes expressed by both modes had similar expression profiles indicating 
the relevance of the ALI model compared to epithelial cells in vivo. Of the genes that 
were different, MUC5AC, a major airways mucin, gene expression was increased in 
brushed cells compared to ALI cells, whilst MUC2 gene expression was observed in 
brushed cells only (Dvork et al., 2011), suggesting both models have a similar number 
of secretory cells, the mucin profile of secretions may be different.  
 
Culture of bronchial epithelial cells in spheroids also allows for cellular differentiation 
(Castillon et al., 2004; Deslee et al., 2007). Here isolated epithelial cells are cultured 
either under static conditions or under horizontal rotation and form spheres of 
differentiated epithelial cells. Spheroid models have been shown to contain polarised 
cells with beating cilia, tight junctions, a basal cell population (Castillon et al., 2004; 
Deslee et al., 2007), however these models cannot be maintained at ALI or used for co-
culture studies.  
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1.7.1 Inflammatory responses of airway epithelium in vitro to LPS exposure 
Under submerged conditions BEAS-2B respond to LPS challenge by increasing IL-6 
secretion (Schulz et al., 2002). Laan et al., (2004) observe IL-8 secretion from BEAS-
2B cells when cultured under submerged conditions after treatment with 1µg/ml E. coli 
LPS and IL-6 secretion has been observed from submerged cultures of BEAS-2B 
treated with P. aeruginosa LPS (Veranth et al., 2008).  There has been little research 
conducted into the response of BEAS-2B cultured at ALI. Inhalation of PM has been 
implicated in contributing to airways inflammation in existing airway diseases 
(Barraza-Villarreal et al., 2008; Holguin et al., 2007; Sydlick et al., 2006; Tamaoki et 
al., 2004). In vitro investigations into PM induced inflammation are therefore warranted 
to investigate the inflammatory potential of these substances to healthy airways 
epithelium and mechanisms of exacerbation of inflammation in diseased states. 
 
 
1.8 Titanium dioxide 
TiO2 is used in the cosmetic industry as a component of sun block (Nohynek et al., 
2010), in paints as a white pigment (Hext et al., 2005), in the food industry (Lomer et 
al., 2002) and dentistry (Kim & Ramaswamy, 2009). Workers in TiO2 production 
industries are exposed to TiO2 nanoparticles via inhalation (Boffetta et al., 2006). 
Reports on TiO2 exposure have failed to identify definitive links between TiO2 
exposure increased mortality. A large study reported by Boffetta et al., (2004) looking 
at mortality among TiO2 workers (15,017 individuals) from 11 European factories 
failed to identify a statistical link between duration of TiO2 exposure in workers and all 
causes of mortality. However, an increase in mortality due to lung cancer in workers in 
TiO2 production industries compared to national rates was observed when analysing 
data against standard mortality ratios, suggesting carcinogenic effects of TiO2. In 
another study comprising of both estimated exposure and risk analysis by combining 
previously published data of TiO2 airborne distribution in TiO2 nanoparticle production 
industries and effects on cell- based models (human dermal fibroblasts), Liao et al., 
(2008) identified that TiO2 workers have no significant risk of lung inflammation, 
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however, a cytotoxic response was likely to be observed with “high” TiO2 nanoparticle 
(NP), (10-30nm diameter) exposure.   
TiO2 is classified as a group B carcinogen, i.e, possibly carcinogenic to humans 
according to the International Agency for Research on Cancer (IARC). Further, in vitro 
studies of TiO2 exposure suggest detrimental effects on the human airways (Hussain et 
al., 2010; Park et al., 2008; Singh et al., 2007). 
 
1.8.1 Inflammatory and cytotoxic effects of TiO2 on airways epithelium in 
vitro 
Along with inducing increased mucin secretion from airway epithelial cells, as 
measured by enzyme-linked lectin assay (Chen et al., 2010) TiO2, in particular UFTiO2, 
can induce an inflammatory response in airway epithelial cells. UFTiO2 treatment of 
A549 cells resulted in increased mRNA expression and secretion of IL-8 (Singh et al., 
2007).  Increased expression (Park et al., 2008) and secretion (Zhao et al., 2009) of IL-8 
has been demonstrated with submerged cultures of the bronchial epithelial cells BEAS-
2B in response to TiO2. Directional secretion of these inflammatory mediators has yet 
to be investigated in epithelial cells cultured at ALI. Since inflammatory mediator gene 
expression differs between submerged and ALI cultures (Ross et al., 2007) secretion 
profiles may also differ.   
 
Apoptosis is also a consequence of airway epithelial cell exposure to TiO2. In terms of 
cell morphology, 16HBE14o cells undergo membrane blebbing, cell shrinkage and 
DNA fragmentation after exposure to TiO2 (40µg/cm
2
 for 4 hours; Hussain et al., 
2010). Increased apoptosis (measured by annexin V staining) and protein activity of the 
apoptotic signalling molecules caspase 3, bax, p53 and caspase 9, along with increased 
intracellular ROS (Shi et al., 2010) and decreased GSH (Park et al., 2008) levels are 
observed in submerged cultures of BEAS-2B after TiO2 exposure.   
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1.8.2 Cellular uptake of TiO2 
Bhattacharya et al., (2009) demonstrate uptake of TiO2 into BEAS-2B (engulfment by 
protruding filopodia from BEAS-2B cell membrane) with localisation of particles to the 
peri-nuclear region. TiO2 aggregates have also been identified within vacuoles, vesicles 
and lamellar bodies of A549 cells (Singh et al., 2007; Stearn et al., 2001). Cellular 
uptake of TiO2 may result in further detrimental effects as TiO2 has been identified to 
impair respiratory control index, decrease oxygen consumption and disrupt 
mitochondrial membrane potential (Freyre-Fonseca et al., 2011). 
  
1.8.3 Translocation of TiO2 particles 
Exposure of the airways epithelium to TiO2 in vivo results in inflammation and local 
epithelial cell apoptosis. Prolonged TiO2 exposure or lung overload, and therefore 
prolonged inflammation, may result in widespread airways tissue damage. Rothen-
Rutishauser et al., (2007) observe translocation of TiO2 in vitro through multiple cell 
layers. Using a co-culture model of the airways consisting of monocyte derived 
macrophages (MDM) seeded apically onto A549 cells (A549 cells were first seeded 
onto the apical side of a Transwell
®
 insert) with monocyte derived dendritic cells 
(MDDC) underneath the epithelial cells (seeded on the underside of the Transwell
® 
insert), cells were exposed apically to TiO2 (5µg/ml) for 24 hours. TiO2 was observed 
in all three cell types indicating particle translocation between cells.   
 
In vivo, TiO2 particles have been observed in the air spaces, epithelial cells, endothelial 
cells, basement membrane (within the collagen fibrils) and capillaries of rats 1 hour 
after inhalation exposure (Geiser et al., 2005; Muhlfeld et al., 2007). Direct exposure  
of the endothelium to PM initiates an inflammatory response.  Ultrafine ambient air 
particles (4 hour incubation with 100µg/ml) up-regulate gene expression and secretion 
of IL-8 and IL-6 in human primary pulmonary aortic endothelial cells (Karoly et al., 
2007). Further, Qu et al., (2010) observe that primary microvascular endothelial cells 
exposed to urban air dust (100µg/ml) respond with a time dependant increase in IL-6 
secretion. 
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Owing to the ability of endothelial cells to secrete inflammatory mediators after PM and 
LPS challenge, and the observation that PM translocate to the endothelium in vivo, 
along with the cytokine induced up-regulation of endothelial cell adhesion molecules, 
inclusion of endothelial cells into airway models of PM exposure should be considered. 
A multi-cell model of the airways epithelium and endothelium would allow 
investigations into whether epithelial cell derived cytokines (induced by PM exposure) 
act upon the endothelium to further release chemokines for leukocyte recruitment and 
up-regulate adhesion molecule expression for leukocyte extravasation.  
 
1.9 Co-culture 
Multi-cell models such as co-culture models are a step towards bridging the gap 
between in vitro models and in vivo systems. These permit the study of several cells 
responding after a stimulus, for example the collaboration between airways epithelium 
via cytokine and chemokine secretion, endothelial activation and neutrophil 
recruitment. Furthermore accessory cells or support cells may aid in target cell growth, 
differentiation and resistance to challenge. For example, in Parkinson’s disease models 
the inclusion of an astrocyte support monolayer enhances dopaminergic neuronal 
proliferation and survival (under basal and hydrogen peroxide challenge) in 
mesencephalic neuronal cultures (Drukarch et al., 1997; Langevold et al., 1995).  
Regarding the airways, the presence of a fibroblast layer in NHBE cultures increases 
epithelial cell proliferation  under submerged conditions (Skibinski et al., 2007), cilia 
formation and increased TER (suggesting tight junction formation) in ALI cultures 
(Pohl et al., 2009). 
 
In terms of airway co-cultures to investigate inflammatory events, epithelial cells have 
been co-cultured with endothelial cells in order to investigate leukocyte migration, 
however in these models the epithelial cells are cultured under submerged conditions 
(Casale & Corolan, 1999; Choudhury et al., 2010) and are therefore not representative 
of the airways epithelium in vivo.   
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Mogel et al., (1998) developed a co-culture of airway epithelial cells and HUVEC 
where BEAS-2B cells were cultured on the apical surface of Transwell
®
 inserts with 
ECV304 HUVEC cells in the basolateral compartment. Whilst the orientation of the 
cells was representative of in vivo, the BEAS-B were cultured under submerged 
conditions rather than at ALI. However, a synergistic effect between the two cells types 
was observed after apical exposure to 0.15ppm ozone for 90 minutes. Levels of IL-8 
and IL-6 were detected in the co-cultures that exceeded the sum of secretion from 
endothelial cells and epithelial cells monocultures after ozone stimulation.  
 
A potential role for airways co-cultures is the identification of biomarkers of airways 
toxicity and inflammation following exposure to novel test materials. For example, 
biomarkers of acute and chronic inflammation of airways, or biomarkers of response to 
challenge  may aid in the assessment of cosmetic compound testing. Ideally, in vitro 
models (required to replace animal cosmetic toxicity studies) exposed to cosmetic 
compounds will be screened for the presence of these biomarkers.  
 
1.10 Biomarkers  
Biomarkers are biological compounds, usually proteins, which reflect and allow 
detection of pathologic progression (disease states) and pharmacologic processes (drug 
treatment) (Tarrant, 2010). Biomarkers can be used to investigate the toxicity regarding 
structural or functional consequences of exposure to compounds such as PM and 
chemical/cosmetic compounds or bacteria/bacterial products such as LPS. Pathologic 
biomarkers should be specific and sensitive for toxicological exposure or disease state 
and be early onset with a practical half-life to allow detection (Tarran, 2004).  Once 
identified (in vitro or in vivo), biomarkers of human disease must be first validated by 
comparison to established disease or exposure stages (Tarran, 2004).   
 
Cytokines and chemokines are attractive potential biomarkers as their expression and 
secretion profiles in inflammation and disease are often intensively investigated. 
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However, cytokines have short half–lives, significant biological variability between 
subjects and overlapping expression profiles between similar diseases (Tarran, 2004). 
Further, cytokines are often bound and carried by serum albumin (Granger et al., 2005), 
which is more abundant in serum than cytokines by several orders of magnitude. The 
presence of albumin decreases the resolution of protein separation and sensitivity of 
protein identification in proteomics (Granger et al., 2005), a method used in the 
identification of biomarkers. Albumin removal of samples results in loss of cytokines in 
samples, for example IL-8 detection in albumin-depleted LPS (1ng/ml E. coli 0111:B4) 
blood samples was only 26% of non-albumin depleted samples (Granger et al., 2005).     
 
Despite the pitfalls of the presence or depletion of albumin in samples, proteomics is a 
powerful tool used for identification of biomarkers. Ostroff et al., (2010), using 
proteomics methods, identified 12 biomarkers of stage I-III non-small cell lung cancer; 
including up-regulated levels of MIP-4 and pleiotrophin and decreased expression 
levels of cadherin-1 in serum. Proteomics has been used to identify decreased levels of 
heat shock protein-27 in atheroma plaques and the atheroma secretome (Vivanco et al., 
2008). 
 
1.11 Proteomics 
The global protein changes of a particular treatment on a given proteome (plasma, cell 
proteome for example) can be identified by proteomics, a method where by proteins are 
separated using two dimensional electrophoresis, analysed for expression changes using 
statistics, and identified using mass spectrometry. 
 
1.11.1 Two Dimensional electrophoresis 
2-DE (whereby proteins are separated first by the isoelectric point and then by their 
molecular weight) was first carried out in the 1950’s (Isaaq et al., 2008). Proteins are 
focused according to their isoelectric point on strips with carrier ampholytes in 
acrylamide to produce gels with immobilised pH gradients (IPG) (Gorg et al., 2004). 
Proteins are then further separated according to their molecular weight and the resultant 
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protein map is visualised using protein stains (Gorg et al., 2004). Several protein stains 
exist including Coomassie blue, silver stain or fluorescent stains such as Flamingo™. 
Flamingo™ stain is not as sensitive as silver nitrate stains for lower concentration spots 
(silver nitrate has a sensitivity of 100pg-1ng, Miller et al., 2006) with a sensitivity of 
0.5ng to 1µg protein (BioRad), however, silver nitrate can result in varying staining 
intensities between replicates as it is not an end point stain (Miller et al., 2006) unlike 
Flamingo™. Once spots have been identified by the software protein expression levels 
measured as density are compared between treatments. 
  
1.11.2 Statistical analysis of spot expression changes between treatments 
To detect differentially expressed proteins between control and treatment groups, 
densitometry analysis software can be utilised. Progenesis SameSpots (Nonlinear 
Dynamics, Newcastle Upon Tyne, UK) analysis software used in 2-D analysis, analyses 
the significance between spot expression profiles. The first step in gel analysis is the 
selection of a reference gel which has the most spots and spot expression levels in 
common with all other gels. Progenesis Samespots then normalises the spot volumes 
and intensities in all other gels to the reference gel. Any expression differences (up- or 
down-) are then identified and analysed using ANOVA and a statistical power 
calculation based on expression variance between gels.  Progenesis SameSpots also 
presents data by principal component analysis (PCA), where by all the spots within a 
given experiment are shown on a biplot, with the gels. Experimental variation between 
duplicate gels of the same treatment can be visualised along with differentially 
expressed proteins between treatments, as shown by clustering of spots. Examination of 
the spot clustering compared to gel positions can also highlight spot expression profiles.   
 
For example, Figure 1.6 shows a PCA plot for 4 treatment groups. The duplicate gels 
for the treatment group assigned the orange dots, have a large space between them 
indicating a large experimental variation. Considering spot expression profiles for spot 
20, the treatments designated the orange and blue spots will have a low expression of 
this spot compared to the treatment with the orange spot.  
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Figure 1.6: PCA analysis plot. PCA plot showing duplicate gels for 4 different treatment 
groups (coloured dots) and expression profiles of all the proteins spots across all gels. The 
image and explanation is adapted from 
/www.nonlinear.com/products/progenesis/samespots.asp. 
  
1.11.3 Digestion of proteins of interest 
Once significantly altered spots have been identified across experimental gels the next 
step is removal of proteins from the gel and peptide digestion. Enzymes such as trypsin 
are used for peptide digestion as they have known cleavage sites, which is important for 
identification of protein matches against a database. Peptide masses identified by mass 
spectrometry are compared against theoretical peptide masses from in situ digestion. 
Peptide masses are governed by the location of cleavage sites within the protein (Canas 
et al., 2006; Siepen et al., 2006). Trypsin is commonly used as it is low cost and has 
high cleavage specificity (Siepen et al., 2006). 
 
1.11.4 Mass Fingerprinting using mass spectrometry 
The peptide sequences of tryptic digests are determined using mass spectrometry.  LC-
MS involves separating the peptides first according to their hydrophobicity. The 
peptides are then ionised using one of 2 methods; matrix-assisted laser desorption 
ionisation (MALDI) or electrospray ionisation (ESI). ESI has the advantage lower flow 
rate of peptides to increase sensitivity (Canas et al., 2006; Yates et al., 2009). A heated 
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capillary aids the removal of ionised droplets from the ionisation source to the mass 
analyser which determine the mass-to-charge (mz) ratio of the ion. There are 3 main 
types of mass analyser; the first is a time of flight (TOF) analyser in which ions are 
accelerated along the analyser with lighter ions arriving at the detector first (Canas et 
al., 2006; Yates et al., 2009). The second type is a quadrupole mass analyser. Here, 
radiofrequency (RF) alternative currents and DC currents are applied to 4 poles, with 
the DC the frequency of the DC current alternates between the rods causing an 
oscillating electrical current in the analyser (Canas et al., 2006). Ions are filtered out of 
the analyser according to their m/z stability (Yates et al., 2009). The third type ion trap 
in which the ions are separated according to their m/z resonance frequency (Yates et al., 
2009). The linear ion trap LTQ has been coupled to an orbitrap mass analyser to 
produce the LTQ-orbitrap mass spectrometer (Thermo-Scientific) which is capable of 
tandem mass spectrometry (Yates et al., 2009).  
 
 
Figure1.7: Schematic of b and y ions. During CID the peptide fragments by splitting of the 
amide bond resting in b and y ions. Image adapted from Canas et al., 2006.  
 
In tandem mass spectrometry, a full scan is completed on a peak from the liquid 
chromatograph to identify the parent ion (known as a full ms scan) by the orbitrap 
(Yates et al., 2009). A zoom scan on of this peak identifies the charge of the ion 
allowing the mass to be determined. The ion is then selected and fragmented using 
collision-induced fragmentation (CID). CID results in a spectra of b and y ions which 
are fragments where the amide bond of the peptide backbone has split during CID 
(Canas et al., 2006) (Figure 1.7).    
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The sequence of the peptide can then be determined from these ions, for example if a 
peptide had the following sequence Ω-κ-β-α-Φ(where the Greek letters represent amino 
acids to be determined by mass fingerprinting), the b1 ion molecular weight would 
equal Ω. The b2 ion molecular weight is Ω + κ, and so on. During mass fingerprinting 
the amino acid sequence can be determined by calculating the difference in molecular 
weight of each ion. Fragmentation occurs in the LTQ ion trap (Yates et al., 2009).  
 
1.12 Challenges in airway proteomics 
To enhance the potential for proteomics coupled with mass spectrometry for 
investigations into global protein changes after airways challenge in vivo and 
identification of biomarkers of airways exposure some challenges need to be overcome. 
Tissue biopsies from lungs are not readily available (Bharti et al., 2007), furtheremore, 
tissues obtained from biopsies, where mortality was due to respiratory illness, show 
chronic inflammatory signs, so early responses of exposure cannot be identified.  Serum 
is more readily available and its collection is non-invasive, however, serum proteomics 
has inherent difficulties owing to the large complexity of serum composition, the 
presence of abundant proteins and variability between individuals (Bharti et al., 2007). 
Use of in vitro models for identification of biomarkers of response limitations die to 
removes variability between individuals tissue availability, and once identified, may be 
used to screen for early lung injury and inflammation. 
 
The aforementioned evidence has provided an overview of our present understanding of 
particle induced inflammation in the lungs and has highlighted the need for novel in 
vitro techniques to be developed which are relevant physiologically that can provide 
robust measures of any inflammatory response to unknown particles. 
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1.13 Aim and objectives 
The airways epithelium is the first point of contact for inhaled pathogenic material such 
as LPS and non-biological compounds such as PM, however, early lung exposure and 
inflammatory events are difficult to detect. Current in vitro models of airways 
inflammation are limited as the majority do not encompass important immune 
(neutrophils and macrophages) and non-immune (endothelial cells) cells important in 
the airways inflammatory response. Whilst animal studies allow detailed examination 
of mechanisms and cells involved in airways inflammation, they are fundamentally 
different from humans in their physiology and immunology. Development of robust and 
valid co-culture models of the airways, in particular where epithelial cells undergo 
mucociliary differentiation and culture at ALI, may allow detailed toxicity 
investigations of inhalable toxic material and subsequent identification of biomarkers of 
response to exposure.  
 
The overall aim of this thesis is to develop a co-culture of the human airways for 
toxicity testing and identification of novel biomarkers of response to particles. 
The specific objectives are; 
1) To characterise BEAS-2B morphology at ALI compared to NHBE 
2) To develop an epithelial/endothelial co-culture model 
3) Investigate inflammatory mediator secretion from this model to LPS (from 
respiratory and non-respiratory bacterium) and a range of PM 
4) Determine GSH oxidation and cell viability after LPS/PM challenge 
5) Identify biomarkers of response using proteomics and LC-MS/MS 
6) Conduct proteomics and LC-MS/MS on albumin-depleted plasma samples from 
particle treated rats, where histopathological and trancriptomic analysis was 
undertaken elsewhere by Carthew et al., (2006). 
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Chapter 2: Materials and methods 
2.1: Materials 
2.1.1: General consumables 
All reagents were purchased from Sigma (Poole, UK) unless otherwise stated. Cell 
culture consumables were purchased from Appleton Woods (Birmingham, UK). 
Penicillin (500,000Uml
-1
) /streptomycin (500,000µgml
-1
), foetal calf serum (FCS) gold, 
amphotericin B and trypsin- ethylenediaminetetraacetic acid (EDTA) were purchased 
from PAA Laboratories Ltd. (Somerset, UK).  BD Falcon Transwell
®
 inserts were 
purchased from VWR (Leicestershire, UK). IPG 3-10 strips, Flamingo™ protein stain, 
Criterion 4-20% gradient ready gels and Biolyte 3/10 ampholytes were purchased from 
BioRad (Hertfordshire, UK). QCL-1000

 Chromogenic Limulus amebocyte lysate 
(LAL) endpoint assay kit (Lot GL0969) was purchased from Lonza (Basel, 
Switzerland).  Vectashield hard set mounting medium containing 4’,6-diamidino-2-
phenylindole (DAPI) was purchased from Vector Laboratories (Peterborough, UK). 
Immobilon

 Western Enhanced Chemiluminescent substrate (ECL) was purchased 
from Millipore (Watford, UK), X-ray film and DeStreak solution was purchased from 
Amersham Biosciences (Buckinghamshire, UK).  Trypsin Gold, ProteaseMAX 
surfactant Tryspsin enhancer, Glutathione-Glo and CellTiter-Blue were purchased from 
Promega (Southampton, UK). Percoll™ (1.13g/ml) was purchased from GE Healthcare 
Bio-Sciences (Buckinghamshire, UK). Nurtient broth and Mueller-Hinton agar were 
purchased from OXOID LTD. (Basingstoke, UK). Recombinant human IL-8 (Lot 
BA3109111) was purchased from R&D systems (Oxfordshire, UK), 4 well microscope 
slides were purchased from C.A. Hendley (Essex) ltd. (Essex, UK). Phenol, Kodak 
GBX developer and Kodak GBX fixer and replenisher were purchased from Sigma 
(Poole, UK). Nunc Maxisorb ELISA plates, microscope slides (1.0-1.2mm thick) and 
coverslips (0.13-0.17mm thick) were purchased from Fisher Scientific (Loughborough, 
UK). Immersol™ immersion oil was purchased from Carl Zeiss Ltd (Hertfordshire, 
UK). Petri dishes were purchased from Sarstedt Ltd. (Leicester, UK). 
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2.1.2: Particles 
Particles S2219200, S2218600 and S2429901 were provided by Unilever (Colworth) as 
test particles. S2218600 is an ester derived from a coparticle of methyl vinyl ether and 
maleic anhydride with butanol. S2218600 is clear yellow suspension and is insoluble in 
water. The particle was supplied in a vehicle of 74.82% (v/v) water, 22.12% (v/v) 
ethanol, 1.84% (v/v) diisopropanolamine and 1.22% (v/v) aminomethylpropanol. Upon 
receipt the particle was made to a stock of 10mg/ml in PBS and stored at -20°C. 
S2429901 is derived from a coparticle of methyl vinyl ether and maleic anhydride. 
S2429901 was supplied as a white powder and is water-soluble. S2219200 was 
provided as an opaque, viscous white suspension in 99.09% (v/v) water and 0.91% (v/v) 
aminomethylpropanol and is insoluble in water. S2219200 is a high-molecular weight 
coparticle of methyl- and ethyl methacrylate and butyl acrylate. Upon receipt the 
particle was made to a stock of 10mg/ml in PBS and stored at -20°C. Fine titanium 
dioxide (TiO2, anatase form, lot k342358-48) was purchased from VWR 
(Leicestershire, UK), ultra-fine titanium dioxide (UFTiO2, anatase form, Cat 637254) 
was purchased from Sigma (Poole, UK). Stock concentrations of 10mg/ml 
particles/particle were prepared in PBS and stored at -20°C prior to use. 
 
 
2.1.3: Antibodies 
Mouse monoclonal anti-cytokeratin 8 (0.5mg/ml ab9023 lot 369887), mouse 
monoclonal anti-cytokeratin 5 (1mg/ml ab9272 lot 369886), mouse monoclonal anti- 
mucin5AC (ab3649 clone 45m1), mouse monoclonal anti-VWF (clone 2Q2134, 
0.4mg/ml) and mouse monoclonal anti-fibroblast surface antigen clone IB10 
(0.2mg/ml) were purchased from Abcam (Cambridge, UK). Mouse IgG kappa (Mopc 
21, 5mg m-7894 lot 084k4857), and goat anti-mouse fluorescein isothiocyanate 
conjugate (FITC F0527 lot 046k6082) were purchased from Sigma. Mouse monoclonal 
anti-vimentin clone v9 was purchased from GeneTex, Inc (Autogen Bioclear Ltd. 
Wiltshire, UK). Mouse monoclonal anti-ZO-1 [0.5mg/ml lot 570628A) was purchased 
from Invitrogen (Paisley, UK). Horseradish peroxidase (HRP) conjugated sheep anti-
mouse IgG (NA931V lot 356283) was purchased from Amersham Biosciences 
(Buckinghamshire, UK). 
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2.2: Methods 
2.2.1: Cell culture 
  2.2.1.1: Epithelial cell culture 
BEAS-2B, passage 22-61 (SV40 transformed normal human bronchial epithelial cells 
were purchased from American Type Culture Collection (ATCC), LGC Promochem, 
Middlesex, UK. Product number ATCC-CRL-9609, lot 58121836) and tested negative 
for mycoplasma. NHBE cells passage 1-3 were purchased from Promocell, Lot 
5092901.17 Heidelberg, Germany. BEAS-2B and NHBE were maintained in airway 
epithelial cell growth medium (Promocell, Heidelberg, Germany) supplemented with 
5% (volume/volume v/v) heat inactivated foetal calf serum (Appleton Woods, 
Birmingham, UK), penicillin/streptomycin (final concentration of 5,000Uml
-
1/5,000μgml-1 respectively) and manufacturer’s supplement (bovine pituitary extract 
(0.004ml/ml) human recombinant EGF (10ng/ml), human recombinant insulin 
(5µg/ml), hydrocortisone (0.5µg/ml), epinephrine (0.5µg/ml), triiodo-L-thyronine 
(6.7ng/ml), transferrin (10µg/ml) and retinoic acid (0.1ng/ml); concentrations listed are 
final concentrations after supplementation) (Promocell Heidelberg, Germany). BEAS-
2B and NHBE were cultured in human placental type IV collagen-coated (Sigma, 
Poole, UK)  80cm
2
 tissue culture flasks until confluent. Flasks were coated with 
10µg/cm
2
 collagen in 3% (v/v) glacial acetic acid for 30 minutes at room temperature. 
Collagen was then removed and flasks washed 3 times with 5ml PBS 
 
Cells were passaged by washing with PBS followed by incubation with 2.5ml trypsin-
EDTA (0.05% trypsin for BEAS-2B, 0.025% trypsin for NHBE) (PAA Laboratories 
Ltd, Somerset UK) at 37
°
C (BEAS-2B) or room temperature (NHBE) until 80% of cells 
were detached. Trypsin was inactivated by addition of 5ml fully supplemented airway 
epithelial cell culture media. Cells were pelleted by centrifugation at 220xg for 4 
minutes, resuspended with 1ml fully supplemented airway epithelial cell media and 
counted using an improved Neubauer haemocytometer, diluted 1:4 in Tryphan blue. 
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2.2.1.2: Epithelial cell culture on Transwell
®
 inserts 
 
BEAS-2B and NHBE were seeded onto collagen-coated Transwell
®
 inserts (0.65cm 
diameter, 0.4μm pore size) at 1x105 cells/ml in 300µl airway epithelial cell growth 
medium, with 600µl airway epithelial cell media in the basolateral compartment. On the 
fourth day of culture, cells were grown at ALI by removal of culture media from the 
apical compartment, to induce mucociliary differentiation and, basolateral medium was 
replenished at this point.  The basolateral medium was replenished at 4-5 day intervals 
(cells were cultured on Transwell
®
 inserts for 11-14 days).  
 
2.2.1.3: HPMEC culture 
Normal human pulmonary microvascular endothelial cells (HPMEC) were purchased 
from Promocell (lot 8112001.9 Heidelberg, Germany) and maintained in endothelial 
cell culture media supplemented with manufacturer’s supplement (FCS (0.02ml/ml), 
endothelial cell growth supplement (0.004ml/ml), recombinant human EGF (0.1ng/ml), 
heparin (90µg/ml) and hydrocortisone (1µg/ml), concentrations listed are final 
concentrations after supplementation); and penicillin/ streptomycin (final concentration 
of 5,000 Uml
-1
/5,000μgml-1 respectively). HPMEC were cultured in 25cm2 tissue 
culture flasks until confluent. Cells were passaged by washing with 2ml PBS followed 
by incubation with 1ml trypsin-EDTA (0.04% trypsin) at room temperature until 80% 
of cells were detached. Trypsin was inactivated by addition of 3ml fully supplemented 
endothelial cell culture media. Cells were pelleted by centrifugation at 220xg, 4 
minutes, resuspended with 1ml fully supplemented endothelial cell medium and 
counted using a Neubauer haemocytometer. 
 
2.2.1.4: Co-culture of BEAS-2B cells and HPMEC 
BEAS-2B cells were cultured on collagen-coated Transwell
®
 inserts as described 
above. HPMEC were seeded in 24 well culture plates at 5x10
4
 cells/well in 1ml 
endothelial cell culture media overnight. HMPEC media was replenished with 600µl 
endothelial cell media and BEAS-2B cultured at ALI on Transwell
®
 inserts with a TER 
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of >45Ωxcm-2 were added to the wells. Cells were left for 4 hours to equilibrate prior to 
treatments. 
 
2.2.2: TER 
Airway epithelial cell medium (300µl) was added to the apical compartment of cultures 
grown at ALI and the TER measured using an Epithelial Voltohmmeter with STX2 
chopstick electrodes (World Precision Instruments). Measurements were taken 3 times 
for each well. A blank reading (TER of an empty collagen-coated Transwell
®
 insert) 
was subtracted. TER measurements are expressed as ohms (Ω) x cm2.  
 
2.2.3: FITC-dextran permeability measurements 
 
BEAS-2B and NHBE grown at ALI on Transwell
®
 inserts were treated apically with 
200µl 40kDa FITC-dextran (1mg/ml stock) for 24 hours, on day 0, 4, 7, 11 and 14 of 
culture at ALI. The basolateral (B) and apical (A) media were collected after 24 hour 
incubation; the apical surface of the cells was washed twice with 200µl PBS and the 
washes were collected and combined with the apical medium. Fluorescence was 
determined at an excitation (EX) wavelength of 488nm and emission (EM) wavelength 
of 520nm using a SpectraMax GeminiXS fluorimeter (Molecular Devices). The cell 
monolayer permeability was calculated as the basolateral fluorescence as a percentage 
of total fluorescence (B/(A+B))*100. 
 
2.2.4: Endotoxin content determination of LPS and particles by limulus 
amebocyte lysate (LAL) assay 
 
In order to determine whether particles contained endotoxin contamination the 
endotoxin content of particles (200µg/ml from a 10mg/ml stock, diluted with endotoxin 
free LAL water) was determined with the QCL-1000
®
 Chromogenic LAL Endpoint 
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assay, according to the manufacturer’s instructions. The LAL was also carried out on 
isolated and purchased LPS to determine endotoxin content.  
 
The principle of the QCL-1000
®
 Chromogenic LAL endpoint assay is as follows; a pro-
enzyme the limulus amebocyte lysate, is activated in the presence of endotoxin and 
catalyses the removal of the coloured compound p-nitroaniline (pNA) from a colourless 
substrate (Ac-lle-Glu-Ala-Arg-pNA). The amount of pNA released is measured 
spectrophotometrically (405-410nm) and is proportional to the amount of endotoxin 
present.  Endotoxin standard (25 endotoxin units (EU) EU/ml) was used to create a 
standard curve with a low standard of 0.1EU/ml and high standard of 1EU/ml. Results 
are expressed as endotoxin content in EU/ml.  
 
2.2.4: IL-8/IL-6 Enzyme-linked immunosorbent assay (ELISA) 
 
Apical and basolateral media from LPS- or particle-treated cells were analysed for IL-8 
or IL-6 by ELISA (IL-8; 900-K18, IL-6; 900-K16, Peprotech, London, UK). A Nunc 
maxisorb ELISA plate was coated overnight at 4°C with 0.5µg/ml goat-anti human IL-8 
or 1µg/ml goat-anti human IL-6 (100µl/well) in 0.05M carbonate/bicarbonate buffer 
(Sigma, C3041) and subsequently washed 3 times with 200µl wash buffer (0.05% (v/v) 
Tween-20 in saline, and blotted dry. The plate was then blocked for 1 hour at room 
temperature with 300µl/well 1% (weight/volume, w/v) BSA in PBS. After blocking the 
plate was washed 3 times as above and incubated with 100µl/well standards and 
samples for 2 hours at room temperature. The IL-8 standard curve consisted of 
recombinant human IL-8 diluted in reagent diluent (0.05% (v/v) Tween-20, 0.1 % (w/v) 
BSA in PBS) to the following concentrations; 10,000pg/ml, 2000pg/ml, 1000pg/ml, 
500pg/ml, 250pg/ml, 125pg/ml, 62.5pg/ml and 0pg/ml. The IL-6 standard curve 
consisted of recombinant human IL-6 serially diluted in reagent diluent (0.05% (v/v) 
Tween-20, 0.1 % (w/v) BSA in PBS) with a high standard of 2000pg/ml. The plate was 
then washed as above and incubated with 100µl/well 0.25µg/ml biotinylated goat anti-
human BD-2 IL-8 or 0.25µg/ml biotinylated goat anti-human IL-6 for 2 hours at room 
temperature, followed by 3 times washing as above and incubation with 100µl/well 
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avidin-HRP (1:2000) for 30 minutes at room temperature. The plate was washed 3 
times as above before incubation with 100µl/well SigmaFast o-phenylenediamine 
(OPD). Colour development was stopped by addition of 50µl/well 1M HCL and 
absorbance read using a BioTek EL800 microplate reader (BioTek instruments, 
Bedfordshire, UK) at 490nm. Sample IL-8 and IL-6 concentration was extrapolated 
from the standard curve and expressed as pg/sample by correction for sample volume.  
 
  
2.2.6: CellTiter-Blue
®
 viability assay 
After LPS- or particle-treatment matter incubation, cell viability was assessed using the 
CellTiter-Blue
®
 viability assay. The principle of the assay is as follows: after treatment 
cells are incubated with the non-fluorescent CellTiter-Blue
®
 solution containing 
resazurin. Viable cells metabolically reduce resazurin into the fluorescent resorufin, 
which is released into the culture medium. After incubation with LPS or particles 
supernatants were removed and cleared at 295xg for 2 minutes and stored at -20°C. 
Cells were incubated with CellTiter-Blue
®
 (diluted 1:5 in appropriate cell culture 
medium) for 4 hours at 37°C in the dark. For co-culture studies Transwell
®
 inserts 
containing BEAS-2B were removed to separate wells so so that viability of each 
compartment could be assessed separately. After incubation with CellTiter-Blue
®
, 
supernatants from Transwell
®
 inserts were removed to a 96 well plate and fluorescence 
measured at Ex560nm, Em590nm using a SpectraMax GeminiXS fluorimeter 
(Molecular Devices).  Supernatants from HPMEC cells were measured in situ.  
 
2.2.7: Effect of LPS or particle treatment on BEAS-2B TER 
Westmoreland et al., (1999) observed that sodium carbonate as a positive control for 
airway damage induced a significant time dependent reduction in TER, which 
correlated to loss of viability using MTT. TER was therefore used in the current study 
to investigate the effects of PM or LPS on the airways epithelium barrier. Triton X-100 
was used as a positive control of barrier disruption and did not interfere with 
volthometry. Prior to LPS or particulate matter challenge airway epithelial cell medium 
(300µl) was added to the apical compartment of BEAS-2B cultured at ALI and TER 
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measured using an Epithelial Voltohmmeter with STX2 chopstick electrodes (World 
Precision Instruments). Measurements were taken 3 times for each well. After treatment 
of BEAS-2B at ALI with LPS or particles supernatants were collected and the apical 
surface of cells was washed gently with 100µl airway epithelial cell medium. After 
washing, fresh airway epithelial cell medium (300µl) was added to the apical 
compartment of cultures and TER was determined as above. Results are expressed as 
the TER percentage of control taken before treatment, and the TER percentage of 
control taken after treatment.  
 
 2.2.8: Statistical analysis 
Statistical analysis was undertaken using one-way ANOVA with Tukey’s post test and 
represented at mean ± standard error of the mean (SEM) where experiments were 
conducted at least 3 times and where with a replicate 3 wells were used per treatment. 
Standard deviation (SD) was used where there were less than 3 experimental replicates 
taken, or where in a given replicate the treatments were carried out once only (where 
stated).  
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Chapter 3: Suitability of BEAS-2B and NHBE as in vitro cell models of 
the human airways 
67 
 
3.1: Rationale 
The bronchial epithelial cell line BEAS-2B are widely used as an in vitro model of the 
human airway epithelium under submerged culture conditions, however, the 
morphology of these cells at ALI is not well defined. This study aims to compare and 
contrast the BEAS-2B bronchial epithelial cell line with primary, non-transformed 
NHBE as in vitro models of the human airways cultured at ALI. A suitable culture 
media for co-culture of epithelial cells at ALI with human primary pulmonary 
microvascular endothelial cells has also been investigated. 
 
Cells were cultured at ALI on Transwell
®
 inserts to induce differentiation and were 
characterised by measurement of TER and barrier permeability to indicate the presence 
of a functioning tight barrier. Expression of the tight junction protein ZO-1 and the 
epithelial cell markers cytokeratin 5 and 8 was also investigated. In this system NHBE 
failed to form a functioning tight barrier with tight junction protein expression, and cell 
populations expressed mesenchymal cell markers. BEAS-2B cultured at ALI show 
cytokeratin expression patterns comparable to the airway epithelium in vivo. A 
functioning tight barrier was formed by BEAS-2B with evidence of tight junction 
protein expression and distribution to cell margains.   
 
The morphology of BEAS-2B cells, when cultured at ALI, indicates that these cells 
may be a representative model of the airway epithelium and were used in 
epithelial/endothelial cell co-culture. Endothelial cell culture media was found to be a 
suitable culture media for both cell types without effect on BEAS-2B barrier function. 
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3.2: Introduction 
Both the airways epithelium and endothelium are involved in recruitment of leukocytes 
to the airways after pathogenic or toxic challenge (Bals & Hiemstra, 2004; Danese et 
al., 2007), co-culture of these cells may therefore be valuable in the study of airways 
inflammation after challenge. Casale & Coralan, (1999) characterised a model whereby 
A549 were seeded on the underside of a Transwell
®
 insert and human umbilical vein 
endothelial cells (HUVEC) were seeded in the apical compartment of the insert. 
Chemoattractants were placed in the basolateral compartment and migration of 
granulocytes from the apical compartment to the basolateral compartment.  
 
Choudhury et al., (2010) constructed an epithelial/endothelial cell co-culture with 
16HBE14o and HUVEC in the same orientation as Casale and Corolan, (1999) to 
investigate the effect of endothelial cells on epithelial cell membrane permeability. 
They observed an increased TER in the co-culture model that is greater than the sum of 
the monoculture TER. Using conditioned media from HUVEC cultures Choudhury et 
al., (2010) identified that an endothelial cell secreted mediator is responsible for this 
increase in TER, as conditioned media treatment of 16HBE14o induced an increase in 
TER to levels observed in the co-culture. This study demonstrates that epithelial cell 
morphology in influenced by the presence of endothelial cells.  
 
A further example of an epithelial/endothelial cell co-culture where the epithelial cells 
(in this case H292 epithelial cells) are cultured on the underside of a Transwell® insert 
with HUVEC endothelial cells in the apical compartment is the model described by Mul 
et al., (2000). Mul et al., (2000) observed that in monoculture negligible amounts of IL-
6 are secreted from either cell types, whilst IL-8 is secreted from the epithelial cells 
only (under unstimulated conditions). In co-culture, however, the basal levels of IL-8 
and IL-6 secretion are significantly greater than the epithelial cells alone, highlighting 
the influence of endothelial cells on epithelial cell cultures. 
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Little research has been conducted into the morphology of BEAS-2B, a cell line derived 
from normal epithelial cells, at ALI.  Co-culture of these cells at ALI with human 
pulmonary epithelial cells would be a novel model of the airways in vivo. An immediate 
aim was to therefore characterise the suitability of BEAS-2B cells cultured at ALI as a 
model of the airways epithelium in vivo compared to NHBE cells. Cytokeratin 
expression profiles (basal epithelial cells express cytokeratins 5 and 14 whilst 
differentiated pseudo-columnar cells express cytokeratins 7,8,13 and 19 (Iyonaga et al., 
1997)), barrier function, tight junction formation and mucin secretion are investigated 
and directly compared to NHBE cells which undergo mucociliary differentiation. A 
suitable culture media for construction of an epithelial/endothelial cell co-culture model 
(Figure 3.1) with epithelial cells at ALI has been investigated. 
 
 
 
Figure 3.1: Schematic diagram of BEAS-2B/ human pulmonary microvascular endothelial 
cell co-culture developed in this chapter. BEAS-2B cultured at ALI on Transwell
®
 Inserts in 
co-culture with HPMEC in the basolateral compartment of the well.  
 
Test culture media 
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3.3: Methods 
3.3.1: Characterisation of epithelial cell and endothelial cell cultures  
BEAS-2B and NHBE cells were seeded onto human placental type IV collagen-coated 
(for collagen coating protocol refer to 2.2.1) (10µg/cm
2
) 4-well slides at 5x10
4
 cells/ml 
in 200µl airway epithelial cell medium and cultured until confluent, or on Transwell
®
 
inserts (refer to section 2.2.1.2). Immunohistochemical staining on Transwell
®
 inserts 
was undertaken when a differentiated monolayer was formed as indicated by TER (see 
section 2.2.2) measurements (when a TER of >45 Ω x cm2 was reached, typically after 
11  days of culture at ALI). HPMEC were seeded onto un-coated 4 well slides at 5x10
4
 
cells/ml in 200µl endothelial cell medium.  Cells on Transwell
®
 inserts and 4 well slides 
were fixed with 100µl 100% methanol (pre-cooled) for 20 minutes at -20°C and washed 
3 times with 200µl PBS. Cells were then permeabilised with 100µl 0.1% (v/v) Triton 
X-100 in PBS for 30 minutes at room temperature followed by 3 washes with 200µl 
PBS. Cells were then blocked with 100µl 1% (v/v) normal goat serum in PBS for 1 
hour at room temperature followed by an additional 3 washes with 200µl PBS. Cells 
were incubated with 100µl primary mouse monoclonal anti-cytokeratin antibodies, 
mouse monoclonal anti-fibroblast surface antigen, mouse monoclonal anti-Muc5AC, 
mouse monoclonal anti-vimentin, mouse monoclonal anti-ZO-1, mouse monoclonal 
anti-VWF or isotype-matched control in 1% BSA (w/v) in PBS or 1% BSA in PBS 
alone overnight at 4
°
C. Cells were then washed 3 times with 200µl PBS and incubated 
with 100µl goat anti-mouse FITC-conjugated secondary antibody diluted 1:100 in 1% 
BSA in PBS for 1 hour at 4°C. Cells were washed a final 3 times with 200µl PBS and 
mounted with hard set mounting medium containing DAPI (1 drop/well/insert) and left 
to set for 48 hours at 4°C in the dark. Images were taken on a Zeiss Axiovert 200M 
fluorescent microscope using objective 63 (magnified 63 times) with a DAPI filter 
(exposures of 5-20ms) and a FITC filter (exposures of 50-150ms). ZO-1 images were 
taken at the most apical surface of cells. 
 
3.3.2: TER and FITC-dextran permeability measurements 
TER and FITC-dextran measurements were undertaken as detailed in sections (2.2.2) 
and (2.2.3) respectively. 
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3.3.3: Mucin identification using antibodies to muc5AC 
Apical secretions from BEAS-2B or NHBE were collected by gentle pipettng followed 
by 50µl PBS wash (added to apical secretion). Samples were cleared of cell debris by 
centrifugation (295xg for 2 minutes) and stored at -20° prior to analysis. Porcine gastric 
mucin standard, BSA (as a negative control), samples of fully supplemented airway 
epithelial cell medium and serum-free medium (as blanks), and apical secretions were 
blotted onto a nitrocellulose membrane using a hybridisation manifold under vacuum 
(total volume of 50µl/well for each sample). The membrane was subsequently blocked 
in tris-buffered saline with 0.05% (v/v) Tween-20 (TTBS) with 3% (w/v) BSA prior to 
overnight incubation with primary mouse monoclonal anti-muc5AC antibody (diluted 
1:500 in TTBS with 0.3% (w/v) BSA), at room temperature. The membrane was 
washed 3 times with TTBS for 15 minutes per wash, prior to incubation with HRP-
conjugated sheep anti-mouse antibody (diluted 1:5000 in TTBS with 0.3% (w/v) BSA) 
for 1 hour 30 minutes at room temperature. After a further 6 times ten minute washes 
with TTBS the membrane was treated with Immobilon
®
 ECL and exposed to film for 3 
minutes prior to being visualised with Kodak GBX developer and fixer.    
 
3.3.4: Barrier integrity of BEAS-2B cultured in endothelial cell culture 
medium 
BEAS-2B were cultured on collagen-coated Transwell
®
 inserts (as described in section 
2.2.1.2). On day 0 of culture at ALI basolateral media was replenished with either 
600µl airway epithelial cell media or 600µl endothelial cell culture medium. Barrier 
integrity was measured during culture at ALI in both culture media using TER and 
FITC-dextran permeability as described above.  
 
3.3.5: Co-culture of BEAS-2B cells and HPMEC cells 
BEAS-2B were co-cultured with HPMEC as described in section 2.2.1.4. 
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3.4: Results 
 
3.4.1: Submerged populations of BEAS-2B express both epithelial cell markers 
cytokeratin 5 and cytokeratin 8  
In order to identify basal cells within populations of BEAS-2B and NHBE, cells were 
grown under submerged conditions and expression of the epithelial cell-specific 
markers, the cytokeratins 5 and 8, has been analysed. The results show that, under 
submerged conditions BEAS-2B express both the basal cell marker cytokeratin 5 
(Figure 3.2A), and the differentiated cell marker cytokeratin 8 (Figure 3.2B).  Under 
submerged conditions NHBE cells showed only non-specific staining (for controls see 
10.1.2.3) using antibodies against both the epithelial cell markers cytokeratin 5 (Figure 
3.2C) and cytokeratin 8 (Figure 3.2D).  
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A)          B)  
                BEAS-2B 
 
C)      D)     
             NHBE 
  
Figure 3.2: Submerged cultures of BEAS-2B express both epithelial cell markers 
cytokeratin 5 and cytokeratin 8. BEAS-2B (A and B) and NHBE (C and D) were seeded 
on collagen-coated 4 well slides at a density of 5x10
4
cells/ml and grown to confluence for 3 
days. Cells were fixed with 200µl pre-cooled methanol, permeabilised with 0.1% Triton X-100 
in PBS and blocked with 1% (v/v) normal goat serum in PBS, as described in 3.3.1.  Cells were 
then incubated with mouse-monoclonal antibody to cytokeratin 5 (A and C) or, cytokeratin 8 (B 
and D) at 1:250 in 1% (w/v) BSA in PBS, overnight at 4
°
C. Cells were then washed and 
incubated with FITC-conjugated goat anti-mouse secondary antibody (1:100 in 1% (w/v) BSA 
in PBS) for 1 hour at room temperature. Cells were mounted in DAPI and images taken using 
Zeiss Axiovert 200M fluorescent microscope, images are representative of 4 separate 
experiments for BEAS-2B, bar size is 16µm. 
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3.4.2: BEAS-2B cultured at ALI express both basal and differentiated epithelial 
cell markers.  
In order to investigate whether differentiated populations of BEAS-2B and NHBE, cells 
were grown on collagen-coated Transwell
®
 inserts at ALI, an analysis of the expression 
profile of the cytokeratins undertaken. Figure 3.2 shows that, when grown at ALI, 
BEAS-2B express the markers for basal and differentiated epithelial cells (cytokeratin 5 
(Figure 3.3A) and cytokeratin 8 (Figure 3.3B) respectively).  When cultured at ALI, 
NHBE cell populations consist of very few cytokeratin 5 positive basal epithelial cells 
(Figure 3.3C), however, a larger population of cytokeratin 8 positive differentiated 
epithelial cells was observed (Figure 3.3D and E).  Figures 3.3D and E are Z- stack 
images moving through the multiple cell layers for the same population of NHBE cells, 
and show that cytokeratin 8 positive, differentiated epithelial cells are dispersed 
throughout the cell population. 
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 Cytokeratin 5    Cytokeratin 8 
A)     B)    
       BEAS-2B 
C)     D) 
       NHBE 
E) 
         NHBE 
Figure 3.3: BEAS2B cultured at ALI express both basal and differentiated epithelial cell 
markers. BEAS-2B (A and B) and NHBE (C, D and E) were seeded on collagen-coated 
Transwell
®
 inserts at a density of 1x10
5
 cells/ml and cultured at ALI to induce differentiation. 
Cells were fixed with 200µl methanol at -20
°
C after which the membranes were excised. 
Blocking was achieved with 1% (v/v) normal goat serum in PBS and cells were permeabilised 
with 0.1% (v/v) Triton X-100 in PBS, as described in 3.3.1.  Cells were then incubated with 
mouse-monoclonal antibody to cytokeratin 5 (A and C) or cytokeratin 8 (B, D and E) diluted 
1:250 in 1% (w/v) BSA in PBS overnight at 4°C. Cells were washed and incubated with FITC-
conjugated goat anti-mouse secondary antibody (1:100 in 1% (w/v) BSA in PBS) for 1 hour at 
room temperature Cells were mounted in DAPI and images taken using Zeiss Axiovert 200M 
fluorescent microscope, images are representative of 4 separate experiments for BEAS2B and 3 
separate experiments for NHBE. D and E are images separated from a z-stack whereby D was 
taken at the bottom of the cell populations and E at the top. Bar indicates 16µm. 
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3.4.3: BEAS-2B cultured at ALI express the tight junction protein ZO-1 at the site 
of cell-cell contact.  
As part of the respiratory defence system, differentiated epithelia produce a tight barrier 
against pathogens by formation of tight junctions between neighbouring cells. In order 
to characterise the differentiation of BEAS-2B and NHBE grown at ALI on Transwell
®
 
inserts, staining for the tight junction protein, ZO-1, was undertaken.  An investigation 
of the expression of ZO-1 was also undertaken on submerged BEAS-2B and NHBE in 
order to determine whether tight junction formation is specific to cells grown at ALI. 
Figure 3.4B indicates that BEAS-2B show ZO-1 localisation at the site of cell-cell 
contact (Figure 3.4B) suggesting tight junction formation in these cells when cultured at 
ALI. Under submerged conditions BEAS-2B express ZO-1, however, there is no 
defined localization of the protein to junctions between neighbouring cells (Figure 
3.4A). No ZO-1 staining was observed in NHBE cells cultured under submerged 
conditions (Figure 3.4C), whilst punctate staining was observed when cells cultured at 
ALI were stained (Figure 3.4D). 
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 Submerged    ALI 
A)     B) 
   BEAS-2B 
C)     D)  
   NHBE 
 
Figure 3.4: BEAS-2B cultured at ALI express the tight junction protein ZO-1 at the site of 
cell-cell contact. BEAS-2B and NHBE were seeded on collagen-coated 4 well slides until 
confluent (A and C) or Transwell
®
 inserts at ALI until a TER of 45Ω x cm2 was reached for 
BEAS-2B (B) or for 11 days for NHBE (D). Cells were fixed with 200µl methanol at -20°C.  
Cells were permeabilised with 0.1% Triton X-100 and blocked with 1% (v/v) normal goat 
serum in PBS before overnight incubation with mouse-monoclonal antibody to ZO-1 diluted 
1:250 in 1% (w/v) BSA in PBS at 4°C. Cells were washed with PBS and incubated for 1 and 
half hours with FITC-conjugated goat anti-mouse secondary antibody (1 in 100 in 1% (w/v) 
BSA in PBS) at 4°C. Cells were mounted in DAPI and images taken using Zeiss Axiovert 
200M fluorescent microscope. Images are representative of 3 separate experiments. Bar 
indicates 16µm.  
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3.4.4: TER of BEAS-2B increases and FITC-dextran permeability decreases 
during culture at ALI.  
Functional assessment of barrier integrity of epithelial cell cultures on Transwell
®
 
inserts can be investigated using TER, which measures the electrical resistance through 
the paraceullar pathway (between apical and basolateral compartments of cells grown 
on Transwell
®
 inserts). As a tight barrier is formed the electrical resistance increases. 
Decreased permeability of the epithelial cell monolayer to solutes is also an indicator of 
barrier formation. 
 
During culture at ALI BEAS-2B form a functioning tight barrier as TER increases with 
time (Figure 3.5). By day 11 of culture at ALI BEAS-2B have a TER of 79±26 Ω x 
cm
2
; however, at this time of culture the TER was extremely variable. By day 14 at 
ALI, TER was significantly increased compared to day 0 ALI. Permeability of BEAS-
2B to 40kDa FITC-dextran significantly decreased (P<0.01) during culture at ALI 
compared to day 0 ALI, with only 20.7±3.6% of FITC-dextran permeating the cell 
monolayer by day 11 of culture at ALI. 
 
NHBE cells cultured at ALI failed to form a functioning tight barrier as indicated by the 
lack of increase in TER, or reduction in FITC-dextran permeability, when seeded at the 
same cell density as BEAS-2B (1x10
5
/ml, Figure 3.5B). Indeed the FITC-dextran 
permeability at day 14 ALI (78.9±23.8%) was similar to that of a collagen-coated insert 
without cells (93±2.4%). TER of these cells at day 0 ALI was 27±4 Ω x cm2; this stayed 
stable during culture at ALI with cells having a TER of 28±4 Ω x cm2 at day 14 ALI 
(Figure 5B).  
 
When seeded at the higher cell density of 2.5x10
5
/ml NHBE cells again failed to build 
up a functioning tight barrier with a TER of 20±12 Ω x cm2 on day 0 ALI which 
showed a non-significant decrease to 12±7Ω x cm2 by day 11 of culture at ALI. 
Permeability of NHBE to the solute FITC dextran at day 0 of ALI was 36.7±3.6%, but 
this did not change significantly (34.2±2.2% by day 11 ALI, Figure 3.5C). 
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Figure 3.5: TER of BEAS-2B but not NHBE cells increases and FITC-dextran 
permeability decreases during culture at ALI. BEAS-2B (A) and NHBE (B and C) were 
seeded on collagen-coated Transwell
®
 inserts at a density of 1x10
5
/ml (A and B) or 2.5x10
5
/ml 
(C) in 300μl medium. On the fourth day of culture, apical medium was removed and cells were 
grown at ALI (Day 0). TER measurements were taken at day 0, 4, 7, 11 and 14 of culture (black 
columns), using an empty Transwell
®
 insert as a blank (see section 2.2.2). After TER 
measurements were conducted, cells were incubated for 24 hours with 200μl FITC-dextran 
(1mg/ml stock) and fluorescence of apical and basolateral medium was measured at excitation 
488nm emission 520nm (see section 2.2.3). FITC-dextran permeability of an empty collagen-
coated Transwell
®
 insert is 93±2.4%. Permeability is calculated as FITC-dextran in the 
basolateral compartment as a percentage of total fluorescence (white columns). N=3. Data are 
expressed as mean ± standard deviation (SD) * P <0.05 compared to TER at day 0 ALI, ++ 
P<0.01 compared to FITC-dextran in the basolateral compartment permeability at day 0 ALI.  
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3.4.5: NHBE cultured at ALI secrete muc5AC 
The mucociliary escalator plays a vital role in protection of the airways from inhaled 
pathogens and particulates. In order to determine whether BEAS-2B or NHBE cultured 
at ALI secrete mucin, apical secretions were gently collected from the apical surface of 
cells during culture at ALI (up to day 14) and stored at -20°C. Once all samples were 
collected, apical secretions were pooled, and a dot blot for the major airways mucin 
muc5AC was performed. The presence of muc5AC in BEAS-2B secretions was not 
detected, however muc5AC was detected in apical secretions from NHBE apical 
secretions (Figure 3.6).  
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Figure 3.6: NHBE cultured at ALI secrete muc5AC.Apical secretions were collected from 
BEAS-2B and NHBE cultured at ALI and transferred to nitrocellulose membrane using a 
hybridization manifold under vacuum. Porcine gastric mucin was used as a standard, BSA, PBS 
and quiescent airway epithelial cell media (QAEM) serve as negative controls. Membranes 
were blocked with 3% (w/v) BSA in TTBS prior to incubation with anti-muc5AC antibody 
overnight (1:500 in 0.3% (w/v) BSA in TTBS). Membranes were incubated with HRP-
conjugated sheep anti-mouse secondary antibody (1:5000 in 0.3% (w/v) BSA in TTBS) for 1.5 
hours before incubation with ECL and visualisation via exposure to X-ray film for 3 minutes. 
Image is representative of 3 separate experiments for standard curve and BEAS-2B secretion, 
and 2 separate experiments for NHBE secretions.  
PBS 
10µg mucin 
7.5µg mucin 
5µg mucin 
2.5µg mucin 
1.25µg mucin 
QAEM 
BEAS-2B 
NHBE 
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3.4.6: Evidence for epithelial to mesenchymal transition in NHBE cultures. 
Since NHBE cells failed to form a functioning tight barrier, measured by both barrier 
permeability and formation of tight junctions, and had very few epithelial cells in the 
cell population (as indicated by cytokeratin staining), EMT in NHBE cells was 
investigated. Cells both under submerged conditions and at ALI were stained for the 
EMT marker vimentin, and for the fibroblast surface antigen. Cells were also stained 
with anti-Mmuc5AC, as there is evidence of mucin secretion at ALI, to identify mucus 
secreting cells and therefore define an epithelial population. Submerged and ALI cells 
were stained to investigate whether culture condition favours growth of any epithelial 
cells rather than transformed mesenchymal cells.   
 
NHBE cells under both culture conditions were positive for fibroblast surface antigen 
(Figure 3.7A and 3.7B) and the EMT marker vimentin (Figure 3.7C and D). Non-
specific staining similar to that observed with isotype control (see section 10.1.2.3) was 
observed when NHBE cells were stained with antibody against muc5AC, regardless of 
culture conditions (Figure 3.7E and 3.7F). 
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Submerged culture   Culture at ALI 
A)     B) 
  
C)     D)  
  
E)     F) 
  
Figure 3.7: Evidence for EMT in NHBE cultures. NHBE were seeded on collagen-coated 4 
well slides until confluent (A, C & E) or Transwell
®
 inserts at ALI (B, D & F) for 11 days. 
After fixing, cells were permeabilised with 0.1% (v/v) Triton X-100 and blocked with 1% (v/v) 
normal goat serum in PBS before overnight incubation with mouse-monoclonal antibody to 
fibroblast surface antigen (A and B),  vimentin (C and C) or muc5AC (E and F), diluted 1:250 
in 1% (w/v) BSA in PBS at 4°C. Cells were washed with PBS and incubated for 1 and half 
hours with FITC-conjugated goat anti-mouse secondary antibody (1:100 in 1% (w/v) BSA in 
PBS) at 4°C. Cells were mounted in DAPI and images taken using Zeiss Axiovert 200M 
fluorescent microscope. Images are representative of 3 separate experiments. Bar indicates 
16µm. 
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3.4.7: Expression of VWF in HPMEC cultures.  
The purity of primary HPMEC was determined by expression of the specific endothelial 
cell marker VWF. As HPMEC cells will be used in co-culture experiments they were 
also examined for expression of the epithelial cell markers cytokeratin 8 and 5, to 
ensure no epithelial cell contamination. The results show that HPMEC stocks were 
positive for the endothelial cell marker VWF with localisation consistent that is 
vesicular (Figure 3.8A) and negative for both epithelial cell markers, cytokeratin 5 
(Figure 3.8C) and cytokeratin 8 (Figure 3.8D). HPMEC stained with antibody isotype 
matched control (IgG1) were negative for cell staining (Figure 3.8B). 
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A)      B) 
    
C)      D) 
   
 
Figure 3.8: Expression of VWF in HPMEC cells. HPMEC were seeded on 4 well slides and 
cultured until confluent. Cells were fixed with 200µl methanol at -20°C, permeabilised with 
0.1% (v/v) Triton X-100 and blocked with 1% (v/v) normal goat serum in PBS before overnight 
incubation with mouse-monoclonal antibody to VWF (A), IgG1 (B) cytokeratin 5 (C) or 
cytokeratin 8 (D), diluted 1:250 in 1% (w/v) BSA in PBS at 4°C. Cells were washed with PBS 
and incubated for 1 and half hours with FITC-conjugated goat anti-mouse secondary antibody 
(1:100 in 1% (w/v) BSA in PBS) at 4°C. Cells were mounted in DAPI and images taken using 
Zeiss Axiovert 200M fluorescent microscope. Images are representative of 3 separate 
experiments. 
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3.4.8: BEAS-2B cultured at ALI in endothelial cell medium maintain barrier 
integrity. 
 
Once constructed, the co-culture will consist of BEAS-2B cultured at ALI and HPMEC 
in the basolateral compartment of the 24 well companion plate into which the 
Transwell
®
 insert is submerged (Figure 3.1). In this model the basolateral medium of 
the Transwell
®
 insert will be shared between HPMEC and BEAS-2B, therefore a single 
medium suitable for both BEAS-2B and HPMEC culture is required. As culture of 
BEAS-2B at ALI has been shown to be stable it was investigated whether these cells 
would maintain barrier integrity if cultured with endothelial cell culture medium.   
 
Culture of BEAS-2B in endothelial cell medium for either 5 or 8 days had no 
significant effect on TER. After 8 days of culture at ALI, TER in epithelial cell medium 
was 45±6 Ω x cm2 and 46±8Ω x cm2 in endothelial cell culture medium. Similarly 
FITC-dextran permeability through the cell layer was unaffected by culture in 
endothelial cell medium compared to culture in airway epithelial cell medium. FITC-
dextran permeability was 13.7±2% in endothelial cell medium and 16.5±1.7 in airway 
epithelial cell medium at day 8 of culture at ALI (Figure 3.9). 
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Figure 3.9: BEAS-2B cultured at ALI in endothelial cell medium maintain barrier 
integrity. BEAS-2B were seeded on collagen-coated Transwell
®
 inserts at a density of 
1x10
5/ml in 300μl media. On the fourth day of culture, apical medium was removed and cells 
were grown at ALI (day 0) in either airway epithelial cell culture medium (black bars) or 
endothelial cell culture medium (clear bars). A) TER measurements were taken at day 5 and 8 
of culture, using an empty Transwell
®
 insert as a blank (see section 2.2.2). After TER 
measurements were conducted cells were incubated for 24 hours with 200μl FITC-dextran (B). 
Apical and basolateral media was then recovered and fluorescence measured at excitation 
488nm emission 520nm and expressed as basolateral fluorescence as a percentage of total 
fluorescence. FITC-dextran permeability of an empty collagen-coated Transwell
®
 insert is 
93±2.4%. Results are expressed as FITC-dextran in the basolateral compartment as a percentage 
of total fluorescence (white columns). N=4. Data are expressed as mean ± SEM.  
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3.5: Discussion 
BEAS-2B cells are widely used under submerged conditions as an in vitro model of 
human airways epithelium, especially in inhalation toxicity studies (Cha et al., 2007; 
Noah et al., 1995; Petacchia et al., 2009, Veranth et al., 2007). However the 
morphological features of these cells when cultured at ALI are less well characterised 
compared to NHBE. The present study has evaluated the differentiation phenotype, and 
thus suitability of BEAS-2B as a model of the airway epithelium. BEAS-2B 
differentiation, measured by means of cytokeratin expression, tight junction and barrier 
formation, and mucin secretion were directly compared to NHBE grown at ALI. 
 
Results from the current study culturing NHBE at ALI failed to replicate those by other 
authors whereby a pseudostratified ciliated mucus-secreting epithelium with tight 
junctions have been observed (Keisemer et al., 2009; Lin et al., 2007, Ross et al., 2007; 
Sajjan et al., 2008).  In the current study NHBE cells cultured at ALI failed to form 
tight junctions as evident by ZO-1 staining and did not show increasing TER whereas 
Lin et al., (2007) observed a maximal TER of 766±154 Ω x cm2 with these cells. The 
presence of retinoic acid in cell culture media and culture on a collagen substratum have 
both been shown to enhance epithelial cell differentiation (Gray et al., 1996, Wu et al., 
1997), however,  culture conditions in the current study include both retinoic acid as a 
component of the culture medium and a collagen basement membrane on the 
Transwell
®
 insert.  
 
Initially in the current study NHBE were seeded on the inserts at a density of 1x10
5
 
cells/ml. Culturing NHBE at a higher seeding density as used by Lin et al., (2007) 
resulted in a lower percentage permeability of FITC-dextran (34.19±2.19%) at day 11 
of culture at ALI. However, the TER again was low (12.07±6.68 Ω x cm2). These 
results suggest that FITC-dextran permeability is at least in part influenced by cell 
number as at the higher cell density NHBE failed to increase TER and were negative 
for tight junction staining as measured by ZO-1.    
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It is possible that the NHBE cells underwent EMT, due to stress, which would explain 
the lack of tight junction formation and failure of NHBE to produce increasing TER at 
ALI. EMT was therefore investigated in NHBE submerged and ALI cultures by 
staining for vimentin and fibroblast surface antigen. Under both culture conditions 
NHBE cells were positive for both EMT markers. The lack of epithelial cell markers 
under submerged conditions may indicate that in these conditions mesenchymal cells 
outgrow epithelial cells whereas culture at ALI allows for some epithelial cell growth as 
there was presence of few cytokeratin 5 cells with a larger cyokeratin 8 population in 
NHBE at ALI. Furthermore mucin was observed in apical secretion of NHBE at ALI, 
despite immunohistochemical analysis failing to show mucin positive cells.  The 
presence of an underlying population of mesenchymal fibroblasts within initial cell 
cultures which outgrew epithelial cells may account for the presence of vimentin and 
fibroblast surface antigen positive cells in NHBE cultures, or cells may have undergone 
EMT due to the stress, possibly as a result of sub-optimal culture conditions. 
 
The current study aimed to characterise the suitability of BEAS-2B at ALI as an in vitro 
model of the human airways by direct comparison to NHBE cells, however, as NHBE 
cells in the current study contained large populations of mesenchymal cells results 
obtained with BEAS-2B will be compared to current literature of epithelial cell culture 
at ALI. 
 
Under submerged conditions, BEAS-2B expressed both the basal epithelial cell marker 
cytokeratin 5 and the differentiated epithelial cell marker cytokeratin 8. The presence of 
cytokeratin 8 expression in BEAS-2B cells under submerged conditions suggests that 
these cells are at least in part differentiated. This may be a consequence of their 
transformation with the SV40 virus, as transformed cells often do not express the 
characteristics of primary cells (Forbes and Ehrhardt, 2005). In support of this 
hypothesis Morris et al., (1985) observe a change in cytokeratin expression in SV40 
transformed keratinocytes whereby decreased expression of cytokeratins 5, 10, 14 16 
and 20 was observed compared to non-transformed keratincytes. Furthermore, 
transformed keratinocytes showed increased expression of cytokeratins 18 and 19 
(Morris et al., 1985).  
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BEAS-2B also express both cytokeratin 5 and 8 when cultured at ALI indicative of a 
differentiated cell phenotype with a basal cell population. The maintained expression of 
cytokeratin 5 in BEAS-2B cultured at ALI suggests the presence of a basal cell 
population indicating that BEAS-2B when cultured at ALI are representative of the 
respiratory epithelium in vivo and are comparable to NHBE cultured on ALI where 
basal cell populations alongside differentiated mucociliary cells have been observed 
(Bonnans et al., 2006; Lin et al., 2007). However, the suggestion that BEAS-2B may be 
partially differentiated anyway means that caution is warranted in analysis of results. 
Further investigations are required to determine whether BEAS-2B at ALI are indeed 
pseudo-columnar differentiated epithelial cells. The presence of ciliated cells in BEAS-
2B cultures at ALI was not investigated in the current study. Results from a mucin dot 
blot detecting the mucin muc5AC in apical secretions show that the BEAS-2B did not 
differentiate into mucus secreting goblet cells.  Mucin secretion by BEAS-2B at ALI 
has not been previously reported, however muc5AC expression in submerged cultured 
of BEAS-2B was shown to be non-significantly increased by treatment with 50nM 
retinoic acid whilst untreated cells showed no muc5AC expression (Kuntz et al., 2006). 
Future work could investigate retinoic acid treatment of BEAS-2B at ALI and electron 
microscopy to see whether mucociliary differentiation can be induced. 
 
BEAS-2B showed a trend towards increasing TER during culture at ALI with TER 
reaching significance at day 14 compared to day 0 ALI suggesting that formation of a 
tight barrier (suggestive of differentiation) occurs over a number of days.  Ross et al., 
(2007) show that mucociliary differentiation of NHBE occurs over a period of 21 days 
with the absence of cilia at day 6 of ALI culture but the presence of cilia at 12 days ALI 
culture which may explain the time dependent increase in TER observed here.  The 
results obtained for TER in the current study for BEAS-2B (91.56±47.96 Ω x cm2) are 
low, however, TER correlates poorly to permeability tracers (Tang and Goodenough, 
2003).  Immunohistochemical staining of tight junction proteins was undertaken to give 
further insight into presence of tight junctions in BEAS-2B cultures.  
 
Petacchia et al., (2009) observed ZO-1 staining in submerged cultures of BEAS-2B at 
the site of cell-cell contact and Woo et al., (2008) observed ZO-1 staining in aquaporin 
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5 transfected BEAS-2B at ALI. Results from the current study confirm that under 
submerged conditions BEAS-2B express ZO-1 however the staining pattern is not 
localised to sites of cell-cell contact. When cultured at ALI ZO-1 was localised to sites 
of cell adhesion i.e. sites of tight junctions. To the author’s knowledge this is the first 
time that ZO-1 staining and therefore tight junction formation has been observed in 
wild type non-challenged BEAS-2B cultured at ALI. As tight junctions are the most 
apical junctional complex between neighbouring epithelial cells (Neissen, 2007) the 
sub-cellular localisation ZO-1 may not have occurred at cell junctions in submerged 
cultures of BEAS-2B as they have not undergone differentiation. It would be interesting 
to observe whether localisation of ZO-1 to cell junctions occurs in stages of culture at 
ALI in a similar manner to mucin secretion and cilia formation.   
 
In order to gain a better understanding of the airway inflammation in response to LPS 
and PM an aim of this study is the construction of an epithelial/endothelial cell co-
culture to represent the airways in vivo. To this end primary human HPMEC in mono-
culture were assessed for purity of culture by staining for the endothelial cell specific 
marker VWF as described by Middleton et al., (2005). Cells were shown to be positive 
for staining with VWF, with a punctuate staining pattern. This staining is typical of 
VWF which is stored in secretory granules termed Weibel-Pallade bodies where it acts 
as an endothelial cell specific carrier protein for coagulation factor VIII (van den 
Biggelaar et al., 2009; Rosenberg, 2000). HPMEC populations were negative for the 
epithelial cell markers cytokeratin 5 and cytokeratin 8, indicating that HPMEC were not 
contaminated with epithelial cells. 
There are only a few pulmonary epithelial/endothelial models characterised in the 
literature, further these models focus on using the model for investigation of 
inflammatory cell extravasation, or barrier permeability studies (Casale & Corolan, 
1999; Chowdhury et al., 2010). In these models the epithelial cells are under submerged 
conditions and while this may be appropriate for permeability and infiltration studies, it 
is not appropriate for the current study which aims to investigate airway inflammation 
at ALI. In the current study BEAS-2B are cultured in the apical compartment of a 
Transwell
®
 insert at ALI with HPMEC in the basolateral compartment of the 
companion plate, attached to the companion plate itself. In this model the apical surface 
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of the endothelial cells is in close proximity to the basolateral surface of the epithelial 
cells, and although this orientation is not observed in vivo, it allows for an ALI 
epithelial culture. Future work could focus on characterising a model whereby HPMEC 
are cultured on the underside of the Transwell
®
 insert allowing for basolateral-
basolateral cell surface contact with ALI culture of epithelial cells.  
 
As the BEAS-2B and HPMEC will be sharing the same culture media whilst in co-
culture a suitable media that allows for BEAS-2B barrier integrity and growth of 
HPMEC is required. Effect of culture media in the study of Casale and Coralan, (1999) 
or Chowdhury et al., (2010) was not investigated as in both cases the cells used were 
cell lines rather than primary cells. Whilst the current study has physiological relevance 
as the endothelial cells are primary human pulmonary cells it has the disadvantage that 
primary cells are less robust than cell lines and often require specific manufactured 
culture media. The barrier integrity of BEAS-2B at ALI in endothelial cell culture 
media was therefore investigated. No differences in either TER or FITC-dextran 
permeability were observed when BEAS-2B were cultured in epithelial cell culture 
media or endothelial cell culture media for up to 8 days. Co-culture studies described in 
later chapters of this thesis will therefore include endothelial cell culture media in the 
endothelial cell compartment. 
 
3.6: Conclusion 
The current study aimed to characterise BEAS-2B cultured at ALI as a model of the 
airways epithelium in vivo compared to NHBE cells at ALI. However, NHBE cultures 
in the current study failed to undergo differentiation as measured by tight junction 
formation and barrier integrity. NHBE also contained mesenchymal cell populations, 
either from contaminant cell outgrowth or EMT. BEAS-2B cultured at ALI produced a 
low TER consistent with other reports. BEAS-2B also formed tight junctions as 
measured directly by ZO-1 staining but failed to secrete mucin. Further studies are 
required to investigate whether cilia are formed by BEAS-2B at ALI. As BEAS-2B 
formed tight junctions at ALI with indications of the presence of both basal and 
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epithelial cell populations they were considered a representative model of the airways 
epithelium in vivo.  
 
This study also characterised the purity of HPMEC cultures destined for co-culture 
studies and confirmed that BEAS-2B retain barrier integrity when cultured in 
endothelial cell media at ALI. Together BEAS-2B cultured at ALI with HPMEC in co-
culture are considered as a representative epithelial/endothelial cell model of the human 
airways. This model along with BEAS-2B alone at ALI and HPMEC mono-cultures 
will be used to characterise the effect of LPS and particulate matter exposure in relation 
to inflammatory mediator secretion and identification of biomarkers of toxicity. 
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Chapter 4: LPS stimulation 
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4.1: Rationale 
Culture of epithelial cells at ALI on Transwell
®
 inserts supports the formation of tight 
junctions. Physiological barriers are important to defend the airways against invading 
pathogens. In addition, epithelial cells normally exhibit innate immune response 
properties after challenge. Therefore the propensity for BEAS-2B cells at ALI to 
respond to inflammatory stimuli was investigated. BEAS-2B cultured at ALI are 
sensitive to LPS from E. coli and respond with directional secretion of the inflammatory 
mediators IL-8 and IL-6. ZO-1 localisation to tight junctions in LPS challenged cells 
was disrupted however the integrity of the epithelial barrier was maintained, as 
measured by TER. The BEAS-2B/HPMEC did not produce an inflammatory response 
after E. coli LPS challenge. These results suggest that BEAS-2B at ALI, with and 
without HPMEC, represent a valid model for the study of pathogenic insult to the 
airways epithelium. The co-culture system requires further development.  
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4.2: Introduction 
The airway epithelium serves to protect the airways from invading pathogens by 
forming a protective ion and size selective barrier, via tight junctions (Farquhar and 
Palade, 1963). Epithelial cells cultured on physical supports such as Transwell
®
 inserts 
at ALI, where the apical surface of cells is free of medium and cells receive nutrients 
from a basolateral compartment, can differentiate into mucociliary cells (de Jong et al., 
2003; Gray et al., 1995) which supports formation of tight junctions. Despite having 
morphological features representative of in vivo, submerged cultures of epithelium are 
often utilised for the study of airway inflammation after pathogenic challenge. 
 
Koyama et al., (2000) observed that P. aeruginosa S:10 LPS induces IL-8 secretion 
from A549 cells under submerged conditions. Interestingly, E. coli 0127:B8 LPS 
induced IL-8 secretion from A549 cells to a lesser extent. TLR4/LBP bind the Lipid A 
domain of LPS. Whilst the general structure of LPS is conserved; the degree of 
phosphorylation of the fatty acids, location of fatty acid acyl group and fatty acid chain 
length vary between different species (Rietschel et al., 1994) resulting in differing 
degrees of TLR4 activation and thus different potencies regarding cellular activation.  
Koyama et al., (2000) also reported that  E. coli 0111:B4 LPS induced less IL-8 
secretion from A549 than E. coli 0127:B8 and BEAS-2B responded to E .coli 0111:B4 
LPS (increased IL-8 secretion) only in the presence of serum, a result mirrored in 
experiments undertaken by Schulz et al., (2002). However, Schulz et al., (2002) 
observed that replacement of serum with sCD14, LBP or both failed to result in the 
increased secretion of IL-8 and IL-6 from BEAS-2B as observed with serum and 
suggest that LPS induces inflammatory signalling in BEAS-2B in an undefined CD14-
independent manner.  
 
ALI models have been used to investigate tight junction integrity. Coyne et al., (2002) 
observed that the tight junctions of NHBE cells at ALI are disrupted by 72 hour 
incubation with TNFα and interferon (IFN)γ. Under inflammatory conditions there was 
a decreased number of tight junctional strands (measured by freeze-fracture electron 
microscopy) and a loss of ZO-1 and JAM expression and localisation to the tight 
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junction. It is therefore possible that pathogen-induced inflammation induces disruption 
in airway epithelial cell tight junctions. Therefore, the aim of the current study was to 
investigate the use of BEAS-2B cells cultured at ALI as directional models of 
inflammatory responses of the airway epithelium, measured by phenotype 
charcterisation, barrier function and cytokine secretion after treatment with LPS. The 
response inflammatory response of the BEAS-2B/HPMEC after LPS-challenge was 
also characterised to investigate whether presence of HPMEC alters the BEAS-2B 
inflammatory response.   
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4.3: Methods 
 
4.3.1: LPS isolation from P. aeruginosa and B. cepacia 
In order to test the response of airway epithelial cell cultures to relevant respiratory 
pathogens, LPS was isolated from P. aeruginosa and B. cepacia.  P. aeruginosa and B. 
cepacia, were cultured on commercial blood agar plates overnight at 37°C. A colony of 
each bacterium was used to inoculate a 100ml of sterile nutrient broth which was 
further incubated at 37°C overnight. Following overnight incubation a loop of each 
inoculated broth was streaked out onto sterile agar plates and incubated at 37°C 
overnight to check purity of cultures. Inoculated broth (50ml) was then transferred to 2 
conical flasks containing 2 litres of sterile nutrient broth each and cultured at 37°C on a 
shaker for 48 hours after which 10ml was removed from each flask and from this a loop 
was taken and streaked onto agar plates again to check the cultures for contamination. 
P. aeruginosa and B. cepacia were collected by centrifugation of inoculated nutrient 
broth at 7,871xg for 5 minutes in an Avante JE centrifuge using a JA14 rotor. The 
pellets were then washed once with 50ml sterile water and pelleted again by 
centrifugation at 7,871xg for 5 minutes. Bacterial pellets were then re-suspended in 
100ml sterile water and an equal volume of 80% (v/v) phenol added and stirred at 80°C 
for 30 minutes to lyse cells.  
 
The phenol/bacteria mix was centrifuged at 2,298xg for 20 minutes using a Avante JE 
centrifuge using a JA14 rotor, and the upper phase containing LPS was collected. This 
LPS phenol mix was dialysed in 5 litres non-sterile water for 4 days with 2 water 
changes on the first and fourth day. The dialysate was then collected and 10mM 
magnesium sulphate was added to encourage LPS micelle formation. The LPS was then 
centrifuged in a Beckman Coulter ultracentrifuge for 4 hours at 109,564xg at 4°C using 
a 70Ti rotor. The LPS “jelly like” pellet was resuspended in 10ml sterile water, 
collected into a sterile universal and frozen under liquid nitrogen. The LPS was freeze-
dried overnight, weighed, prepared as 10mg/ml stocks in sterile airway epithelial cell 
culture media and stored at -20°C. 
 
100 
 
4.3.2: LPS endotoxin content determination by LAL assay  
The endotoxin content of LPS isolates was determined using the LAL assay as 
described in section 2.2.4 
 
4.3.3: Cell culture 
4.3.3.1: BEAS-2B and HPMEC mono-culture 
For submerged cell studies, BEAS-2B were seeded onto collagen-coated 24 well plates 
(10µg/cm
2
, see section 2.2.1, at 1x10
5
 cells/well in 1ml airway epithelial cell culture 
medium overnight. For ALI studies BEAS-2B were seeded onto collagen-coated 
Transwell
®
 inserts (as detailed in 2.2.1.2). HPMEC (see 2.2.1.3 for complete 
supplement composition and routine culture) were seeded in 24 well plates (unless 
otherwise stated) at a density of 5x10
4
 cells/well in 1ml endothelial cell medium and 
cultured overnight. 
 
4.3.3.2: Co-culture of BEAS-2B cells and HPMEC cells 
BEAS-2B were co-cultured with HPMEC as described in section in 2.2.1.4.  
 
3.3.4: LPS treatment 
BEAS-2B cultured on Transwell
®
 inserts with a TER >45Ωxcm2, were treated for 24 
hours with LPS isolated from P. aeruginosa strain 5ODR, P. aeruginosa strain10 
(Sigma), E. coli strain 0111B (Sigma) or B. cepacia, (10-1000ng/ml) in 300µl airway 
epithelial cell medium. Control cultures were treated with 300µl airway epithelial cell 
medium alone. BEAS-2B or HPMEC seeded in 24 well plates (seeded at 
5x10
4
cells/well and cultured overnight) were incubated with LPS at concentrations of 
(10-1000ng/ml) in 1ml airway epithelial cell medium (BEAS-2B) or endothelial cell 
medium (HPMEC) for 24 hours. For co-culture studies LPS was added to the apical 
compartment of Transwell
®
 inserts as above. Following the incubation period 
supernatants were collected separately; (apical and basolateral media were collected for 
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cells seeded on Transwell
®
 inserts, and co-culture studies). Cells were washed twice 
with 200µl PBS and lysed for 30 minutes with 1% (v/v) Triton X-100 in PBS with 1% 
protease inhibitor cocktail for 30 minutes on ice. Lysates and supernatants were cleared 
by centrifugation at 295xg for 2 minutes and stored at -20°C prior to analysis.  
 
4.3.5: IL-8/IL-6 ELISA 
Apical and basolateral media from LPS-treated cells were analysed for IL-8/IL-6 by 
ELISA as described in 2.2.5. 
 
4.3.6: CellTiter-Blue
®
 viability assay 
After LPS-treatment, cell viability was assessed using the CellTiter-Blue
®
 viability 
assay as detailed in 2.2.6.  
 
4.3.7: Barrier integrity measurements using ZO-1 staining 
The barrier integrity of BEAS-2B at ALI after LPS treatment was investigated by 
visualisation of tight junctions using an antibody against the tight junction protein ZO-
1.  Cells on Transwell
®
 inserts were fixed with 100µl 100% methanol (pre-cooled) for 
20 minutes at -20°C and washed 3 times with 200µl PBS. Cells were then 
permeabilised with 100µl 0.1% (v/v) Triton X-100 in PBS for 30 minutes at room 
temperature followed by 3 washes with 200µl PBS. Cells were then blocked with 100µl 
1% (v/v) normal goat serum in PBS for 1 hour at room temperature followed by an 
additional 3 washes with 200µl PBS. Cells were incubated with 100µl primary mouse 
monoclonal anti-ZO-1 or isotype-matched control in 1% BSA (w/v) in PBS or 1% BSA 
in PBS alone overnight at 4
°
C. Cells were then washes 3 times with 200µl PBS and 
incubated with 100µl goat anti-mouse FITC-conjugated secondary antibody diluted 
1:100 in 1% BSA in PBS for 1 hour at 4°C. Cells were washed a final 3 times with 
200µl PBS and mounted with hard set mounting medium containing DAPI (1 
drop/well/insert) and left to set for 48 hours at 4°C in the dark. Images were taken on a 
Zeiss Axiovert 200M fluorescent microscope using objective 63 with a DAPI filter 
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(exposures of 5-20ms) and a FITC filter (exposures of 50-150ms). ZO-1 images were 
taken at the most apical surface of cells and 4 fields of view were analysed for each 
replicate and 200 cells in each field were counted. The percent of cells with complete 
tight junctions was analysed by cell counting using Image J software.   
 
4.3.8: Statistical analysis 
Statistical analysis was conducted using one-way ANOVA and Tukey’s post test. 
Results are of at least 3 independent experiments and are expressed as mean ± SEM  
unless stated otherwise.  For Figure 4.3B statistical analysis was conducted using a 
repeated measures one-way ANOVA and Tukey’s post test. 
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4.4: Results 
4.4.1: Endotoxin content of LPS isolates 
In order compare the endotoxin content of isolated LPS compared to commercial strains 
the LAL assay was undertaken. The results show that the P. aeruginosa strain 5ODR 
had the highest endotoxin content (Table 1; 0.775±0.008 EU/ml) whilst the commercial 
strain P. aeruginosa S:10 had the lowest endotoxin content (0.214±0.029 EU/ml). 
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Table 4.1: Endotoxin content of LPS. Endotoxin levels were determined in LPS isolates from 
P. 5ODR, B. cepacia and the commercial strains E. coli 0111B and P. aeruginosa S:10. LPS 
isolates were diluted to 0.05ng/ml and endotoxin content was determined using the LAL assay 
(see section 2.2.4). Results are from triplicate wells of a a single experiment and expressed as 
mean ± SD.  
 
Bacterium    Endotoxin content (EU/ml) 
P. aeruginosa     0.775±0.008 
Strain 5ODR 
 
B. cepacia     0.273±0.012 
 
E. coli 
Strain 0111:B4    0.313±0.053 
 
P. aeruginosa     0.214±0.029 
Strain S:10 
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4.4.2: E. coli and P. aeruginosa S:10 induce IL-6 secretion from submerged 
cultures of BEAS-2B. 
 
In order to determine the inflammatory response of submerged BEAS-2B to LPS from 
airways and non-airways pathogens, cells were seeded in 24 well plates and treated for 
24 hours with LPS from the airway pathogens P. aeruginosa 5ODR and B. cepacia, and 
the non-airways pathogens E. coli 0111B and P. aeruginosa S:10 for 24 hours. After 
incubation, supernatants were collected and assayed by ELISA for the pro-
inflammatory chemokine IL-8 and the pro-inflammatory cytokine IL-6. 
 
LPS from the respiratory pathogens P. aeruginosa 5ODR or B. cepacia failed to induce 
IL-8 or IL-6 secretion from submerged BEAS-2B (control IL-8 secretion 
125.53±38.10pg, 1000ng/ml P. aeruginosa 5ODR 160.72±66.16pg, 1000ng/ml B. 
cepacia 213.58±82.56pg, control IL-6 secretion 134.48±45.36pg, 1000ng/ml P. 
aeruginosa 5ODR 141.57±72.46pg, 1000ng/ml B. cepacia 134.17±82.41pg, Figure 
4.1). LPS from E. coli increased IL-8 secretion from submerged BEAS-2B however this 
increase was both dose independent (100ng/ml; 899.76±435.35pg, 1000ng/ml; 
737.53±188.76pg) and non-significant compared to control. A non-significant increase 
in IL-8 secretion was observed from submerged BEAS-2B incubated with P. 
aeruginosa S:10 (100ng/ml 882.55±575.47pg, 1000ng/ml; 1207±612.81pg). 
Experimental error for IL-8 detection was high (greater than 10%) in E. coli and P. 
aeruginosa S:10 treatments (Figure 4.1A). 
 
Over the range of LPS concentrations tested, a dose independent significant increase in 
IL-6 secretion was observed from E. coli LPS-treated BEAS-2B compared to control 
(control: 134.48±45.36pg, 100ng/ml 632.48±123.1pg P<0.05, 1000ng/ml: 
644.48±163.55pg P<0.05) under submerged culture conditions (Figure 4.1B). P. 
aeruginosa S:10 LPS induced a significant but dose independent increase in IL-6 
secretion from submerged BEAS-2B (control; 134.48±45.36pg, 100ng/ml 
791.12±59.33pg P<0.05, 1000ng/ml 879.37±58.61pg P<0.01). 
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 These results indicate that BEAS-2B do not respond in an inflammatory manner after 
incubation with LPS from the respiratory pathogens P. aeruginosa 5ODR and B. 
cepacia, however, they are responsive to LPS from the non-respiratory E. coli and P. 
aeruginosa S:10 pathogens. 
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Figure 4.1: E. coli and P. aeruginosa S:10 induce IL-6 secretion from BEAS-2B 
significantly. BEAS-2B were seeded on collagen-coated 24 wells plates at a density of 
1x10
5
cells/ml. Cells were treated for 24 hours with 100ng/ml or 1000ng/ml LPS from P. 
aeruginosa 5ODR (PA 5ODR), B. cepacia (BC), E. coli 0111B (E. coli) or P. aeruginosa S:10 
(PA S:10) in fully supplemented airway epithelial cell medium. After treatment supernatants 
were collected and assayed for IL-8 and IL-6 by ELISA. Results are from 3 separate 
experiments (triplicate wells per experiment) expressed as mean ± SEM.*P<0.05 compared to 
control, **P<0.01 compared to control. 
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4.4.3: Viability of submerged BEAS-2B is not affected by LPS challenge. 
In order to determine whether lack of an inflammatory response from BEAS-2B cells 
treated with LPS from airways pathogens was due to epithelial cell death, the effect of 
LPS treatment on BEAS-2B viability was investigated using the CellTiter-Blue
®
 
viability assay. Figure 4.2 shows that there was no significant reduction in BEAS-2B 
viability with any of LPS isolates used at the concentrations tested. Treatment with 1% 
(v/v) Triton X-100 served as a positive control and reduced BEAS-2B viability to 
5.61±0.52 percent of control, P<0.001.  
These results suggest that cell death was not responsible for the lack of inflammatory 
mediator secretion from submerged BEAS-2B treated with LPS from the airways 
pathogens P. aeruginosa 5ODR or B. cepacia. Since BEAS-2B respond to E. coli LPS 
by significant increase in IL-6 secretion without effect on cell viability, further 
experiments were conducted using E. coli LPS isolate. 
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Figure 4.2: Viability of submerged BEAS-2B is not affected by LPS-challenge. BEAS-2B 
were seeded on collagen-coated 24 wells plates at a density of 1x10
5
cells/ml. Cells were treated 
for 24 hours with 100ng/ml or 1000ng/ml LPS from P. aeruginosa 5ODR (PA 5ODR), B. 
cepacia (BC), E. coli 0111:B4 (E. coli) or P. aeruginosa S:10 (PA S:10) in fully supplemented 
airway epithelial cell medium. After treatment supernatants were removed and cells were 
incubated with CellTiter-Blue
®
 (1:5 v/v) in fresh airway epithelial cell culture media for 4 
hours. After incubation fluorescence was measured at excitation 560nm, emission 590nm. 
Results are expressed as mean ± SEM, n=4. ***P<0.001 compared to control. 
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4.4.4: E. coli LPS induces inflammatory mediator secretion from BEAS-2B at ALI 
In order to determine whether E. coli LPS induces increased inflammarory mediator 
secretion from BEAS-2B cultured at ALI in a similar manner to submerged cultures, 
and are therefore a valid epithelial cell model of airways inflammation, cells were 
cultured at ALI on Transwell
®
 inserts and treated apically with E. coli LPS for 24 
hours. After LPS challenge apical and basolateral supernatants were collected 
separately and assayed for IL-8 and IL-6 by ELISA. 
A significant and dose-dependent increase in IL-8 secretion was observed from BEAS-
2B cultured at ALI after E. coli LPS challenge (Figure 4.3A). A significant increase in 
IL-8 secretion in response to 1000ng/ml LPS was observed in both the apical and 
basolateral compartments (apical control; 148.71±27.55pg, apical 1000ng/ml LPS 
391.33±63.82pg (P<0.05). Basolateral control; 291.29±58.20pg, basolateral 1000ng/ml 
LPS 428.62±34.12pg (P<0.05)). 
 
Compared to control a dose independent significant release in IL-6 secretion was 
observed into the basolateral compartment of E. coli LPS-treated BEAS-2B cultured at 
ALI (control; 77.06±2.32pg, 100ng/ml; 147.88±10.4pg, 1000ng/ml 145.24±34.44pg, 
P<0.05). Secretion of IL-6 into the apical compartment from E. coli LPS challenged 
BEAS-2B was non-significantly increased (control; 38.67±23.97pg, 100ng/ml; 
74.22±6.34pg, 1000ng/ml 95.19±19.58pg). 
 
These results show that BEAS-2B cultured at ALI are sensitive to apical E. coli LPS 
stimulation, and that IL-6 release from BEAS-2B cultured at ALI is directional. 
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Figure 4.3: E. coli LPS induces inflammatory mediator secretion from BEAS-2B at ALI. 
BEAS-2B seeded on collagen-coated  Transwell
®
 inserts (see section 2.2.1.2) were challenged 
apically for 24 hours with E. coli LPS (1000ng/ml or 100ng/ml) in fully supplemented airway 
epithelial cell medium, or medium alone as a control. After incubation supernatants were 
collected and assayed for IL-8 or IL-6 secretion by ELISA. Results are expressed as mean ± 
SEM, n=3. A) *P<0.05 versus apical control, +P<0.05 versus basolateral control by One-Way 
ANOVA and Tukey’s post hoc test. B) +P<0.05 versus basolateral control by repeated 
measures One-Way ANOVA and Tukey’s post hoc test. 
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4.4.5: Viability of BEAS-2B cultured at ALI is not affected by LPS-challenge. 
In order to determine whether LPS affects the viability of BEAS-2B cultured at ALI, 
cells were treated with 100ng/ml or 1000ng/ml E. coli LPS for 24 hours and viability 
assessed using the CellTiter-Blue
®
 assay; 1% (v/v) Triton X-100 served as a positive 
control. Neither dose of E. coli LPS affected BEAS-2B viability (Figure 4), whereas 1% 
(v/v) triton X-100 significantly reduced cell viability to 6.32±1.43% of control 
(P<0.001) 
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Figure 4.4: Viability of BEAS-2B cultured at ALI is not affected by LPS challenge. BEAS-
2B cultured at ALI on Transwell
®
 inserts for 11 days as described in 2.2.1.2,  were treated 
apically for 24 hours with E. coli LPS (1000ng/ml or 100ng/ml) or 1% (v/v) Triton X-100 in 
fully supplemented airway epithelial cell culture medium for 24 hours. After treatment 
basolateral media was replenished and cells were incubated apically with CellTiter-Blue
®
 for 4 
hours. Fluorescence was determined at Ex560nm Em590nm, results are expressed as mean ± 
SEM, n=4. P<0.001 compared to control. 
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4.4.6: BEAS-2B barrier remains intact with LPS stimulation. 
Maintenance of a tight barrier is an important mechanism whereby the airway 
epithelium protects against pathogenic infection. In order to determine whether LPS 
stimulation compromises the integrity of the epithelial tight barrier BEAS-2B cultured 
at ALI were treated apically with E. coli  LPS for 24 hours and the change in TER (as a 
measure of barrier integrity) measured. TER readings were taken for each well before 
treatment and normalised to pre-treatment control. After treatments TER was measured 
for each well again and test treatments normalised to control TER at 24 hours. 
Treatment with 1% (v/v) Triton X-100 for 24 hours served as a positive control for 
barrier disruption.   
 
E. coli LPS stimulation at either 100ng/ml or 1000ng/ml had no effect on BEAS-2B 
barrier integrity as measured by TER (106.12±8.57% of control before treatment and 
102.53±9.43 percent of control after treatment for 1000ng/ml LPS, (Figure 4.5)). 
Treatment with 1% (v/v) Triton X-100 significantly reduced TER from 108.5±11.18 
percent of control before treatment to 61.45±9.06 percent of control after treatment 
(P<0.001). These results indicate that apical LPS treatment of BEAS-2B for 24 hours 
does not compromise barrier integrity, as measured by TER. 
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Figure 4.5: BEAS-2B barrier remains intact with LPS stimulation. BEAS-2B were cultured 
at ALI on Transwell
®
 inserts for 11 days as described in section 2.2.1.2.  TER was measured 
and basolateral medium was replenished 4 hours prior to apical treatment with E. coli LPS 
(100ng/ml or 1000ng/ml) or 1% Triton X-100 for 24 hours. After treatment, basolateral medium 
and apical medium were replenished and TER measured. Results are expressed as TER for each 
well before treatment (percent of control before treatment) black bars, and TER for each well 
after treatment (percent of control after treatment) clear bars. Results are expressed as mean ± 
SEM, N=3 with 2 Transwell
®
 inserts for each replicate. **P<0.01 compared to 1% (v/v) triton 
X-100 before treatment.    
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4.4.7: Apical E. coli LPS treatment disrupts ZO-1 localisation in BEAS-2B 
cultured at ALI 
As TER is an indirect measure of tight junction formation, ZO-1 staining after LPS 
treatment was analysed as a direct measure of tight junctions. Figure 4.6 shows that ZO-
1 localisation at the site of cell-cell contact as seen with control cells (Figure 4.6A) was 
not observed following 24 hour treatment with either 100ng/ml or 1000ng/ml E. coli 
LPS (Figure 4.6B and C). When images were analysed by counting the total number of 
cells with intact tight junctions (ZO-1 staining localised around the whole cell), LPS 
treatment significantly affected ZO-1 localisation (51±4 percent of control 100ng/ml, 
48±7 percent of control P<0.01. Figure 4.6D). These results suggest that although TER 
is not affected by LPS treatment disruption of ZO-1 localisation may be occurring. 
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Figure 4.6: Apical E. coli LPS treatment disrupts ZO-1 localisation in BEAS-2B cultured 
at ALI. BEAS-2B cultured on Transwell
® 
inserts at ALI treated with and without 100ng/ml or 
1000ng/ml E. coli LPS for 24 hours were fixed with pre-cooled methanol, permeabilised with 
0.1% (v/v) triton X-100 and blocked with 1% (v/v) goat serum in PBS. Cells were then 
incubated with mouse monoclonal anti-ZO-1 antibody (1:250) in 1% (w/v) BSA in PBS 
overnight at 4°C followed by incubation with goat anti-mouse FITC-conjugated secondary 
antibody (1:100) in 1% (w/v) BSA in PBS. Cells were mounted in mounting medium 
containing DAPI and visualised using a Zeiss Axiovert 200M fluorescent microscope. Images 
are representative of 3 separate experiments with 4 fields of view at the most apical surface 
taken for each replicate. The percent of cells in each field of view with intact ZO-1 localisation 
around the cell (Figure 6A, star) was analysed using Image J software and expressed as percent 
of control **P<0.01 compared to control cells. Scale bar indicated 16µm. 200 cells in each 
image were examined. Results in Figure D are expressed as mean ± SEM. 
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4.4.8: IL-8 secretion is increased significantly from LPS-challenged HPMEC  
The BEAS-2B/HPMEC co-culture model of the airways were challenged apically with 
E. coli to assess the impact of the co-culture on inflammatory response compared to the 
BEAS-2B monoculture. ZO-1 localisation studies of E. coli LPS-treated BEAS-2B 
suggest possible loss of barrier integrity, and LPS may therefore leak through to the 
basolateral compartment. Under these conditions HPMEC would directly be challenged 
with LPS. The response of HPMEC in monoculture to 1000ng/ml E. coli LPS for 24 
hours was therefore investigated, to assess the contribution of HPMEC to LPS 
stimulated co-culture inflammatory response (if observed).  
E. coli LPS induced IL-8 release significantly from HPMEC (Figure 4.7, 3860±260pg 
(P<0.001)) compared to control cells (Figure 4.7, 200±80pg). A non-significant trend 
for an increase in IL-6 secretion was observed from HPMEC treated with E. coli 
(Figure 4.7, control: 790±500, LPS: 2520±1730pg). Experimental error for E coli-
treated HPMEC was greater than 10% (Figure 4.7B).  
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Figure 4.7: IL-8 secretion is increased significantly from LPS challenged HPMEC. 
HPMEC were cultured on 24 well plates at 0.5x10
5
cells/ml overnight prior to challenge with 
1000ng/ml E. coli LPS for 24 hours. After incubation supernatants were collected and assayed 
for IL-8 and IL-6 using ELISA. Results are expressed as mean ± SD, n=3. ***=P<0.001 
compared to control.  
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4.4.9: Stimulation with E. coli LPS does not affect HPMEC viability 
In order to assess the effect of E. coli LPS on HPMEC viability, the CellTiter-Blue
®
 
assay was conducted after LPS challenge. Treatment of HPMEC 24 hours with E. coli 
LPS had no effect on HPMEC viability (Figure 4.8, 1000ng/ml LPS: 99.94±6.69 
percent of control). Treatment of HPMEC with 1% (v/v) triton X-100 for 24 hours 
served as a positive control and reduced HPMEC viability to 9.52±7.86 percent of 
control (Figure 4.8, P<0.001). 
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Figure 4.8: Stimulation with E. coli LPS does not affect HPMEC viability. HPMEC seeded 
in 96 well plates at 8000cells/well were treated for 24 hours with 1000ng/ml E. coli LPS or 1% 
(v/v) triton X-100 for 24 hours. After incubation supernatants were removed and cells were 
incubated with CellTiter-Blue
®
 (1:5 v/v) in endothelial cell culture medium for 4 hours. After 
incubation fluorescence was measured at excitation 560nm and emission 590nm. Results are 
expressed as mean ± SD, n=4, ***P<0.001 compared to control.  
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4.4.10: IL-8 and IL-6 secretion from BEAS-2B/HPMEC co-culture is not affected 
by E. coli-LPS challenge. 
In order to validate the BEAS-2B/HPMEC co-culture as a model of airways 
inflammation the response of the model to E. coli LPS was investigated and compared 
to the response of BEAS-2B (cultured at ALI) and HPMEC monocultures. BEAS-2B 
monoculture showed significant IL-8 secretion with 1000ng/ml E. coli LPS in both 
apical and basolateral compartments (Figure 4.3A). Further HPMEC alone showed 
significant IL-8 secretion after E. coli LPS challenge (Figure 4.7A). However, E. coli 
LPS (1000ng/ml) failed to enhance IL-8 secretion from BEAS-2B/HPMEC co-culture 
in either compartment (Figure 4.9A). Significant directional (into the basolateral 
compartment) IL-6 secretion was seen from BEAS-2B alone treated with E. coli LPS 
(Figure 4.3B). Similarly, there was a significant increase in IL-6 secretion from the 
BEAS-2B/HPMEC co-culture to the basolateral compartment for both control and LPS 
treatment compared to respective apical treatments (Figure 4.9, apical control IL-6: 
165.93±38.81pg, basolateral control IL-6: 916.9±49.4 pg (P<0.001)). IL-6 secretion for 
LPS treatment compared to control, however, was not significantly increased for either 
the apical or basolateral compartment.   
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Figure 4.9: IL-8 and IL-6 secretion from BEAS-2B/HPMEC co-culture is not affected by 
E. coli LPS challenge. BEAS-2B/HPMEC co-culture (for details see 2.2.1.4) was treated 
apically with or without 1000ng/ml E. coli LPS for 24 hours. After incubation supernatants 
were collected and assayed for IL-8 and IL-6 by ELISA. Results are expressed as mean ± SD, 
n=4. ***P<0.001 compared to apical control, ###=P<0.001 compared to apical 1000ng/ml LPS. 
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4.4.11: BEAS-2B/HPMEC co-culture viability is not affected by E.coli LPS 
challenge. 
In order to determine whether challenge with LPS from E. coli affected viability of 
either BEAS-2B or HPMEC within the co-culture, the CellTiter-Blue
®
 assay was 
conducted after LPS challenge. E coli LPS (1000ng/ml for 24 hours) had no effect on 
either BEAS-2B or HPMEC viability in the co-culture model (Figure 4.10). Apical 
treatment of the BEAS-2B with 1% (v/v) triton X-100 for 24 hours significantly 
reduced viability of both BEAS-2B (Figure 4.10, 4.45±0.57 percent of control, 
P<0.001) and HPMEC (7.83±2.6 percent of control, P<0.001). 
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Figure 4.10: BEAS-2B/HPMEC co-culture viability is not affected by E. coli LPS 
challenge. BEAS-2B/HPMEC co-culture (for details see 2.2.1.4) was treated apically for 24 
hours with or without 1000ng/ml E. coli LPS or 1% (v/v) Triton X-100. After treatment the 
BEAS-2B on Transwell
®
 inserts were removed to a separate well in the companion plate and 
both BEAS-2B and HPMEC were incubated with CellTiter-Blue
®
 (1:5 v/v) in airway epithelial 
cell medium (BEAS-2B) or endothelial cell medium  (HPMEC) for 4 hours. After incubation 
fluorescence was measured at excitation 560nm emission 590nm. Results are expressed as 
mean ± SD, n=4. ***=P<0.001 compared to BEAS-2B control, ###=P<0.001 compared to 
HPMEC control.  
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4.5: Discussion 
The airway epithelium has a number of protective mechanisms in place to help prevent 
against pathogenic invasion including tight, semi-permeable junctions between 
neighbouring mucociliary cells (Steed et al., 2010) as well as invoking bacterial 
elimination indirectly through pro-inflammatory cytokine and chemokine release. 
Several cell lines of human bronchial epithelial origin have been investigated as models 
of lung tissue and these include BEAS-2B, Calu-3 and 16HBE14o cells. However, the 
least studied of these is the BEAS-2B cell line, despite the fact that they are derived 
from normal epithelial cells. This contrasts with Calu-3 cells which are derived from 
lung adenocarcinoma cells. Culture at ALI allows for mucociliary differentiation which 
reflects the morphology of the airways epithelium in vivo. 
 
The aim of the current study therefore was to characterise the inflammatory response of 
BEAS-2B cultured at ALI to LPS compared to a submerged cultures of BEAS-2B. The 
ALI model was further investigated in terms of barrier integrity and tight junction 
stability. Once characterised the ALI model was used in construction of a co-culture 
model with the inclusion of HPMEC to further mimic the airways in vivo.  
 
BEAS-2B are bronchial epithelial cells and therefore their response of LPS from 
respiratory pathogens was first investigated. Submerged BEAS-2B were incubated for 
24 hours with 100ng/ml or 1000ng/ml LPS from P. aeruginosa strain 5ODR and B. 
cepacia, for comparison LPS from the non-respiratory pathogens P. aeruginosa S:10 
and E. coli 0111:B4 were also used. The LAL assay was conducted to determine the 
endotoxin levels of each LPS. P. aeruginosa 5ODR has the highest endotoxin content 
whilst the commercial, non-respiratory strain S:10 has the least. A limitation of the 
current study is that cells were treated with equal concentrations of LPS by mass, rather 
than endotoxin content. Despite this cells exhibited a higher inflammatory response to 
E. coli 0111:B4 and P. aeruginosa S:10, rather than P. aeruginosa 5ODR, the isolate 
with the highest endotoxin content. Indeed, IL-8 and IL-6 secretion remained 
unchanged from BEAS-2B after treatment with LPS from either of the respiratory 
pathogens, whilst IL-8 secretion was increased non-significantly, and IL-6 increased 
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significantly with LPS from either E. coli LPS and P. aeruginosa S:10 compared to 
control. Cell viability studies show that the lack of inflammatory response was not due 
to cell death as none of the LPS strains tested significantly affected cell viability. 
Seydel et al., (2003) observe that the EU/ml of synthetic LPS compounds did not 
correlate with inflammatory response from human macrophages and propose that the 
LAL recognises the lipid A backbone rather than the toxic lipid chains. 
 
The fact that increased IL-6 secretion was observed with LPS from E. coli or P. 
aeruginosa S:10 shows that BEAS-2B are responsive to LPS as suggested by their 
expression of TLR4 (Guillot et al., 2004; Schulz et al., 2002), TLR2 and CD14 (a 
glycosyl-phosphatidylinositol (GPI)-linked LPS co-receptor (Elson et al., 2007). 
TLR2/4 and CD14 are both involved in the recognition of LPS (Lu et al., 2008). 
However, it is unclear as to why BEAS-2B showed no inflammatory response with 
respiratory strains of LPS. Raoust et al., (2009) report that mouse primary lung 
epithelial cells with TLR2/4 knockdown still produce the inflammatory mediators KC 
and IL-6 (albeit at a lower concentration than wild type epithelia cells) in response to 4 
hours incubation with P. aeruginosa live bacteria (2x10
4
-10x10
4
 
bacteria/5x10
4
epithelial cells). These results suggest that P aeruginosa LPS is not the 
sole PAMP employed by P. aeruginosa during infection.  Guillot et al., (2004) show 
that TLR-4 is internalised in unstimulated BEAS-2B and suggest this acts to protect the 
epithelium from promotion of an inflammatory state in response to trace amount of 
LPS. Since inhaled particles, for example, urban air particulates often contain LPS 
contamination it is tempting to speculate that the airways minimise inappropriate 
inflammation in response to low levels of respiratory LPS, and therefore stimulation by 
other PAMPs are required as a protective mechanism. Further work to investigate this 
hypothesis could examine whether P. aeruginosa 5ODR and B. cepacia whole bacteria 
or increased LPS doses activates an inflammatory state in submerged BEAS-2B.   
 
E. coli LPS has been observed to induce increased IL-8 secretion from a number of 
airway cell types including A549 (Schulz et al., 2009) and NHBE (Palmberg et al., 
1998). Here, submerged BEAS-2B showed a non-significant increase in IL-8 secretion 
in response to E. coli and P. aeruginosa S:10 LPS, however, the same concentration of 
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LPS from E. coli O26:B6 induced IL-8 secretion after 2, 6 and 18 hours incubation 
from BEAS-2B significantly in a study by Laan et al., (2004). The difference may be 
due to differences in LPS serotype as the O-antigen of LPS can differ in structure 
between LPS bacteria serotypes and genera (Haeffner-Cavaillon et al., 1998). 
Significant IL-8 secretion however, was observed in BEAS-2B cultured at ALI with 
1000ng/ml LPS into both the apical and basolateral compartments. IL-8 is a potent 
neutrophil chemo-attractant, and its release in the basolateral compartment mimics in 
vivo IL-8 secretion into the underlying blood vessels to attract circulating leukocytes 
(Mukaida., 2003). Secretion directed to the apical compartment would allow for a 
gradient of IL-8 whereby leukocytes attracted to the intima traverse the endothelium to 
the epithelial cell and site of infection. Incubation of the BEAS-2B ALI model with 
FITC-dextran at 10kDa, (a similar size to IL-8), shows that the permeability is not 
affected by 24 hour treatment with 1000ng/ml LPS from E. coli. The basolateral IL-8 
concentration detected is indeed due to enhanced directed secretion, rather than 
diffusion of IL-8 through the cell layer due to leakage from the apical compartment or 
diminished barrier integrity (unpublished data Willetts et al., 2011).   
 
IL-8 secretion after LPS from E. coli treatment was altered significantly in BEAS-2B 
cultured at ALI but not submerged, a large experimental variance was observed in the 
submerged culture studies which may mask any IL-8 response.  Ross et al., (2007) 
conducted transcriptional analysis of HBEC during differentiation at ALI and found 
that for a number of genes their expression was increased. IL-8 was one of these genes 
and showed an increase in expression during the initial 10 days of ALI culture, so it is 
possible that airway epithelial cells at ALI have increased expression of the necessary 
genes required to mount an inflammatory response, and may explain the enhanced IL-8 
response observed during ALI in the current study.  Further, although BEAS-2B are 
known to express CD14 and TLR receptors their location in cells cultured at ALI is 
unknown (in submerged BEAS-2B TLR4 is internalised, Guillot et al., 2004), it is 
possible that differentiated cells may show apical polarised expression of these 
receptors, making them more available to bind LPS.  
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Previous studies have shown submerged populations of BEAS-2B to secrete IL-6 in 
response to ≥10µg/ml LPS from E. coli O55:B5 (Schulz et al., 2002) and 1000 
endotoxin units/ml Pseudomonas LPS (Veranth et al., 2008). Here, significant IL-6 
secretion was observed with both 100ng/ml and 1000ng/ml LPS in submerged BEAS-
2B cultures. Furthermore, significant IL-6 secretion was observed in the basolateral 
compartment of BEAS-2B cultures at ALI with 1000ng/ml LPS. BEAS-2B cultured at 
ALI therefore respond in a manner similar to that of submerged cultured regarding LPS 
induced IL-6 secretion. 
 
Pathogenic insult has been shown to induce tight junction disruption in a number of 
epithelial cell types (Kim et al., 2005; Nazil et al., 2010; Yi et al., 2000). Incubation 
with E coli LPS (100ng/ml or 1000ng/ml) for 24 hours had no effect on BEAS-2B TER, 
however, ZO-1 localisation was punctate and fragmented with a significant reduction in 
the number of cells with complete tight junctions with LPS challenge. In contrast, Nazil 
et al., (2010), observed a correlation between decreasing TER and ZO-1 mRNA 
expression and protein localisation at tight junctions in HIV-1 treated primary 
endometrial epithelial cells.  
 
B. cenocepacia infection of 16HBE14o
-
 cells resulted in decreased TER, and disruption 
of occludin at tight junctions with unaltered ZO-1 (Kim et al., 2005), lending further 
support that disruption to ZO-1 localisation and TER may not go hand in hand in tight 
junction disturbance. Yi et al., (2000) observed that in the human corneal epithelial cell 
line THCE, P. aeruginosa LPS challenge resulted in a decrease in TER at 9 hour of 
treatment, with TER returning to baseline at 24 hours of treatment, however, ZO-1 
localisation remained unchanged and ZO-2 localisation was disturbed.  Therefore 
pathogenic insult may cause transient disruption of some tight junction proteins without 
completely diminishing tight junction integrity.  In the current study, stable TER with 
perturbed ZO-1 staining in response to LPS at 24hours may indicate the beginning of 
tight junction disruption, or their composition after repair mechanisms have been 
induced; no cytotoxicity was observed under these conditions as measured by CellTiter-
Blue
®
 analysis and lack of apoptotic nuclei in ZO-1 localisation studies.  
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Tight junctions are composed of several proteins of which the claudin family members 
are responsible for the ion-selectivity of the tight junction whilst ZO-1 family members 
act as scaffold proteins (Steed et al., 2010). It is possible therefore that although ZO-1 
localisation in BEAS-2B treated with LPS is disrupted, claudin localisation may be 
unaffected, and therefore TER remains unaffected.  Further, the number of cells with 
ZO-1 disruption was reduced to ~50% of control with either 100ng/ml or 1000ng/ml 
LPS and such cells may be able to maintain TER. The ZO-1 images were all taken at 
the most apical surface of cell cultures, as BEAS-2B form several cell layers on the 
Transwell
®
 inserts the underlying cells may help maintain TER also.  A limitation of 
the current study is that barrier integrity studies were undertaken immediately after the 
LPS treatment, with no investigation into tight junction integrity during the LPS 
challenge. Electric Cell-Substrate Impedance Sensing (ECIS) allows continuous 
measurement of electrical resistance of cultures by incorporation of a impedance 
sensing chip into the culture without removal of cells from an incubated setting (Heijink 
et al., 2009; Sun et al., 2010). ECIS may therefore be used to monitor the barrier 
function during LPS treatment, as it has been utilised to show disruption to 16HBE14o
-
 
cells treated with Triton X-100, giving similar results to TER  (Sun et al., 2010). ECIS 
along with immunofluorescent staining for tight junction proteins at given time points 
during LPS treatment would allow for a greater understanding of barrier integrity with 
pathogenic insult.  
 
As previously mentioned, during inflammation, the endothelium increases expression of 
adhesion molecules (as a result of increased inflammatory mediator release by epithelial 
cells) to allow passage of inflammatory cells through the endothelium to the site of 
infection by attraction to epithelial-released chemokines. Therefore the effect of 
pathogenic material on endothelial cells alone and an epithelial/endothelial co-culture 
was investigated. LPS induces a non-cytotoxic (LPS treatment had no effect on 
HPMEC viability) inflammatory response in HPMEC cells alone. IL-8 secretion in 
HPMEC cells is significantly increased compared to control. Further, Zhang et al., 
(2011) observed significant IL-8 secretion from HUVEC treated with LPS from E. coli 
(strain 055:B1). Here HPMEC cells secrete 3856±260pg/ml IL-8, whilst Zhang et al., 
(2010) reported 7000pg/ml IL-8 secretion in their HUVEC system. The difference in 
concentration of IL-8 secreted is likely to be due to the fact that the HUVEC in the 
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study by Zhang et al., (2010) show increased IL-8 secretion under resting conditions 
(1000pg/ml) compared with the HPMEC cells of the current study which secrete only 
200±80pg/ml suggesting they are already more primed than HPMEC.  
 
The effect of introducing HPMEC into the BEAS-2B ALI model in terms of cytokine 
secretion after LPS challenge was investigated. Permeability studies in BEAS-2B 
treated with LPS suggest that the barrier is not permeable to solutes of 10kDa (Willetts 
et al., 2011) so the HPMEC cells may never come into contact with the LPS which 
exists as micelles in aqueous solutions with sizes ranging from 200kDa (Jang et al., 
2009) to 1000kDa (Magalhaes et al., 2007). It can therefore be assumed that any 
basolateral secretion of cytokines is from the BEAS-2B cells in response to LPS 
stimulation or from HPMEC cells in response to BEAS-2B secreted cytokines. In 
BEAS-2B mono-culture, basolateral IL-8 concentrations increase nearly 100% with 
1000ng/ml LPS for 24 hours (control IL-8 secretion of 291.29±58.2pg, LPS-induced 
IL-8 secretion 428.62±34.12pg). The presence of HPMEC does not enhance the LPS-
induced increase in IL-8 secretion, which is only increased by 40% in the basolateral 
compartment of the co-culture (control IL-8 secretion 4520±980pg, LPS-induced IL-8 
secretion 6340±2330pg). Further, the significant LPS-induced secretion of IL-6 in the 
basolateral compartment of BEAS-2B at ALI was lost in the co-culture.  
 
Lack of HMPMEC cells due to limited cell doubling of primary populations presented a 
key restriction to the current study. For HPMEC and co-culture studies, treatments were 
carried out singly in three independent experiments, rather than the 3 wells for each 
replicate for BEAS-2B, due to the slow doubling and limited passage of HPMEC. This 
introduced high levels of variability to results. In fact, IL-6 secretion from LPS 
stimulated HPMEC in mono-culture was more than 3 times control IL-6 secretion 
indicating a probable response (control 793.54±509.24pg, LPS stimulation 
2520.79±1725.75). This large variability may mask any small but significant changes in 
cytokine response from the co-culture. Further work would concentrate on growing 
numerous cultures of HPMEC from the same primary cell lots to provide a larger 
HPMEC pool for studies.  
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The expression of adhesion molecules in HPMEC cells after apical treatment of BEAS-
2B with LPS needs investigation to determine whether the current model of 
inflammation represents inflammatory responses in vivo. The presence of the 
inflammatory mediators secreted from LPS activated epithelial cells such as IL-6 are 
predicted to induce adhesion molecule up-regulation in HPMEC cells. This may be 
investigated by stimulation of HPMEC cells with conditioned media from the 
basolateral compartment of LPS-treated and control BEAS-2B, and comparing the 
results to HPMEC treated with a positive stimulator of adhesion molecule up-
regulation.  
 
4.6: Conclusion 
BEAS-2B cultured at ALI respond to E. coli LPS challenge in a physiologically 
relevant manner by directional secretion of IL-6 and IL-8, without loss of viability and 
with tight barrier maintenance regarding solute permeability. The inflammatory 
response of the co-culture is less defined owing to high experimental variability. 
Overall results suggest that BEAS-2B cultured at ALI are an effective model of airway 
inflammation that may have application in investigating effects of pathogens or 
particulates. Further investigations into the response of this model to airway pathogens 
is required. 
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Chapter 5: Particulate matter exposure 
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5.1: Rationale 
 
The airways can be exposed to PM from a number of sources including the workplace, 
pollution or cosmetics. Investigations into any potential health effects from airways PM 
exposure are therefore warranted. BEAS-2B, a normal human airway epithelial cell 
line, under submerged conditions have been previously used in the study of PM toxicity 
under submerged conditions, however, ALI cultures allow for a cell phenotype more 
representative of in vivo conditions. Further, inhaled PM are observed to translocate to 
the endothelium in vivo. The current study aims to characterise the inflammatory, 
cytotoxic and GSH response of BEAS-B cultured at ALI in mono-culture and co-
culture with HPMEC to UFTiO2, TiO2 and test particles S2219200, S2218600 and 
S2429901.  
 
UFTiO2 induced a loss of cell viability and GSH (possibly due to ROS production) in 
BEAS-2B cultured at ALI. Analysis of inflammatory mediator secretion from these 
cells is complicated due to adsorption of chemokines onto the particle surface. The 
neutrophil respiratory burst assay was employed to investigate whether particle bound 
IL-8 remained biologically active. S2429901 induced IL-6 secretion from BEAS-2B 
cultured at ALI and reduced the ability of IL-8 to prime human primary neutrophils for 
the fMLP induced respiratory burst, but, had no effect on cell viability, GSH content or 
barrier integrity. UFTiO2 induced a significant reduction in BEAS-2B mono-culture 
viability, however, when in co-culture with HPMEC, BEAS-2B viability was 
unaffected by UFTiO2 challenge.   
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5.2: Introduction 
 
NPs are commonly used in industrial and commercial products; NP-TiO2 for example is 
used in numerous areas from cosmetics (Nohynek et al., 2010) to the food industry 
(Lomer et al., 2002).  In vitro studies of NP exposure have indicated a link between 
inflammatory and cytotoxic responses and particulate matter size (Gurr et al., 2005, 
Singh et al., 2007).  Using BEAS-2B as an in vitro model of the human lungs the 
cytotoxic potential of ultrafine (UF, 10nm and 20nm) and fine (200nm) TiO2 particles 
was investigated (Gurr et al., 2005). Cellular damage was measured by assessing 
oxidative DNA damage, lipid peroxidation and levels of ROS.  In all cases, the ultrafine 
particles induced more damage than fine particles (Gurr et al., 2005), providing 
evidence that smaller particles with larger surface area and increased chemical 
reactivity are more potent inducers of damage to BEAS-2B than larger diameter 
particles, with relatively smaller surface areas, of the same material.   
 
Intracellular ROS production has been linked to induction of apoptosis and 
inflammation after PM exposure. The antioxidant enzyme catalase inhibits TiO2-
induced increase in GM-CSF expression (Hussain et al., 2009), and carbon black (CB) 
induced DNA fragmentation and caspase activation in 16HBE14o
-
 cells (Hussain et al., 
2010). Further, the combustion derived particle residual oil fly ash (ROFA) induced 
intracellular ROS and increased IL-6 and IL-8 mRNA expression in NHBE. Cytokine 
expression was inhibited by the ROS scavenger dimethylthiourea and the metal chelator 
deferoxamine (Carter et al., 1997). The increased intracellular ROS may be a 
consequence of phagocytosis of particles by cells and activation of NADPH oxidase. In 
addition, the mitochondrion has been implicated as a major source of this increased 
ROS. Indeed Zhao et al., (2009) observed significant induction of mitochondrial ROS 
with 100µg/ml PM10 treatment of submerged primary bronchial epithelial cells and 
Freyre-Fonseca et al., (2011) observed an increase in ROS in mitochondria isolated 
from rat whole lung tissue treated with UFTiO2. NP have been shown to localise to the 
mitochondrial membrane of epithelial cells in vitro (Singh et al., 2007).   
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Increased inflammatory mediator secretion has also been observed from airway 
endothelial cells in response to PM. For example; iron oxide and zinc oxide particles 
induce an increase in IL-8 secretion from human aortic endothelial cells (Gojova et al., 
2007). Similarly, Qu et al., (2010) observed a significant increase in IL-6 secretion 
from human lung microvascular endothelial cells. Furthermore, Geiser et al., (2005) 
observed the presence of TiO2 particles in the endothelium of lung sections from rats 
exposed to TiO2 aerosol, suggesting that the endothelium should also be considered 
during PM and NP toxicity testing.  
 
Airway co-culture models of epithelial cells combined with alveolar macrophages (Fujii 
et al., 2002 & Ishii et al., 2005) or dendritic cells (Rothen-Rutishauser et al., 2008) 
have been described, but models with endothelial cells are rarely employed.   The aim 
of this study is to therefore characterise the inflammatory, cytotoxic and GSH response 
of BEAS-2B cultured at ALI in mono-culture or in a co-culture (characterised in 
chapter 3) with HPMEC after TiO2 or UFTiO2 treatment. Further, three particles of 
unknown composition were also investigated, where in vivo work has been completed 
(in previous unpublished work, Geiser, 2008) elsewhere, to provide insight into the use 
of both cell models for testing compounds of commercial interest. HPMVEC were 
treated with particulates in mono-culture to allow possible interaction between the 2 cell 
types to be investigated when cultured together and challenged with particulates.   
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5.3: Methods 
5.3.1: Particles 
Particles S2219200, S2218600 and S2429901 were provided by Unilever (Colworth) as 
test particles and their composition is described in 2.1.2. TiO2 was purchased from 
VWR and UFTiO2 was purchased from Sigma (Poole, UK). Particles were stored in as 
stock solutions at a concentration of 10mg/ml in PBS and stored at -20°C. 
 
5.3.2: Epithelial cell culture on Transwell
®
 Inserts 
BEAS-2B were seeded onto collagen-coated Transwell
®
 inserts as described in section 
2.2.1.2. 
 
5.3.3: Co-culture of BEAS-2B cells and HPMEC cells 
BEAS-2B were co-cultured on with HPMEC as described in section 2.2.1.4.  
 
5.3.4: Endotoxin content determination of particles by LAL assay 
Bacterial endotoxins can be shed, and bind particulates. In order to determine whether 
particles were contaminated with a bacterial endotoxin which would influence the 
response directly, the endotoxin content of particles (200µg/ml from a 10mg/ml stock, 
diluted with endotoxin free LAL water) was determined with the QCL-1000
®
 
Chromogenic LAL Endpoint assay as described in section 2.2.4. 
 
5.3.5: Zeta potential and particle size 
In order to determine whether particle size was related to the cellular response, two 
sizes of particles were used in the current study. TiO2 was sized in filtered distilled 
water using a Sympa Helios BI particle analyser. According to manufacturer’s details 
UFTiO2 has a diameter of 5nm. For zeta analysis particles were diluted in 1.5ml 1mM 
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Tris-HCl pH 6.8 (20µl from 10mg/ml stock) and analysed using a Brookhaven Zetaplus 
Zeta potential analyser. 
 
5.3.6: Particle treatment of BEAS-2B cells in mono- or co-culture 
Cells were treated with; TiO2, UFTiO2, S2219200, S2218600, or S2429901 to 
investigate size-related effects on cell viability, oxidative and inflammatory response. 
Stock concentrations of 10mg/ml of particles were prepared in PBS and stored at -20°C. 
Stock solutions were diluted to a final concentration of 100μg/ml in quiescent (serum-
free) airway epithelial cell medium. To remove aggregates particles were vortexed for 2 
minutes, sonicated for 30 minutes in a water bath sonicator for 30 minutes and vortexed 
for another 2 minutes prior to addition to cells. BEAS-2B on Transwell
®
 inserts alone 
and co-cultured with HPMEC were apically treated with 300µl of particles or quiescent 
medium alone for 24 hours at 37°C. HPMEC mono-cultures seeded in 24 well plates 
(seeded at 5x10
4 cells/well and cultured overnight) were treated with 100μg/ml particles 
in 1ml fully supplemented endothelial cell medium for 24 hours at 37°C. Cells received 
fully supplemented medium (in the basolateral compartment for BEAS-2B) 4 hours 
prior to treatment. After treatment apical and basolateral media form BEAS-2B mono-
cultures, co-cultures and media from HPMEC cultures were removed, centrifuged to 
remove particulates at 295xg for 2 minutes and stored at -20°C until required for 
analysis of IL-8 or IL-6 by ELISA. Cells were washed twice with PBS (200µl) and 
lysed with 1% (v/v) Triton X-100 in PBS with 1% (v/v) protease inhibitor cocktail for 
30 minutes on ice. Lysates were collected, centrifuged at 295xg for 2 minutes to remove 
particulates and stored at -20°C prior to analysis by proteomics (section 6.2).   
 
5.3.7: CellTiter-Blue
®
 viability assay 
After particles stimulation, cell viability was assessed using the CellTiter-Blue
®
 
viability assay as described in section 2.2.6. 
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5.3.8: IL-8/IL-6 ELISA 
Apical and basolateral media from particle-treated cells were analysed for IL-8 or IL-6 
by ELISA as detailed in section 2.2.5. 
 
5.3.9: Isolation of primary human neutrophils with a discontinuous 
Percoll™ gradient 
Discontinuous Percoll™ gradients (1.079g/ml and 1.098g/ml), as described in Table 
5.1, were prepared by layering 5ml 1.079g/ml Percoll™ on top of 5ml 1.098g/ml 
Percoll™ in non-sterile 25ml tubes incubated overnight at 4°C.  
 Table 5.1: Preparation of Percoll™ solutions for a discontinuous gradient 
Final Percoll™ density  1.079g/ml   1.098g/ml         
Percoll™ (1.13g/ml)  9.85ml            12.41ml 
Water    5.9ml              3.34ml 
1.5M NaCl   1.75ml              1.75ml 
 
Venous blood (10ml) was collected into 1ml of 4% (w/v) sodium citrate and layered on 
top of the Percoll™ gradients (5ml blood per gradient). Ethical approval for collection 
of blood from healthy donors was approved by Aston University.  Informed consent 
was given by each donor, who tested positive for immunity for Hepatitis B. Gradients 
were centrifuged at 4°C for 8 minutes at 150xg followed by 10 minutes at 400xg.  After 
centrifugation neutrophils were collected from the clear fraction of separated blood  and 
briefly mixed with red cell lysis buffer (0.83% NH4Cl (w/v), 0.1% KHCO3 (w/v), 
0.004% Na2EDTA.2H2O (w/v), 0.25% BSA (w/v) in dH2O) in a ratio of 1 part cells to 2 
parts lysis buffer. Cells were then centrifuged at 350xg for 6 minutes (4°C) and washed 
with 2ml PBS before being centrifuged at 350xg for 6 minutes (4°C) and re-suspended 
in 1ml PBS. Cells were counted and viability was determined using tryphan blue 
exclusion. In all cases viability of recovered neutrophils was above 90%.  
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5.3.10: Respiratory burst assay 
IL-8 was pre-treated with 100µg/ml particles (or PBS as a control) for 24 hours at 37°C. 
A white 96 well plate (Grenier BioOne, Promega, Southampton, UK) was coated with 
0.1% (w/v) BSA in PBS (100µl/well) overnight at 4°C. Primary human neutrophils 
were re-suspended to a concentration of 1x10
6
cells/ml in PBS and 100µl cells were 
transferred to a BSA-coated 96 well plate (100µl cells/well) along with 40µl of 
lucigenin (final concentration 100µM) and 40µl PBS.  Neutrophils were incubated at 
room temperature for 30 minutes in the dark. Baseline luminescence was measured for 
10 minutes using an Orion II microplate luminometer (Berthold Detection Systems). 
Cells were stimulated for 15 minutes with 10µl 50ng/ml pre-treated IL-8 (with or 
without incubation for 24 hours with 100µg/ml particles at 37°C) during this time 
luminescence was measured. After stimulation with pre-treated IL-8, the respiratory 
burst was initiated with 1.25µM N-formyl-methionine-leucine-phenylalanine (fMLP) 
and luminescence recorded until signal returned to baseline.   
 
5.3.11: GSH-Glo™ GSH assay for quantification of reduced GSH 
In order to assess the potential of TiO2, UFTiO2 and unknown test particles to induce 
GSH oxidation (and therefore an imbalance in cellular redox state) in BEAS-2B and 
HMPEC, cells were incubated with particles for 2 hours and reduced GSH (referred to 
as GSH) content determined using the GSH-Glo™ GSH assay. The principle of this 
assay is as follows: Cells are incubated with GSH-Glo™ reaction buffer containing 
Luciferin-NT substrate, glutathione S-transferase (GST) and esterase.  GSH converts 
the Luciferin-NT into luciferin, with GST acting as a catalyst. The reaction is stopped 
by addition of Luciferin Detection reagent containing luciferase enzyme to convert the 
luciferin into a luminescent signal.  
 
BEAS-2B were cultured on Transwell
®
 inserts as described in section 2.2.1.2 and 
HPMEC were cultured in 96 well plates at 0.8x10
4
 cells/well until 70% confluent. Cells 
were treated with 10µM L-Buthionine sulfoximine (BSO) for 24 hours to deplete GSH, 
or 100µg/ml particles for 2 hours. After particle or BSO incubation, GSH was 
determined as follows: Cells were incubated for 30 minutes with 100µl GSH-Glo™ 
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reaction buffer containing Lucifererin-NT substrate, esterase and GST. After 
incubation, 100µl Luciferin Detection Reagent luciferease enzyme was added to wells 
for 15 minutes (no leakage of reaction buffers to the basolateral compartment of 
Transwell
®
 was observed during this time).  After incubation with Luciferin Detection 
Reagent lysates were collected from the Transwell
®
 inserts and 96 well plate and 
removed to a white walled 96 well plate for measurement. Luminescence was measured 
using an Orion II microplate luminometer (Berthold Detection Systems).  The 
concentration of GSH in cells was extrapolated from a standard curve constructed using 
GSH (0µM-5µM). 
 
 5.3.12: Statistical analysis. 
Statistical analysis was conducted using a one-way ANOVA and Tukey’s post test 
except in Figure 5.2B where IL-8 is nornalised to 100% and PBS to 0% using a 
repeated measures one-way ANOVA and Tukey’s post test. 
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5.4: Results 
5.4.1: Particle characteristics 
One of the aims of this study was to characterise the effects of two size grades of 
titanium dioxide and particles (S2219200, S2218600 and S2429901) on cell viability, 
inflammatory and GSH redox state and barrier integrity of BEAS-2B cultured at ALI 
and the BEAS-2B/HPMEC co-culture system. As the inflammatory response of both 
BEAS-2B/HPMEC monocultures and co-cultures were being investigated, the presence 
of endotoxin contamination of test particles was determined using an LAL assay.   
 
UFTiO2 endotoxin content was initially above the 1EU/ml, data not shown. Treatment 
in a dry oven 160°C for 4 hours reduced the endotoxin content to a negligible level and 
only heat treated-UFTiO2 was used for further study.  The results indicate that TiO2, 
heat treated-UFTiO2 (hereafter referred to as UFTiO2) and test particles contained 
minimal endotoxin contamination (Table 5.2) as endotoxin levels were below the 
lowest standard provided with the assay (0.1 EU/ml).   
 
Particle size determination was undertaken so that any size-related effects of titanium 
particles may be taken into account during analysis of cell responses, and characterise 
particle size range. Particle sizing of TiO2 was first undertaken using a Brookhaven 
Zeta Analysis analyser using a particle sizing program. The size of the particles was 
found to be 1000nm, however, this is at the upper limits for the analyser accuracy. TiO2 
particles were then sized using a Sympa Helios BI particle sizer (lower limits 
>1000nm). In two separate preparations the TiO2 was found to have a diameter of 
3000nm, however on the third occasion the size of the particles was 1000nm. 
Nevertheless, TiO2 had a mean diameter greater than 1000nm. 
 
UFTiO2 had a diameter of 5nm according to manufacturer’s details. This could not be 
confirmed as 5nm is below the limits of detection for both the Brookhaven Zeta 
Analyser and Sympa Helios BI particle sizer. To rule out any charge related effects of 
titanium particles, the zeta potential of each suspension was analysed. TiO2 and UFTiO2 
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were found to have similar zeta potentials, -38.91±8.74mv and -33.91±5.63mv 
respectively (Table 3).  Particles S2219200, S2218600 and S2429901 were all in the 
fine NP size category and ranged in size from 168-533nm with particle S2218600 
having the largest diameter (533.7±213.79nm, Table 5.2). 
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Table 5.2: Particle characteristics. Endotoxin content of particle (200µg/ml) was determined 
using the LAL assay, results are from a single experiment (measured in triplicate) and within 
assay standard deviations are shown. Titanium dioxide was sized using both a Brookhaven 
Zetaplus Zeta potential analyser using a particle sizing analysis program and a Sympa Helios BI 
particle sizer. The S2219200, S2218600 and S2429901 were sized using a Brookhaven Zetaplus 
Zeta potential analyser using a particle sizing analysis program, n=3, results are expressed as 
mean ± SEM. Ultrafine titanium dioxide is 5nm according to the manufacturer’s details. 
 TiO2 UFTiO2 S2219200 S2218600 S2429901 
Endotoxin 
content 
(EU/ml) 
0.078 ± 
0.003 
<0.001 ± 
0.012 
0.077±0.001 0.078±0.001 0.094±0.003 
Size (nm) 1000-3000 5 168.07±61.67 533.7±213.79 387.3±154.03 
 
Table 5.3: Titanium dioxide Zeta charge analysis. Zeta potential analysis was conducted on 
TiO2 and UFTiO2 diluted in 1mM Tris-HCl pH 6.8 (20µl from 10mg/ml stock) using a 
Brookhaven Zetaplus Zeta potential analyser, results are expressed as mean ± SEM n=3.  
 TiO2 UFTiO2 
Zeta potential (mV) -38.91 ± 8.74 -33.91 ± 5.63 
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5.4.2: S2429901 induces increased IL-6 secretion to the apical and basolateral 
compartment of BEAS-2B cultured at ALI. 
UFTiO2 has been previously shown to significantly increase IL-8 expression and 
secretion compared to TiO2 in A549 cells (Singh et al., 2007). In order to determine 
whether the BEAS-2B airways epithelium model used in this study behaves in a similar 
manner, cells were exposed apically to TiO2 and UFTiO2 (100µg/ml for 24 hours in 
serum free airway epithelial media) and apical and basolateral secretion of IL-8 was 
determined using ELISA. Secretion of IL-6 in response to titanium particles was also 
investigated.  There was a significant (P<0.05) decrease in apical secretion of IL-8 
following UFTiO2 treatment (control: 1922.5±164.6pg, UFTiO2: 1052.5±362.3pg) by 
ELISA (Figure 5.1A). This apparent reduction is due to loss of detection of UFTiO2-
bound IL-8 (Appendix 3).  Basolateral IL-8 secretion was not affected by TiO2 
treatment (Figure 5.1A).   
Particles S2219200, S2218600 and S2429901 had no impact on IL-8 secretion to either 
compartment (Figure 5.1C), There was a non-significant trend towards greater IL-8 
secretion in the basolateral compartment under control conditions compared to the 
apical compartment (Figure 5.1C). IL-6 secretion was not significantly affected by 
either TiO2, UFTiO2 (Figure 5.1B), S2219200 or S221800 (Figure 5.1C). In 
TiO2/UFTiO2-stimulations; basal secretion of IL-6 was directional with significantly 
greater IL-6 secretion into the basolateral compartment under control conditions 
compared to the apical compartment (apical control: 13.4±2.8pg, basolateral control: 
253.7±18.1pg). However, this effect was not observed in particle studies.  Particle 
S2429901 induced significantly greater IL-6 release in both apical and basolateral 
compartments compared to control (apical control: 24.85±8.96pg, apical S2429901; 
366.71±11.85pg P<0.001. Basolateral control 77±13.8pg, basolateral S2429901 
163.8±8.1pg P<0.001, Figure 5.1D). 
 
These results suggest that particles TiO2, S2219200 and S2218600 are non-
inflammatory to BEAS-2B whilst S2429901 is inflammatory regarding IL-6 secretion. 
No size-related inflammatory mediator effects were observed since increased IL-6 
secretion did not correspond to either the largest or smallest test particle within the 
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range of 168-3000nm. Also, IL-8 secretion from UFTiO2 treated cells cannot be 
measured by ELISA due to interference with the assay (see Figure 10.8). 
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Figure 5.1: S2429901 induces increased IL-6 secretion to the apical and basolateral 
compartments from BEAS-2B at ALI. BEAS-2B were cultured on Transwell
®
 inserts until a 
TER of >45Ω x cm2 was achieved (see section 2.2.1.2). BEAS-2B were treated apically with 
100µg/ml particles in serum free airway epithelial cell medium for 24 hours. After treatment 
apical and basolateral supernatants were collected, cleared at 295xg for 2 minutes and stored at 
-20°C before analysis of IL-8 (A and C) and IL-6 (B and D) secretion by ELISA. Results are 
expressed as mean ± SEM, n=3. A and B) *=P<0.05 compared to apical control. D) 
***=P<0.001 compared to apical control, ##=P<0.01 compared to basolateral control using 
one-way ANOVA and Tukey’s post test. Clear bars represent secretion to the apical 
compartment, black bars represent secretion to the basolateral compartment. 
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5.4.3: S2429901 reduces the priming effect of  IL-8 on fMLP induced respiratory burst in 
neutrophils.  
As UFTiO2 bound IL-8 is not detected by ELISA (Appendix 3), a method was sought to 
allow investigations into whether particle-bound IL-8 remains bioactive. IL-8 primes 
human primary neutrophils for the fMLP induced respiratory burst (Dias et al., 2008). 
Human recombinant IL-8 was therefore incubated with test particles for 24 hours at 
37°C under the same conditions as cell stimulations. Primary human neutrophils were 
then treated with particle bound IL-8, IL-8 alone as a positive control or PBS (as a 
negative control) for 15 minutes prior to induction of the respiratory burst by fMLP.  
 
The respiratory burst is induced by fMLP and this effect is enhanced by IL-8 priming. 
Luminescence is significantly lower when primary human neutrophils are pre-treated 
with PBS rather than IL-8 (Figure 5.2A and B, 34±3 percent of control P<0.01). TiO2- 
and UFTiO2- bound IL-8 is capable of priming the respiratory burst (IL-8; 306.8±11.1% 
of PBS + fMLP, TiO2; 331.9±23.6% of PBS + fMLP; UFTiO2; 239.4±45.7% of PBS + 
fMLP, Figure 5.2A). S2219200 and S2219200 also had no impact on the ability of IL-8 
to prime the neutrophil respiratory burst (Figure 2B).  Particle S2429901 however, 
resulted in a significant reduction in the respiratory burst priming activity compared to 
IL-8 alone (IL-8, 306.8±11.1% of PBS + fMLP; S2429901, 218.5±28.8% of PBS + 
fMLP Figure 5.2B) suggesting that the presence of particle results in loss of IL-8 
function. 
 
These results show that although UFTiO2-bound IL-8 is not detected by ELISA; it 
remains functional in its ability to prime the neutrophil respiratory burst.  
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Figure 5.2: S2429901 reduces the priming effect of  IL-8 on fMLP induced respiratory 
burst in neutrophils. Recombinant human IL-8 was incubated for 24 hours at 37°C with 
100µg/ml particles. Human primary neutrophils were isolated using a discontinuous Percoll™ 
gradient (see section 5.3.9) and pre-treated with IL-8 (control) particle bound IL-8 or PBS for 
15 minutes in the presence of lucigenin. After pre-treatment with IL-8 respiratory burst was 
induced using fMLP (see section 5.3.10).  Results are expressed as mean ± SEM, n=5, 
**=P<0.01 compared to IL-8, ###=P<0.001 compared to PBS using one-way ANOVA, 
*=P<0.05 compared to IL-8 when IL-8+fMLP is normalised to 100% and PBS to 0% using 
repeated measures one-way ANOVA and Tukey’s post test. 
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5.4.4: UFTiO2 decreases BEAS-2B viability but TiO2 and particles have no effect. 
It has been reported that UFTiO2 is more toxic than TiO2 to submerged cultures of 
BEAS-2B (Gurr et al., 2005). In order to determine whether this is observed in the 
mono- and co-culture model presented in this study, BEAS-2B cultured at ALI were 
exposed to TiO2 and UFTiO2  (100µg/ml for 24hours) and cell viability assessed using 
the CellTiter-Blue
®
  viability assay. The toxic potential of the particles S2219200, 
S2218600 and S2429901 was also investigated. 
 
Figure 5.3A shows that treatment of BEAS-2B with UFTiO2 results in a significant loss 
of cell viability compared to control (69.1±8.8 percent of control, P<0.05) whereas TiO2 
had no significant effect on cell viability.  Cells were incubated with 1% (v/v) Triton X-
100 as a positive control for cell death, and viability was reduced to 9.5±4.6 percent of 
control under these conditions (P<0.001, Figure 5.3A). 
 
There was no significant reduction in viability when BEAS-2B were incubated with 
S2219200 or S2218600 indicating that these particles are not cytotoxic to BEAS-2B 
cells (Figure 5.3B).  Particle S2429901 showed a non-significant trend towards 
decreasing BEAS-2B viability (Figure 5.3B). 
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Figure 5.3: UFTiO2 decreases BEAS-2B viability but TiO2 and particles have no effect. 
BEAS-2B cultured on Transwell
®
 inserts until a TER of >45Ω x cm2 was achieved (see section 
2.2.1.2) were treated apically with 100µg/ml particles or 1% (v/v) Triton X-100 in serum free 
airway epithelial cell medium for 24 hours. Prior to addition to cells particles were vortexed for 
2 minutes, sonicated in a water bath sonicator for 30 minutes and vortexed for a further 2 
minutes to remove aggregates. After treatment supernatants were removed and BEAS-2B 
incubated with CellTiter-Blue
®
 reagent (1:5 v/v in serum free airway epithelial cell medium) for 
4 hours in the apical compartment. After incubation, apical media was removed to a 24 well 
plate and fluorescence measured at ex560nm em590nm. Results are expresses as mean ± SEM, 
n=3, *P<0.05 compared to control, ***P<0.001 compared to control using one-way ANOVA 
and Tukey’s post test.  
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5.4.5: UFTiO2 results in a loss of cellular GSH content in BEAS-2B at ALI 
During oxidative stress, reduced GSH becomes oxidised (GSSG) and excessive ROS 
production in cells therefore can lead to a loss in GSH levels as GSSG is rapidly 
exported from cells via p-glycoprotein transporters. Here, GSH levels were measured 
using the GSH-Glo™ GSH assay. UFTiO2 has been shown to induce more ROS 
damage to A549 cells (Singh et al., 2007) and submerged BEAS-2B (Gurr et al., 2005) 
owing to its larger surface area to mass ratio than TiO2. It was therefore investigated 
whether any change in GSH levels was observed in BEAS-2B cultured at ALI with 
UFTiO2 compared to TiO2. The GSH removing potential of S2219200, S2218600 and 
S2429901 was also investigated. As a positive control for GSH loss, positive control 
cells were incubated for 24 hours with BSO, an inhibitor of GSH synthesis (Figure 5.4).  
 
Figure 5.4A shows that BSO significantly decreases cellular GSH concentration 
(control: 32±1µM, BSO: 9±3µM P<0.001) compared to control BEAS-2B at ALI. 
When control values are normalised to 100% and BSO to 0%, UFTiO2 treatment results 
in significant reduction of GSH in BEAS-2B (control: 32±1µM, UFTiO2: 27±1µM 
P<0.05). TiO2, S2219200, S2218600 and S2429901 did not alter GSH levels (Figure 
5.4B).  
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Figure 5.4: UFTiO2 results in a loss of cellular GSH content in BEAS-2B at ALI. BEAS-2B 
cultured on Transwell
®
 inserts until a TER of >45Ω x cm2 was achieved,  were treated apically 
with 100µg/ml particles for 2 hours or 10µM BSO for 24 hours. After incubation reduced GSH 
levels were determined using the GSH-Glo™ GSH assay (materials and methods) Results are 
expressed as mean ± SEM n=3 ***=P<0.001 compared to control, **=P<0.05 compared to 
control where control is normalised to 100%, BSO normalised to 0% using a repeated measured 
one-way ANOVA and Tukey’s post test.  
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5.4.6: Effect of particles on BEAS-2B barrier function  
A major function of the airways epithelium is the maintenance of a semi-permeable 
tight barrier against inhaled pathogens and particulates. UFTiO2 treatment resulted in a 
loss of BEAS-2B viability and S2429901 was found to induce a pro-inflammatory 
response in BEAS-2B as measured by increased IL-6 secretion. To determine whether 
loss of viability or an inflammatory environment influences barrier integrity, TER was 
analysed. TER measurements were taken before particle treatment and normalised to 
control. After incubation with particles TER measurements were taken again and 
normalised to control TER after treatment.  
 
Neither TiO2, UFTiO2 (Figure 5.5A) nor particles (Figure 5.5B) compromised barrier 
integrity as measured by TER. Incubation of BEAS-2B with 1% (v/v) Triton X-100 
resulted in a significant loss of barrier integrity (P<0.001) with TER before treatment 
being 106±11 percent of control and TER after treatment being 45±5 percent of control. 
These results show that the loss of viability after UFTiO2-challenge or increased 
inflammation as a result of S2429901-challenge do not compromise BEAS-2B barrier 
integrity significantly.  
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Figure 5.5: Particles have no effect on BEAS-2B barrier integrity. BEAS-2B were cultured 
on Transwell® inserts until a TER of >45Ω x cm2 was achieved (see section 2.2.1). TER was 
recorded before apical treatment with 100µg/ml particles or 1% (v/v) Triton X-100 in serum 
free airway epithelial cell medium, or with serum free medium alone (control) for 24 hours and 
normalised to control (black bars). After incubation culture medium as replenished and TER 
was recorded again and normalised to control well after treatment (open bars). Results are 
expressed as mean ± SEM, from 3 separate experiments with 2 Transwell
®
 inserts per treatment 
in each experiment **=P<0.01 compared to 1% (v/v) Triton X-100 percent of control before 
treatment using one-way ANOVA and Tukey’s post test.  
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5.4.7: Particle treatment does not induce increased inflammatory mediator 
secretion from HPMEC  
The epithelial barrier is maintained in particle treated BEAS-2B (measured by TER). 
However, any affect of particle treatment on inflammatory mediator secretion from 
HPMEC was examined so any contribution of HPMEC cells to inflammation induced 
by particle could be determined in the event of epithelial barrier disruption. HPMEC 
alone were exposed to particles for 24 hours, and supernatants were assayed for the 
inflammatory mediators IL-8 and IL-6.  
 
Figure 6 shows that neither IL-8 secretion (Figure 5.6A) nor IL-6 secretion (Figure 
5.6B) was altered after incubation with TiO2, UFTiO2 or particles. These results suggest 
that test particles are non-inflammatory to the endothelium alone.  
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Figure 5.6: Particle treatment does not induce increased inflammatory mediator secretion 
from HPMEC. HPMEC were seeded in 24 well plates at 5x10
4
cells/well and cultured 
overnight. Cells were incubated with 100µg/ml particles in fully supplemented endothelial cell 
medium for 24 hours. Prior to addition to cells particles were vortexed for 2 minutes, sonicated 
in a water bath sonicator for 30 minutes and vortexed for a further 2 minutes to remove 
aggregates. After treatment supernatants were collected, cleared at 295xg for 2 minutes and 
stored at -20°C until analysis. IL-8 and IL-6 was analysed using IL-8 and IL-6 ELISA 
respectively. Results are expressed as mean ± SEM, n=3.  
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5.4.8: TiO2 and UFTiO2 reduce HPMEC viability 
In order to determine whether the lack of inflammatory response of particle exposed 
HPMEC was due to loss of cell viability, HPMEC were exposed to 100µg/ml particles 
or particles for 24 hours, after which the CellTiter-Blue
®
 viability assay was performed. 
As a positive control for loss of viability, cells were incubated with 1% (v/v) Triton X-
100. 
The results show that both TiO2 and UFTiO2 incubation significantly reduced HPMEC 
viability (TiO2 77±1% of control, UFTiO2; 69.1±4% of control, Figure 5.7A, P<0.05). 
Treatment with 1% (v/v) Triton X-100 reduced cell viability to 9.5±4.6 percent of 
control (P<0.001). There was no loss of viability in particle-treated HPMEC (Figure 
5.7B).  
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Figure 5.7: TiO2 and UFTiO2 reduce HPMEC viability. HPMEC were seeded in 24 well 
plates at 5x10
4
cells/well and cultured overnight. Cells were incubated with 100µg/ml particles 
in fully supplemented endothelial cell medium for 24 hours after which supernatants were 
collected and cells were incubated with CellTiter-Blue
®
 reagent (1:5 v/v) in fully supplemented 
endothelial cell media for 4 hours. After incubation fluorescence was measured at ex560nm 
em590nm. Results are expressed as mean ± SD n=3, *=P<0.05 compared to control, 
***=P<0.001 compared to control using one-way ANOVA and Tukey’s post test.  
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5.4.9: Particles treatment does not induce oxidative stress in HPMEC.  
In order to determine whether the loss of cell viability observed with TiO2 and UFTiO2 
exposed HPMEC may be due to oxidative stress,  levels of GSH were investigated in 
HPMEC-treated with particles for 2 hours. The effect of particles of cellular GSH was 
also determined.  Cells were incubated for 24 hours with BSO which inhibits synthesis 
of GSH. BSO incubation depleted the HPMEC GSH concentration significantly (Figure 
5.8, control; 14±0µM, BSO; 0.2±0.1µM GSH, P<0.001). Neither TiO2 nor UFTiO2 had 
any effect on HPMEC GSH, suggesting that loss of viability with these particles in 
HPMEC was not due to oxidative stress; there was also no loss of GSH in HPMEC 
when treated with particles (Figure 5.8).   
  
161 
 
A) 
C
on
tro
l
M
)

B
S
O
 (1
0
2
Ti
O 2
U
FT
iO
0
5
10
15
20
***
G
S
H
 (

M
)
 
B) 
C
on
tro
l
M
)

BS
O
 (1
0
S2
21
92
00
S2
21
86
00
S2
42
99
01
0
5
10
15
20
***
G
S
H
 (

M
)
 
Figure 5.8: Particle treatment does not induce oxidative stress in HPMEC. HPMEC were 
seeded in a 96 well plate at 8000cells/well and incubated overnight. Cells were treated with 
10µM BSO for 24 hours or 100µg/ml particles for 2 hours in fully supplemented endothelial 
cell medium. After incubation supernatants were removed and GSH content determined using 
the GSHGlo™-GSH assay. Results are expressed as mean ± SD, n=2, ***=P<0.001 compared 
to control.  
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5.4.10: S2429901, but none of the other particles tested, induces IL-6 secretion to 
the apical compartment of BEAS-2B/HPMEC co-cultures.  
An aim of the current study was to expose the BEAS-2B/HPMEC co-culture to TiO2, 
UFTiO2 and particles to determine if the inflammatory response and viability mirror the 
mono-cultures experiments or whether there was any synergism/antagonism between 
the two cell types. The inflammatory response of the co-culture after 24 hour apical 
exposure to 100µg/ml particle was measured by analysis of IL-8 and IL-6 secretion. 
 
Figure 5.9A shows that secretion of IL-8 into the apical compartment was reduced non-
significantly compared to control with TiO2 (control: 5585.3±1509.456pg, TiO2: 
2739.41±767.78pg). Basolateral IL-8 secretion was unaffected by particle treatment, 
however, a large experimental error was observed during IL-8 detection.   
 
IL-6 secretion into the basolateral control was significantly greater than in the apical 
compartment (apical control: 165.93±33.82, basolateral control; 920±49.4pg). IL-6 
secretion in both the apical and basolateral compartment was un-changed after TiO2 or 
UFTiO2 challenge (Figure 5.9B).  These results suggest that TiO2 and UFTiO2 are not 
inflammatory to the airways epithelium. S2219200 and S2218600 were found to be 
non-inflammatory to BEAS-2B and HPMEC monocultures (Figure 1C-D and 6C-D 
respectively). S2429901 induced an inflammatory response in BEAS-2B with 
significantly increased IL-6 secretion after 100µg/ml S2429901 treatment for 24 hours 
(Figure 5.1D). As with BEAS-2B mono-cultures there was no significant increase in IL-
8 secretion from BEAS-2B/HPMEC co-culture model (Figure 5.9C). S2429901 induced 
IL-6 secretion into the apical compartment of the co-culture model (apical control: 
165.9±33.8pg, apical S2429901: 724±24.9pg P<0.01, Figure 5.9D). Again, IL-6 
secretion was shown to be directional with significantly greater IL-6 secretion into the 
basolateral compartment than the apical compartment for both titanium and particle 
(Figure 5.9B and 5.9D P<0.001).  
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In order to determine whether there was any synergism or antagonism regarding 
inflammatory mediator secretion between the BEAS-2B and HMVEC total IL-8 or IL-6 
from mono-culture studies were compared the total for co-culture studies (it appears 
that there is greater IL-8 secretion in co-culture studies for the particle stimulation. 
However in BEAS-2B mono-cultures there was much lower IL-8 secreted from particle 
stimulated cells than TiO2 stimulated cells (Figure 5.1).   
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Figure 5.9: S2429901 but none of the other particles tested,  induces IL-6 secretion to the 
apical compartment of the BEAS-2B/HPMEC co-culture. HPMEC were seeded in a 
companion plate at 5x10
4
cells/well and cultured overnight, after which media was replenished 
with 600µl endothelial cell medium and BEAS-2B previously cultured on Transwell
®
 inserts 
with a TER greater than 45Ω x cm2 were placed in the well. The co-culture was treated apically 
for 24 hours with 100µg/ml particles in serum free airway epithelial cell medium, or serum free 
airway epithelial media alone. After exposure supernatants were collected and cleared at 295xg 
for 2 minutes and stored at -20°C until analysis by IL-8 and IL-6 ELISA. Results are expressed 
as mean ± SEM, n=4, **=P<0.01 compared to apical control, ###=P<0.001 compared to apical 
control. Clear bars represent secretion to the apical compartment, black bars represent secretion 
to the basolateral compartment. 
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5.4.11:BEAS-2B/HPMEC co-culture viability is not affected by particle exposure  
The particles were previously shown to have no cytotoxic effects on either BEAS-2B 
(Figure 5.3) or HPMEC (Figure 5.7). However, UFTiO2 was found to be toxic to both 
BEAS-2B (Figure 5.3) and HPMEC mono-cultures (Figure 5.7) and TiO2 was toxic to 
HPMEC (Figure 5.7). The effect on cell viability of these particles on the BEAS-
2B/HPMEC co-culture was therefore investigated in order to determine whether the co-
culture responds in a similar manner to the mono-cultures. There was no loss of cell 
viability with either cell type in the co-culture after TiO2, UFTiO2 or particle treatment 
(Figure 5.10).  
 
These results suggest that the co-culture model is more resistant to particle induced cell 
death than either cell type alone.  
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Figure 5.10: BEAS-2B/HPMEC co-culture viability is not affected by particle exposure. 
HPMEC were seeded in a companion plate at 5x10
4
cells/well and cultured overnight, after 
which media was replenished with 600µl endothelial cell medium. HPMEC were then 
combined with BEAS-2B cultured on Transwell
®
 inserts with a TER greater than 45Ω x cm2. 
The co-culture was treated apically for 24 hours with 100µg/ml particles in serum free airway 
epithelial cell medium, or serum free airway epithelial media alone. After incubation BEAS-2B 
on Transwell
®
 inserts were removed to a separate well and incubated with 300µl CellTiter-
Blue
®
 (1:5 v/v in airway epithelial cell media) for 4 hours. HPMEC were incubated with 1ml 
CellTiter-Blue
®
 (1:5 v/v in endothelial cell media) for 4 hours. After incubation fluorescence 
was measured at excitation 460nm emission 590nm. Results are expressed as mean ± SD, n=4, 
***=P<0.001 compared to apical control, ###=P<0.001 compared to basolateral control.  
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5.5: Discussion 
Most of the research conducted into the inflammatory and cytotoxic effects of NP on 
the airways in vitro has been conducted on submerged mono-cultures of airways 
epithelial cells (Park et al., 2008; Singh et al., 2007 & Veranth et al., 2007). These do 
not entirely mimic the in vivo airways where epithelial cells are at ALI. Further, since 
endothelial cells themselves release inflammatory cytokines in response to PM (Gojova 
et al., 2007) and NP have been observed to translocate to the endothelium (Geiser et al., 
2005), co-cultures of epithelial and endothelial cells may provide a better understanding 
into the toxic and inflammatory effect of NP exposure. The aim of this study was to 
therefore characterise the inflammatory response of BEAS-2B cultured at ALI and 
BEAS-2B/HPMEC co-culture model to TiO2 and UFTiO2 at 100µg/ml for 24 hours, 
and any associated toxicity. Particles, dose and incubation period were chosen as they 
are commonly used in the study of airways inflammation (Ishii et al., 2005; Newland & 
Richter, 2008; Sakamoto et al., 2007; Veranth et al., 2007). The inflammatory, 
cytotoxic and oxidative response of cells to S2219200, S2218600 and S2429901, were 
also undertaken. In vivo studies have already been conducted elsewhere (Gaiser, 2008).  
 
Size has been shown to be a determining factor in the cellular response of airway 
epithelial cells after exposure to PM (Singh et al., 2007). The size of the particles in this 
study was therefore characterised. TiO2 was found to be a heterogeneous mix of fine to 
coarse particles with diameter of 1000nm-3000nm. UFTiO2 has a diameter of 5nm as 
per manufacturers details. As direct comparisons between TiO2 and UFTiO2 will be 
made during this study, the charge of particles (zeta potential) was also investigated 
since zeta particle charge has also been shown to affect cell-particle interaction 
(Dausend et al., 2008). TiO2 and UFTiO2 were found to have a similar negative charge, 
so charge-related effects of the particles on the cells can be eliminated. S2219200, 
S2218600 and S2429901 are of unknown composition so charge analysis was not 
undertaken since any results observed may be due to particle composition. Size 
determination showed that all three particles are indeed NP as the size range was 168-
533nm.   
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The endotoxin content of particles was determined in order to rule out endotoxin-
induced cell responses after particle challenge. The particles were shown to have 
negligible endotoxin contamination; endotoxin levels were shown to be below the 
lowest standard in the assay kit (0.1 EU/ml). US Food and Drug Administration (FDA) 
state that medical devices may contain endotoxin levels of ≤0.5 EU/ml (Gorbet and 
Sefton, 2005). Further, Ishii et al., (2005), reported that endotoxin content of particulate 
matter up to 6.4EU/ml does not result in an inflammatory response in lung epithelial 
cells, therefore, any inflammatory response observed here is solely due to the particles 
themselves. 
 
TiO2 has been previously shown to induce IL-8 secretion from and increased mRNA 
expression in airway epithelial cells, (Park et al., 2008; Singh et al., 2007 & Veranth et 
al., 2007. The results of the present study conversely showed a significant decrease in 
IL-8 secretion from BEAS-2B treated with UFTiO2 compared to TiO2 which was likely 
to be due to adsorption of IL-8 onto UFTiO2 resulting in a reduced detection of IL-8 by 
ELISA (Chapter 10). Whether UFTiO2 bound IL-8 remains functional was investigated 
by measuring the ability of particle-bound IL-8 to prime the human primary neutrophil 
respiratory burst. This analysis has relevance to the present study as increased numbers 
of neutrophils have been observed in BAL fluid of TiO2 treated rats (Renwick et al., 
2004) possibly due to increased chemokine activity. Neither TiO2, UFTiO2, S2219200 
or S2218600 affect the ability of IL-8 to prime the neutrophil respiratory burst for 
enhanced response to fMLP. These results suggest that IL-8 secreted in response to 
UFTiO2 remains biologically active, however future work is required to determine 
whether UFTiO2 challenged BEAS-2B respond by increased IL-8 production, and a 
Boydem chemataxis chamber could be used to determine the chemotactic potential of 
particle-bound IL-8.  
 
Pre-incubation with S2429901 significantly reduced the priming affect of IL-8. 
Adsorption studies showed that S2429901 did not significantly reduce IL-8 detection by 
ELISA (Appendix 3)  nor did the presence of this particle affect the luciferase signal of 
the respiratory burst assay (Chapter 10) or the baseline signal of neutrophils without 
luciferase. It is therefore not clear as to why there was a reduction in the respiratory 
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burst priming with S2429901. This particle may have exhibited cytotoxic effects 
towards primary human neutrophils thereby resulting in loss of the respiratory burst. 
Further work should investigate the effect of S2429901 on neutrophil viability; previous 
studies have shown dose-dependent cytotoxicity towards this particle in rat epithelial 
and fibroblast cell types (Gaiser et al., 2009) and there was a trend towards decreased 
viability in BEAS-2B cultured at ALI after S2429901 exposure.  Taken together these 
results suggest that particles S2219200, S2218600 and S2429901 do not induce an 
increase in IL-8 secretion in the airways epithelium, but IL-8 activity may be 
influenced/inhibited in the presence of S2429901. 
 
Urban air PM10, ROFA and DEP have all been reported to increase IL-6 secretion from 
airway epithelial cells in vitro (Auger et al., 2006; Carter et al., 1997 & Ishii et al., 
2005). The current study shows that incubation of BEAS-2B cells either alone or in co-
culture with S2429901 results in increased IL-6 secretion. There are several possible 
explanations for the lack of IL-6 response to TiO2 that was observed in the current 
study compared to published data. First, the increased IL-6 secretion in ROFA-treated 
NHBE was due to the presence of transition metals on the particle surface (Carter et al., 
1997) the presence of which have been suggested to induce an inflammatory response 
via ROS production through the Fenton reaction (Carter et al., 1997). Here, TiO2 was 
found to have no effect on GSH suggesting that ROS was not increased. Another 
possible explanation for the lack of IL-6 response is the difference in cell type. Carter et 
al., (1997) and Ishii et al., (2005) observe significant IL-6 secretion in response to PM 
by NHBE cells. Veranth et al., (2007) noted that NHBE secrete far greater basal levels 
of IL-6 than BEAS-2B,  suggesting that the regulatory control of IL-6 expression may 
also differ. Stimulation of NHBE cells cultured at ALI with particles may therefore 
result in increased secretion of IL-6, however the aims of the present study are to 
validate the BEAS-2B cultured at ALI as a model of airways inflammation, rather than 
a comprehensive analysis of the inflammatory potential of the particles to the airways. 
 
Veranth et al., (2008) also observed that cell culture media influences the IL-6 response 
of submerged cultures of BEAS-2B when treated with the same particle species. Zhao 
et al., (2009) reported that submerged cultures of NHBE secrete significant levels of 
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GM-CSF, IL-6, IL-8 and IL-1β response to 24 hour treatment with 100µg/ml PM10 
compared to submerged control cells, whilst the same cells cultured under ALI with the 
same treatment only show significant secretion in IL-6 compared to control cells 
cultured at ALI. These results imply that the culture conditions themselves also govern 
the inflammatory response observed and may explain the discrepancy between this 
work and published data regarding IL-6 secretion. The closest comparison to the 
present study is that by Veranth et al., (2007), who treated submerged BEAS-2B 
cultured in either KGM or LHC-9 media with 100µg/ml TiO2 or UFTIO2 for 24 hours, 
and observed no significant increase in IL-6 secretion, a result mirrored in the current 
study with BEAS-2B cultured at ALI.  
 
TiO2 has been shown to increase ROS and cell death in NHBE, 16HBE14o (Hussain et 
al., 2010) and BEAS-2B (Gurr et al., 2005; Park et al., 2008). An important contributor 
to the toxicity and cell signalling activity of ROS is a change in cellular redox state due 
to reactions between ROS and thiols on GSH (Forman et al., 2009). Cell viability and 
GSH content (as a measure of redox stress) were therefore investigated in the current 
study. Here, BEAS-2B cultured at ALI showed a significant reduction in both cell 
viability and GSH content with UFTiO2-treatment compared to control, this response 
was not observed with TiO2. Similarly Gurr et al., (2005) observed that UFTiO2 
induced significant oxidative DNA damage, lipid peroxidation, ROS and micronuclei 
formation in submerged cultures of BEAS-2B. Despite the differences in methods 
between Gurr et al., (2005) and the current study, they both show increased oxidative 
stress and cell damage after UFTiO2 challenge. Further, Park et al., (2008) observed a 
significant reduction in cellular GSH and viability in submerged BEAS-2B with 
UFTiO2. The oxidative and cytotoxic response of BEAS-2B cultured at ALI show good 
agreement with published data from submerged BEAS-2B, and lend support to BEAS-
2B cultured at ALI as a valid model for investigations into PM toxicity.  
 
An important function of airway epithelial cells is to maintain a tight barrier against 
invading pathogens and toxins. As UFTiO2 induced a loss of cell viability 
investigations were carried out to determine if the BEAS-2B cell barrier was 
compromised by UFTiO2 and other test particle exposure by analysis of TER. There 
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was no change in TER with any of the test particles used indicating no loss of barrier 
integrity. Westmoreland et al., (1999) reported no change in TER after  TiO2 treatment 
in 16HBE14o, however, they also observed no change in cell viability. The size of the 
TiO2 used in the study by Westmoreland et al., (1999) was not reported making 
comparisons difficult. However, sodium carbonate treatment caused loss of viability 
which was mirrored with loss of TER. Caraballo et al., (2011) showed that 
transepithelial electrical conductance in response to PM treatment in rat alveolar 
epithelial cells, did not mirror permeability changes using lanthium nitrate, a compound 
reported to not pass through tight junctions under normal conditions. Results reported in 
this chapter suggest that the BEAS-2B barrier (electrical resistance) was not 
compromised; further investigations into tight junction integrity by lanthium nitrate 
permeability or tight junction protein localisation studies would support this finding.  
 
Comparisons into inflammatory mediator secretion between the current BEAS-2B ALI 
model and other published models are difficult, due to chemokine adsorption onto PM 
and effects of differing culture conditions and cell types. Nethertheless, the  viability 
and oxidative stress studies are in agreement with those reported for TiO2 and UFTiO2 
(Gurr et al., 2005; Park et al., 2008). The BEAS-2B ALI model was therefore adopted 
in a co-culture of the airways by incorporation of a HPMEC cell layer. To this end the 
contribution of the endothelial compartment to the inflammatory response, endothelial 
viability and GSH concentration were determined in response to all test particles.  
 
IL-8 or IL-6 secretion from HPMEC alone was not modified with any of the particles 
tested, compared to control. In contrast Qu et al., (2010) reported a significant increase 
in IL-6 secretion from human lung blood microvascular endothelial cells (HMVEC-
LB1) treated with 100µg/ml urban air PM2.5, and this increase in IL-6 secretion was 
sustained over 24 hours. In the present study, both TiO2 and UFTiO2 reduced HPMEC 
viability which contrasts with the result obtained from Yu et al., (2010) where TiO2 
treatment had no affect on cell viability. However, Yu et al., (2010) treated cells with a 
dose of particles ten-fold less than used in this study, and this difference in particle dose 
may account for the increase in cytotoxicity observed here in response to particles. 
UFTiO2 induces greater oxidative stress in airway epithelial cells than TiO2 (Singh et 
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al., 2007). There was however, no oxidative stress induced in HPMEC exposed to 
either UFTiO2 or TiO2 as measured by GSH levels.  
 
Acute challenge with S2219200, S2218600 and S2429901 did not induce a significant 
inflammatory response in HPMEC and had no effect on cell viability or GSH 
suggesting that these particles are non-inflammatory and not cytotoxic to pulmonary 
endothelial cells. The reduction in IL-8 detection in UFTiO2 treatment was not observed 
with HPMEC cells; this is likely to be due to the presence of FBS in the culture media. 
FBS proteins would bind to the particles thereby inhibiting cytokine binding. Indeed 
Val et al., (2010) show a reduced adsorption of GM-CSF to particles by inclusion of 
serum into culture media.  A significant loss of IL-8 detection in apical supernatants by 
ELISA was not observed in UFTiO2-treatment of the co-culture however, in these 
experiments there was a lot of variability within the control treatments. TiO2, S2219200 
and S221800 were non-inflammatory to BEAS-2B cells in mono-culture, and were also 
non-inflammatory in the co-culture model, suggesting that the co-culture model has a 
similar sensitivity to the mono-cultures.  
 
S2429901 increased IL-6 secretion from BEAS-2B significantly, however, this particle 
failed to induce an increase in IL-6 secretion in the co-culture. It may be that the 
presence of the HPMEC cell layer provides protection against airway inflammation in 
vitro. Mogel et al., (1998) reported that co-cultures of endothelial cells and epithelial 
cells show greater inflammatory mediator secretion in response to stimuli than the 
mono-cultures combined. Mogel et al., (1998) investigated BEAS-2B cells that were 
cultured on the apical surface of Transwell
®
 inserts with ECV304 HUVEC cell line in 
the basolateral compartment compared with BEAS-2B in the apical compartment under 
submerged conditions. The co-culture was exposed to 0.15ppm ozone for 90 minutes 
without medium in the apical compartment. While the cell orientation and types were 
very similar to the current study, the synergism observed by Mogel et al., (1998) was 
not observed here. 
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The loss of viability with HPMEC cells observed with TiO2 and UFTiO2 is not 
observed in the HPMEC compartment of the co-culture model and this is likely to be 
due to the presence of the BEAS-2B presenting a physical barrier to protect the 
endothelium from direct particle exposure. TER suggests that BEAS-2B barrier 
remained intact during particle treatment. TER measurements were not undertaken on 
the co-culture after particle treatments. UFTiO2 has been shown to translocate through 
cell layers by Rothen-Rutishauser et al., (2008) in a triple cell model of A549 cell on 
Transwell
®
 inserts with alveolar macrophages in direct contact on the apical surface of 
A549 and monocyte derived dendritic cells on the underside of the insert. Particles 
added apically in solution were observed in all 3 cell types after 24 hour incubation. A 
limitation of the present study is that, due to limited expansion of HMVEC cells, the 
location of particles was not investigated. Future work could include investigation of 
particle transport through the BEAS-2B epithelial barrier to the endothelial 
compartment to make further comparisons between the co-culture model and in vivo 
reports of particle localisation within endothelial cells.  
 
5.6: Conclusion 
The inflammatory response of the BEAS-2B ALI model in response to titanium is 
complicated by cytokine adsorption onto particles and varying cytokine responses of 
cells under different culture conditions. A size-dependent loss of cell viability and GSH 
(indicative of ROS production) was observed with titanium treated BEAS-2B cultured 
at ALI, similar to those reported elsewhere in submerged models. The current ALI 
model presents a closer representation of epithelial cell phenotype in vivo and is 
therefore a compelling model for study of PM induced lung inflammation. The co-
culture model requires further investigations however. Investigations into particle 
translocation within the model would also allow for characterisation and validation of 
the model when compared to in vivo studies. 
  
174 
 
Chapter 6: Proteomic identification of airway inflammation 
biomarkers
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6.1: Rationale 
Proteomics, is the study of all the protein isoforms within a cell, tissue or bodily fluid at 
a given time, such as plasma. The proteins within these samples undergo expression 
changes during cellular events, for example during inflammation the plasma proteome 
shows expression changes in acute-phase protein. Proteomics is therefore a powerful 
tool which can provides un-biased (global protein expression changes are analysed 
rather than selecting to identify expression changes of a given protein) analysis of up- 
and down-regulated proteins and identification of post-translational modifications 
within a sample. This method may prove useful in the identification of early biomarkers 
of disease and biomarkers of particulate matter exposure and response. Comparable in 
vitro biomarkers of risk profiles to those observed in vivo may be considered to 
substantiate in vitro testing and allow for high throughput and rapid reproducibility.   
 
The current study aims to use proteomics to investigate effects of either TiO2 or 
UFTiO2 on the cell proteome of BEAS-2B differentiated at ALI and to identify early 
toxicity biomarkers of toxicity on repeat doses of particle exposure in rats. 
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6.2: Introduction 
The Cosmetic Directive now rules that cosmetic testing on animals will be banned after 
2013 (7
th
 Amendment of the European Union Cosmetic Directive, 2003). This 
necessitates development of robust and valid in vitro models that represent 
physiological systems.  By comparative analysis between these in vitro models and in 
vivo experiments, it is anticipated that common biomarkers of toxicity and disease 
states may be observed which may subsequently allow for early diagnosis of toxicity 
and disease from in vitro tests alone (Ocak et al., 2009; Matt et al., 2008), or allow 
exposure profiles to be identified. 
 
Approaches in identification of biomarkers of exposure, response, or disease include 
genomics and proteomics. Genomics, the study of all the genes in an organism, is a 
powerful tool, although, mRNA expression and protein expression are not tightly 
related (Aldred et al., 2004; Ocak et al., 2009); indeed post-translational modifications 
(PTM), such as phosphorylation, which may act as on/off signals for protein functions 
are not identified in genomic analysis (Ocak et al., 2009; Matt et al., 2008; Zhou et al., 
2005). In contrast, proteomics allows for post-translational modifications to be 
identified (Zhou et al., 2005 & Lim et al., 2004) and was first described in the early 
70’s (Rabilloud et al., 2010). Proteomics involves separation of proteins within a 
sample first by their iso-electric point (pI, the pH at which the proteins have no net 
charge) followed by separation based on their molecular weight (Matt et al., 2008).  
The proteins are then visualised using protein stains and digested from the gel with site-
directed proteases such as trypsin. Peptide digests are then analysed by mass 
spectrometry (MS).  
 
Proteomic analysis of UFTiO2-treated BEAS-2B has identified up-regulation 
inflammatory and ROS associated proteins including macrophage migration-inhibitory 
factor (Cha et al., 2007), superoxide dismutase and peroxiredoxin-1 (Ge et al., 2011) 
and proteins involved in mitochondrial dysfunction, ERK signalling, cell cycle and 
myc-mediated apoptosis signalling pathways (Ge et al., 2011). However, in these 
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studies BEAS-2B were cultured under submerged conditions, proteomic analysis of 
TiO2 treated BEAS-2B cultured at ALI has not been described previously.  
 
The aim of this study is to identify early biomarkers of toxicity/exposure from model 
systems exposed to commercially relevant particles. Proteomic analysis was undertaken 
on lysates from BEAS-2B (cultured at ALI) exposed to both fine and UF-TiO2 
S2219200, S2218600 and S2429901, to identify possible biomarkers of epithelial 
damage after inhalation exposure. Proteomic analysis was also undertaken on plasmas 
from rats treated with a methyl vinyl ether/maleic anhydride copolymer (referred to as 
020310), which is a water-soluble particle with an average molecular weight of 
62,000Da or positive control (a copolymer of methyl methacrylate, ethyl methacrylate 
and butyl acrylate of a molecular weight of 700,000Da, which is not soluble in water, 
but can be suspended in aqueous solution), referred to as MM/EM/BA and negative 
control of saline. Rats were further separated into 9 or 22 week recovery groups for 
each treatment, whereby plasma samples were collected either 9 or 22 weeks after the 
last polymer treatment. 
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6.3: Methods 
6.3.1: Endotoxin content by LAL assay.  
Endotoxin content of particle stocks were determined using the QCL-1000
®
 LAL assay 
as described in section 2.4.4. 
 
6.3.2: TiO2 depletion from TiO2 -treated BEAS-2B cell lysates or BSA 
samples  
PM in cell lysates following cell challenge with particles prevented subsequent 
proteomic analysis. To overcome this problem a depletion method was sought that 
would allow removal of particles from cell lysates without removal of protein. 
Extraction buffers containing the reducing agent dithiothreitol (DTT) (1mM) or DTT 
plus 1% (v/v) Tween-20 were added to lysates from particle- treated BEAS-2B, or to 
5mg/ml BSA, and then samples were vortexed for 2 minutes. “No particle”-treatment 
served as a control. Lysates were then passed through Microcon
®
 YM-100 100KDa cut 
off filters (Sigma; z648094, Poole, UK) as per manufacturer’s instructions at 14,000xg. 
Protein content of both <100KDa and > 100KDa fractions was determined using the 
bicinchoninic acid (BCA) method as detailed in section 6.3.6. To clear particles without 
filtration, lysates were either left to stand for 1 hour to sediment particles prior to 
centrifugation at 23800xg for 10 minutes at 15°C (Wang et al., 2005) or centrifugation 
at 14,000xg for 30 minutes (Cha et al., 2006). Protein concentrations of supernatants 
were subsequently determined using the BCA assay and proteomic analysis was 
undertaken. 
 
6.3.3: Proteomic analysis 
Cleared cell lysates from particle-treated cells, or un-cleared lysates from particle-
treated cells (50μg) were lyophilised and re-suspended in 180μl rehydration buffer (6M 
urea, 2M thiourea, 2% (w/v) CHAPS, 2% (w/v) SB3-100, 40mM Tris HCl and 
bromophenol blue to colour) with 2.4μl DeStreak and 1μl ampholyte (biolytes3/10). 
The resuspended sample (180μl) was loaded in a well of the rehydration plate (Protean 
IEF, BioRad, Hertfordshire, UK) covered with Criterion IPG strip pH range 3-10, 
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overlaid with mineral oil and rehydrated overnight at 20
°
C. Solubilised proteins focused 
by isoelectric point onto Criterion IPG strip using a ramping program of 500V for 
500Vh, 3500V for 3500Vh, 3500V for 90kVh in a Protean IEF Cell (BioRad, 
Hertfordshire, UK). Gels were then equilibrated for 20 minutes in 7ml equilibrium 
buffer (6M urea, 20% (v/v) glycerol, 2% (w/v) sodium dodecyl sulphate (SDS), 0.375M 
Tris-base pH8.8). Proteins were separated in a second dimension by molecular weight 
on 4-20% Tris-glycine gradient gels for 150 minutes at 90V in BioRad criterion cell 
tanks (BioRad, Hertfordshire, UK) with TGS running buffer (3.03g Tris HCl pH8.3, 
14.4g glycine, 1g SDS). Proteins were detected using Flamingo™ fluorescent protein 
stain (Linear range of 0.5-100ng, BioRad, Hertfordshire, UK) for 5 hours. Gels were 
scanned on a Pharos FX™ Plus Molecular Imager (BioRad, Hertfordshire, UK). A thin 
layer of water was added to gels prior to scanning to allow for removal of dust from the 
gel surface. Up- or down-regulated protein spots (Significance by ANOVA <0.05 and 
statistical power >0.8) were identified.  
 
6.3.4: Analysis of protein spots by Progenesis SameSpots 
After scanning, analysis of protein spots was conducted using Progenesis SameSpots as 
follows. Gels are cropped so that an area containing all the proteins spots is collected. A 
reference image is then selected, the reference image is one where the spot profiles 
differ the least from all other gels. Damaged areas/saturated areas are then removed and 
spots are matched by the analysis software. After matching spots in damaged or 
saturated areas not previously removed can be excluded (Progenesis SameSpots 
removes spots which have a small spot area but high volume intensity (indicative of a 
speckle), these parameters can be edited). Spot volumes are then normalised to the 
reference gel and the user then defines the experimental design, after which, results and 
statistics for up- or down-regulated spots can be observed.   
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6.3.5: Polymer treatment of rats 
Proteomic analysis was carried out on plasma from polymer treated rats, where polymer 
treatment was undertaken previously and reported by Carthew et al., (2006). Briefly the 
10 week old male Wistar rats were treated on 3 separate occasions (2 week intervals 
between treatments) with varying doses of polymer 020310, a copolymer of methyl 
vinyl ether and maleic anhydride (10 rats per group). The high dose group received a 
total of 12mg/kg polymer 020310 (individual doses of 4mg/kg), the intermediate dose 
group received a total of 1.2mg/kg polymer 020310 (3 individual doses of 0.4mg/kg) 
and the low dose group received a total of 0.3mg/kg polymer 02310 (3 individual doses 
of 0.1mg/kg). A co-polymer of methyl methacrylate/ ethyl methacrylate and butyl 
acrylate (MM/EM/BA) was used as a positive control (rats received a total dose of 
12mg/kg, over 3 treatments with 2 week intervals) and a negative control group 
received saline. Treatment groups were further divided into 9 week recovery groups 
(plasma collected 9 weeks after final treatment) and 22 week recovery group (plasma 
collected 22 weeks after final treatments). All treatments were administered by 
intratracheal instilliation via the oropharynx. Treatments were conduceted by, Carthew 
et al., (2006) and plasma samples were provided by Dr P Carthew (Unilever). 
  
In order to remove the major plasma protein albumin and immunoglobulins from rat 
plasma samples provided by Carthew et al., (2006), ammonium sulphate was added to 
plasma (0.277g/ml) and rotated at 4°C for 30 minutes followed by centrifugation at 
11337xg for 15 minutes. The resulting pellet was re-dissolved with 3ml of 1mM 
potassium chloride with 1mM imidazole, pH7. The protein concentration of samples 
was then determined using the BCA protein assay. Equal concentrations of sample 
(5mg) were grouped according to treatment. Groups were numbered 1-10 blindly and 
group IDs were disclosed after spot analysis, Table 6.1. Albumin-depleted plasma-pools 
were desalted into PBS using 10ml disposable chromatography columns (BioRad, cat 
732-2010). The BCA assay was performed (see section 6.3.6) on albumin-depleted de-
salted plasma-pools to determine final protein concentrations of the groups.  
 
  
181 
 
Table 6.1: Analysis design for rat plasma samples 
Blinded group Treatment group 
Group 1 Negative control, 9 weeks 
Group 2 Negative control, 22 weeks 
Group 3 Low dose treatment, 9 weeks 
Group 4 Low dose treatment, 22 weeks 
Group 5 Mid dose, 9 weeks 
Group 6 Mid dose, 22 weeks 
Group 7 High dose, 9 weeks 
Group 8 High dose, 22 weeks 
Group 9 MM/EM/BA, 9 weeks 
Group 10 MM/EM/BA, 22 weeks 
 
6.3.6: BCA assay for protein determination. 
Protein concentration of rat-plasma samples and cell lysates was determined using the 
bicinchoninic acid assay. The principle of the assay is as follows: Copper(II) is dose-
dependently reduced to copper(I) by protein and bicinchoninic acid subsequently forms 
a purple product in the presence of copper(I) which can be detected by adsorption at 
570nm. Briefly, 10µl samples and standards (0-1mg/ml BSA diluted in distilled water) 
in a 96 well plate were incubated with 200µl/well working solution of 4% (v/v) 
copper(II) sulphate diluted 1:50 in bicinchoninic acid) for 30 minutes at 37°C. The plate 
was then left to equilibrate for 10 minutes at room temperature prior to measurement of 
absorbance at 570nm. Protein concentrations of samples were extrapolated from the 
standard curve using BSA as a standard (0-1mg/ml) and expressed as mg/ml.  
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6.3.7: Proteomic analysis of pooled plasma 
Albumin-depleted pooled-plasmas (50μg) were concentrated to a pellet using an 
eppendorf concentrator plus (Jencons, VWR, West Sussex, UK) and proteomic analysis 
was undertaken as above 
 
6.3.8: Protein digestion from gel pieces 
Gel pieces were excised over a UV light box, removed to Protein LoBind eppendorf 
tubes (Sigma) and washed with 200µl distilled water for 30 seconds whilst vortexing. 
Gel pieces were destained twice with 200µl methanol:50mM NH4HCO3 (1:1 v/v) with 
vortexing for 1 minute, followed by dehydration for 5 minutes with 200µl acetonitrile 
(Fisher scientific, Loughborough, UK):NH4HCO3 (1:1 v/v). The supernatant was 
discarded and gel pieces further dehydrated with 100% acetonitrile for 30 seconds. Gel 
pieces were dried using an Eppendorf concentrator plus followed by reduction with 
100µl 25mM DTT in 50mM NH4HCO3 at 56°C for 20 minutes. After incubation the 
supernatant was discarded and gel pieces were alkylated with 100µl 55mM 
iodoacetamide in 50mM NH4HCO3 at room temperature for 20 minutes in the dark, 
followed by 2 washes with 400µl distilled water. Gel piece were then dehydrated and 
dried as before. Peptides were digested from the gel pieces by incubation with 20µl 
12ng/µl Trypsin Gold (Promega, Southampton, UK) in 0.01% ProteaseMAX™ 
Surfactant (Promega):50mM NH4HCO3 for 10 minutes. Samples were then overlayed 
with 30µl 0.01% ProteaseMAX™ Surfactant:50mM NH4HCO3 with gentle vortexing 
for 30 seconds followed by incubation at 50°C for 1 hour. Samples were centrifuged at 
12,000xg for 10 seconds and the solution containing the peptide digests was removed to 
a fresh Protein LoBind eppendorf tube. Trypsin was inactivated by addition of 0.5% 
trifluoroacetic acid (Fisher scientific, Loughborough, UK). Samples were stored at -
20°C until analysis by mass spectrometry. 
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6.3.9: Liquid chromatography mass spectrometry/mass spectrometry (LC-
MS/MS) Experiment 
The mass spectrometer used in this research was obtained from the Birmingham Science 
City Translational Medicine:  Experimental Medicine Network of Excellence project, 
with support from Advantage West Midlands (AWM) and performed by Dr Cleidiane G 
Zampronio. UltiMate
®
 3000 high performance liquid chromatography (HPLC) series 
(Dionex, Sunnyvale, CA USA) was used for peptide concentration and separation. 
Samples were trapped on Precolumn Cartridge, Acclaim PepMap 100 C18, 5µm, 100A 
300um i.d. x 5mm (Dionex, Sunnyvale, CA USA) and separated in Nano Series™ 
Standard Columns 75 µm i.d. x 15 cm, packed with C18 PepMap100, 3 µm, 100Å 
(Dionex, Sunnyvale, CA USA). The gradient used was from 3.2% to 44% solvent B 
(0.1% (v/v) formic acid in acetonitrile) for 30 min. Peptides were eluted directly (~ 300 
nL min
-1
) via a Triversa Nanomate nanospray source (Advion Biosciences, NY) into a 
LTQ Orbitrap Velos ETD mass spectrometer (ThermoFisher Scientific, Germany). The 
data-dependent scanning acquisition was controlled by Xcalibur 2.7 software. The mass 
spectrometer alternated between a full FT-MS scan (m/z 380 – 1600) and subsequent 
collision-induced dissociation (CID) MS/MS scans of the 20 most abundant ions. 
Survey scans were acquired in the Orbitrap with a resolution of 30,000 at m/z 400 and 
automatic gain control (AGC) 1x10
6
. Precursor ions were isolated and subjected to CID 
in the linear ion trap with AGC 1x10
5
. Collision activation for the experiment was 
performed in the linear trap using helium gas at normalized collision energy to 
precursor m/z of 35% and activation Q 0.25. The width of the precursor isolation 
window was 2 m/z and only multiply-charged precursor ions were selected for MS/MS. 
 
The MS and MS/MS scans were searched against NCBInr database using Mascot 
algorithm (Matrix Sciences). Variable modifications were deamidation (N and Q), 
oxidation (M) and phosphorylation (S, T and Y). The precursor mass tolerance was 5 
ppm and the MS/MS mass tolerance was 0.8Da. Two missed cleavages were allowed 
and were accepted as a real hit protein provided at least two high confidence peptides 
were identified. Peptides with an Expectation value (E value) of greater than 0.001 were 
disregarded. Peptide sequences for each protein were searched through uniprot.org blast 
search to give additional scores and E values. 
184 
 
6.4: Results 
6.4.1: Development of an optimal method of particle clearance from cell lysates. 
During proteomic analysis of TiO2-treated BEAS-2B lysates, electrical resistance 
occurred during the iso-electric focusing stage causing the gels to melt. In order to 
investigate whether the presence of particles was responsible for the electrical 
resistance, methods for total clearance of particles from cell lysates were developed.  
 
To optimize the approach for removing particles from cell lysates without losing 
protein, BSA was used as a target for particles instead of cell lysates. BSA was treated 
with TiO2 followed by treatment with the reducing agent DTT (1mM) and the detergent 
Tween-20 (1% v/v) to remove the bound protein from the particles. The BSA-particle 
solution was then passed through a 100KDa cut- off filter to remove particles from the 
solution. A BCA protein assay was conducted on the cleared samples (samples were 
diluted 1:10 as the detection limits of the BCA is 1mg/ml) in order to determine protein 
concentration. BSA (5mg/ml) that had not been treated or cleared through the 100kDa 
cut off filters was used as a control (Table 6.2).  
 
Table 6.2 shows that protein was lost during filtration in the absence of particles, and 
this could not be fully recovered by addition of 1mM DTT with 1% (v/v) Tween-20. 
Protein loss was also observed with TiO2 particle treatment, however, there was a 
similar protein loss observed with BSA alone, and again protein was not recovered with 
1mM DTT plus 1% (v/v) Tween-20. 
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Table 6.2: Recovery of BSA after treatments with TiO2, 1% Tween-20 and 1mM DTT and 
separation through 100kDa cut off filters. BSA (5mg/ml) was treated with either 1mM DTT 
and 1% (v/v) Tween-20, TiO2 or 1mM DTT and 1% (v/v) Tween-20 and TiO2 followed by 
filtration through 100KDa cut off filters at 14,000xg. Protein content of the filtrate (<100KDa 
fraction) was determined. Filtered BSA and un-filtered BSA serve as controls. Results are 
expressed as percent protein recovered. N=3, filtration = cleared through 100KDa cut off filter.  
Treatment Percent protein recovery 
None 99.7 ± 0.36 
Filtration 59.8 ± 0.43 
1mM DTT + 1% Tween + filtration 67.68 ± 0.4 
TiO2 + filtration 67.94 ± 0.91 
TiO2+ 1mM DTT + 1% Tween + filtration 66.6 ± 0.85 
 
Protein recovery after filtration was further investigated with lysates from control cells, 
TiO2-treated cells or control cell lysates with TiO2 added prior to filtration (Table 6.3). 
Protein loss was still evident after using the 100KDa cut off filters; however, there was 
no significant loss of protein due to particles. 
 
Table 6.3: Protein recovery from <100KDa fraction of filtered cell lysates. BEAS-2B were 
treated with 100µg/ml TiO2 for 24 hours (TiO2 lysate) in airway epithelial cell medium or with 
airway epithelial cell medium alone (control lysate) at 37°C. Cells were then lysed with 1% 
Triton-X100 with protease inhibitor cocktail (1%). Lysates as collected or control lysate with 
addition of 100µg/ml TiO2 were cleared through 100KDa cut off filter as per manufacturer’s 
instructions. Protein content of <100KDa fraction was determined using BCA assay and percent 
protein recovery expressed as protein in <100KDa fraction relative to total concentration before 
filtration. N=2 
Condition Percent protein recovered 
Control lysate 48.51 - 71.12  
TiO2 lysate 47.35 – 54.18 
TiO2 added to control lysates 52.29 – 56.97  
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6.4.2: 2-DE analysis following centrifugation for removal of TiO2 resulted in areas 
of protein loss from gels.  
As filtration methods for removal of particles from cell lysates results in protein loss, 
centrifugation methods of particle removal from lysates were investigated.   
 
Initially, samples were allowed to stand for 1 hour at room temperature to sediment 
particles, then centrifuged for 10 minutes at 23800xg at 15°C. Protein recovery from 
this method was typical for BEAS-2B cell lysates (control lysate 0.530mg/ml, TiO2-
treated 0.411mg/ml) however, during the iso-electric focussing stage of proteomic 
analysis electrical resistance occurred again resulting in melting of the IPG-strips. 
Failure of focusing on any single strip e.g. lysates from TiO2-treated cell, results in 
damage to all strips being focussed at the same time. 
 
A second alternative centrifugation method for clearing particles from cell lysates was 
investigated. This method involved centrifugation at 14,000xg for 30 minutes. The 
protein yield was similar for both control (0.545mg/ml) and TiO2-treated lysates 
(0.508mg/ml). During iso-electric focusing electrical resistance did not occur, however, 
there were some areas on the IPG strip (pH 3-10) where melting had occurred, as a 
consequence some areas of the 2D gels were protein free (Figure 6.1, boxed area). 
Since this method allowed iso-electric focusing to run without electrical resistance, it 
was adopted to permit proteomic analysis of lysates from particle-treated differentiated 
BEAS-2B.  
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Figure 6.1: 2-DE analysis following centrifugation for removal of TiO2 from cell lysates 
resulted in areas of protein loss from gels. BEAS-2B were cultured under submerged 
conditions at 1x10
5
 cells/ well in a non-collagen-coated 24 well plate. Once confluent cells were 
treated with 100µg/ml TiO2 in quiescent media, or quiescent media alone (not shown), for 24 
hours at 37°C. Cells were then lysed with 1% (v/v) TritonX-100 with 1% (v/v) protease 
inhibitor cocktail. Lysates were cleared by centrifugation at 14000xg for 30 minutes; 50µg 
lysate was then rehydrated onto a 3-10pH range IPG strip overnight at 20°C. Samples were 
focused in a Protean IEF cell at 500V for 500Vh, 3500V for 3500Vh and finally 3500V for 
90kVh. After focusing gels were equilibrated and focused in the 2
nd
 dimension on 4-20% 
gradient Tris HCl gels at 90V for 150 minutes. Proteins were then fixed and stained with 
Flamingo™ protein stain overnight. Gels were scanned on a Pharos FX™ Plus Molecular 
Imager. n=1. The boxed area indicates an example of a protein-free area. 
pI 3 pI10 
MW 
97.4kDa 
14.4kDa 
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6.4.3: Proteomic analysis of lysates from TiO2 and UFTiO2-treated BEAS-2B 
results in poorly resolved gels. 
After a method of particle clearance from lysates that would allow for iso-electric 
focussing was obtained, cell lysates from TiO2, UFTiO2 or control-treated differentiated 
BEAS-2B were analysed using 2-D electrophoresis to investigate whether particle-
treatment alters the cell proteome. IPG-strips with a narrower pH range (pH 4-7) were 
used to further improve resolution of proteins (Figure 6.2). Protein spots between 
treatments were then analysed for statistical significance using Progenesis Same Spots 
software.  
 
Although iso-electric focussing occurred normally without electrical resistance 
separation of proteins was poor in the 1
st
 dimension of electrophoresis as large streaks 
were evident across the gels (Figure 6.2A). Large areas of unresolved proteins were 
also evident (these areas were cropped from the gels during analysis). As protein 
resolution was poor analysis of the proteins with Progenesis Same Spots did not result 
in accurate matched protein spots between gels, and consequently spot matching was 
carried out manually. In total 35 spots were identified across the 3 groups (control, TiO2 
and UFTiO2), however only 1 protein spot, spot 327, showed a statistically significant 
difference, ANOVA p<0.05 and statistical power >0.8. (Figure 6.2A shows the spot 
position and expression profile from Progenesis SameSpots). The analysis of this spot 
(Figure 6.2B, outlined by the square) shows this spot to be poorly matched across 
treatment groups, since the gels were off poor quality regarding 1
st
 dimension 
separation of the proteins,  identification of the protein within this spot by mass 
spectrometry was not pursued.  
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A)   
 
 
B)  
control TiO2 UFTiO2 
   
 
C)  
 
Figure 6.2:  Proteomic analysis of lysates from TiO2 and UFTiO2-treated BEAS-2B 
resulted in poorly resolved gels.  2D gels of BEAS-2B on Transwell
®
 inserts treated with 
100µg/ml particles for 24 hours. Lysates were focused on IPG strips with a pH range of 4-7. 
Proteins were then resolved in the second dimension and stained with Flamingo™ protein stain. 
Spots were manually matched across gels and analysed for statistically significant changes in 
expression using Progenesis Same Spots software.  Significantly up- or down-regulated proteins 
(ANOVA p=<0.05 statistical power >0.8) were identified. A) reference gel identifying 
significantly altered spots, (B) representative image of the significantly altered spot across 
treatment groups (C) graphical representation of normalised spot expression profile for the 
significantly altered spot. A is a representative gel from the control group, Lysates from 3 
indivual experiments were pooled and 2 gels were run per pool. 
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6.4.4: Proteomic analysis of particle-treated BEAS-2B cultured at ALI 
Particles S2219200, S2218600 and S2429901 are non-toxic (as measured by CellTiter-
Blue
®
, (see chapter 2.2.6) to BEAS-2B at ALI. S2219200 and S2218600 are non-
inflammatory to BEAS-2B whilst S2429901 induced IL-6 secretion from these cells. 
Proteomic analysis was undertaken on lysates from particle-treated BEAS-2B at ALI to 
determine any biomarkers of exposure or response. In total 337 confirmed protein spots 
were identified. Statistical analysis spot expression profiles for all particles and control 
determined that only spot 583 (Figure 6.3A, highlighted by a yellow border) was 
significantly altered between treatments. However, 3-dimensional representation of this 
spot shows it to be in an area poorly focused and is a “smear” rather than an individual 
protein spot (Figure 6.3C), protein identification of this spot was therefore not carried 
out.      
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A)  
 
B)  
 
C)  
 
Figure 6.3: Proteomic analysis of particle-treated BEAS-2B cultured at ALI. 2D gels of 
BEAS-2B on Transwell
®
 inserts treated with 100µg/ml particles for 24 hours. Lysates for each 
treatment were pooled and focused on IPG strips with a pH range of 4-7. Proteins were then 
focused in the second dimension and stained with Flamingo™ protein stain. Gels were analysed 
using Progenesis Same Spots software.  Significantly up- or down-regulated proteins (ANOVA 
P<0.05 statistical power >0.8) were identified. A) reference gel showing all identified spots. 
The yellow border outlines spot 583. B) normalized expression profile of spot 583. C) three 
dimensional representation of spot 583 in all gels. Lysates from 3 individual experiments were 
pooled and three gels were run per pooled lysate.   
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6.4.5: 2-DE analysis of pooled plasmas identified a total of 80 spots with 
differential expression 
In order to determine whether biomarkers of exposure could be determined from in vivo 
expreiments, plasmas from rats exposed to polymer 020310 or MM/EM/BA (Carthew 
et al., 2006) were depleted of albumin and analysed by 2-DE. Despite albumin 
depletion of rat plasma samples, the 2D gels showed intense staining in areas with a pH 
and molecular weight consistent with albumin staining patterns. Mass spectrometry 
analysis confirmed this area as albumin. Progenesis SameSpots identified 362 spots in 
total across all 20 gels, 80 of which were confirmed as protein spots by visual 
inspection (Figure 6.4). Spot areas containing speckles, or spots in areas of protein 
streaks were excluded.  
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Figure 6.4: 2-DE analysis of pooled plasmas identified a total of 80 spots with differential 
expression.  Plasma samples were grouped according to treatment and albumin depleted with 
ammonium sulphate, 50µg plasma was then rehydrated onto IPG strips (pH3-10) and 
rehydrated overnight. The protein-loaded rehydrated strips were focused by isoelectric point in 
a Protean IEF Cell (BioRad, Hertfordshire, UK). Gels were then equilibrated and proteins were 
separated by molecular weight on 4-20% Tris-glycine gradient gels for 150 minutes at 90V and 
detected using Flamingo™ fluorescent gel stain. Gels were scanned on a Pharos FX™ Plus 
Molecular Imager (BioRad, Hertfordshire, UK) and protein spots were analysed by Progenesis 
SameSpots software (Nonlinear Dynamics, Newcastle upon Tyne, UK).  The large dark area in 
the centre of the gel has a staining pattern consistent with albumin staining patterns (confirmed 
by LC-MS/MS) and was therefore ignored during analysis.  
 
  
pI 10 
MW 97.4 
kDa 
MW 14.4 
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6.4.6: Analysis of protein spots from plasmas of rats in polymer treatment groups 
Analysis was undertaken on the plasma samples from polymer 020310, MM/EM/BA or 
saline treated rats between treatment groups by time and dose of polymer exposure. All 
treatments were analysed against experiment 1, the negative control at 9 weeks; and 
each treatment group at 22 weeks recovery, was compared against the corresponding 
negative control at 22 weeks. All treatments at 9 weeks were compared to the 
corresponding treatment at 22 weeks. Table 6.4 details those spots that were identified 
as both significant in volume by ANOVA, and for further confidence in results, spots 
that also had a statistical power analysis of >0.8. Analysis of experiment 1 (negative 
control, 9 week recovery) versus 5 (mid dose polymer 020310 treatment, 9 week 
recovery) did not show any significantly altered spots.  
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Table 6.4:  Polymer 020310 treatment-sensitive spots from plasma that showed a 
significant expression change by ANOVA (P<0.05) and statistical power analysis (>0.8). 
Plasma samples were grouped, albumin-depleted 50µg plasma and focused by 2-DE. Proteins 
were detected using Flamingo™ fluorescent gel stain. Gels were scanned on a Pharos FX™ 
Plus Molecular Imager (BioRad, Hertfordshire, UK) and protein spots were analysed by 
Progenesis SameSpots software (Nonlinear Dynamics, Newcastle upon Tyne, UK).  
Significantly up- or down-regulated spots were identified using ANOVA (p<0.05) and with a 
statistical power of >0.8 (high statistical power).  Up-regulated spots are in bold font, down-
regulated spots are in normal font. The fold change in protein expression for each spot is in 
brackets. 
Experiment ANOVA p<0.05, plus statistical 
power>0.8 
Negative control 9 week recovery 
versus negative control 22 week 
recovery 
323 (1.2), 275 (1.1), 416 (1.3) 
Negative control 9 week recovery 
versus low dose polymer 9 week 
recovery 
323 (1.4) 
Negative control 9 week recovery 
versus low dose polymer 22 week 
recovery 
275 (2.6), 186 (1.4) 
Negative control 9 week recovery 
versus mid dose polymer 22 week 
recovery 
181 (2.1), 275 (1.3) 
Negative control 9 week recovery 
versus high dose polymer 9 week 
recovery 
156 (2.3) 
Negative control 9 week recovery 
versus high dose polymer 22 week 
recovery 
243 (3.3) 
Negative control 9 week recovery 
versus MM/EM/BA 9 week recovery 
275 (2.7), 368 (1.3), 274 (3.3), 156 (1.9) 
Negative control 9 week recovery 
versus MM/EM/BA 22 week recovery 
416 (1.4) 
Negative control 22 week recovery 
versus MM/EM/BA 22 week recovery 
125 (1.5), 426 (1.9) 
High dose polymer 9 week recovery 
versus high dose polymer 22 week 
recovery 
243 (4.8), 74 (1.4) 
MM/EM/BA 9 week recovery versus 
MM/EM/BA 22 week recovery 
194 (1.4), 134 (1.8), 151 (1.9), 426 (1.4) 
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6.4.7: Differentialy expressed protein spots in positive control MM/EM/BA-treated 
animals compared to negative control animals   
Analysis of treatment groups allows dose-response or time-related effects to be 
investigated. Progenesis SameSpots performs this analysis by PCA and results are 
presented as the log normalised volumes for significantly altered spots across various 
treatment groups, and shows the volume of spot obtained from each of the duplicate 
gels (samples were pooled and then 2 gels were run from the pool) for each treatment.  
In this view, gel outliers (when one of the replica gels is a poor match for the rest of the 
gels within a given treatment group) and expression levels of all the spots across the 
experiment can be examined.  
 
PCA analysis was undertaken on the plasma protein spots from negative controls and 
MM/EM/BA-treated animals in order to investigate the effects of polymer treatment on 
the plasma proteome. In negative control versus MM/EM/BA analysis, a total of 4 
protein spots were identified as being significantly altered in volume (spots 288, 151, 
274 and 125). Spot 151 expression is high in both negative control and MM/EM/BA-
treated animals at 9 weeks (groups 1 and 9 respectively) with a 2 fold lower expression 
in negative controls and MM/EM/BA-treated animals at 22 weeks (groups 2 and 10, 
Figure 6.5). Spots 274 (2.4 fold expression change) and 288 (3fold expression change) 
both show increased expression with MM/EM/BA positive control treatment regardless 
of recovery time (Figure 6.5), whilst spot 125 (1.5 fold expression change) shows 
decreased expression with polymer at 9 and 22 weeks after treatment (Figure 6.5). 
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Figure 6.5: Differentialy expressed protein spots in positive control MM/EM/BA-treated 
animals compared to negative control animals. Progenesis SameSpots group analysis of 
albumin-depleted pooled-plasma from rats 9 and 22 weeks post-lung instillation with negative 
control or MM/EM/BA. A) reference gel is shown which identifies the position of significantly 
altered spots B) graphical representation of log normalised volumes for each spot. C) 
representative image of spot 125 across treatments, D) representative image of spot 151 across 
treatments. E) representative image of spot 274 across treatments. F) representative image of 
spot 288 across treatments. Group 1 is negative control at 9 week recovery, group 2 is negative 
control at 22 weeks recovery, group 9 is MM/EM/BA 9 weeks recovery, group 10 is 
MM/EM/BA at 22 weeks recovery. 
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6.4.8: Effect of polymer 020310-dose on the rat plasma proteome following 9 weeks 
recovery or 22 weeks recovery 
In order to investigate whether dose-response effects on the rat plasma proteome are 
observed following 020310 polymer treatment, independent group analyses of spot 
volume were undertaken on all 2D gels from rats receiving low, mid and high polymer 
020310 doses compared to negative control at 9 weeks recovery; and 22 weeks 
recovery.  
 
At 9 weeks recovery two proteins spots were identified as being significantly altered in 
volume with polymer 020310 treatment (spots 156 and 380, Figure 6.6A). Expression 
of protein 380 (3.8 fold expression change) was decreased in a dose-dependent manner 
with polymer 020310 treatment (Figure 6.6A). Expression of protein spot 156 (2.9 fold 
expression change) was increased in high dose polymer 020310 treatment compared to 
negative control, however, the response did not show a trend towards a dose-dependent 
increase (Figure 6.6A). 
 
At 22 weeks recovery, a single protein spot showed significant alteration in volume 
with polymer 020310-treatment (Figure 6.6B). Spot 151 (1.8 fold expression change) 
showed increased expression in low-dose polymer 02031-treatment compared to 
negative control, expression then decreased to below negative control levels for high-
dose polymer treatment (Figure 6.6B).   
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Figure 6.6: Effect of polymer 020310-dose on the rat plasma proteome following 9 weeks 
recovery (A) or 22 weeks recovery (B) after lung instillation. PCA analysis was undertaken 
on albumin depleted pooled-plasma from rats treated with negative control or increasing doses 
of 020310 polymer. (A) Spot volume profiles for those plasma protein spots showing dose-
dependent effect of polymer 020310 treatment at 9 weeks recovery, B) representative image of 
spot 380, C) representative image of spot 156. D) spot volume profile for spot 151, E) 
representative image of spot 151.   
151 
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6.4.9: MS/MS identification of significantly altered spots from polymer-treated 
rats 
As many of the spots that were identified by PCA as being significantly altered in 
response to polymer are low abundant spots, two test spots were selected for mass 
spectrometry analysis to test the sensitivtity of peptide detection from tryptic digests. 
The non-significantly altered spot, spot 45 (Figure 6.7, arrow head) was chosen as a 
spot with high abundance and the significantly altered spot, spot 274 (Figure 6.7, arrow) 
was chosen as a spot with low abundance. Spot 45 was identified as ceruloplasmin by 
mass spectrometry whilst spot 274 was unidentified. Due to lack of identification of low 
abundant spots, only spots with a similar abundance to spot 45 (426, 125, 134, 151 and 
368) were selected for analysis by mass spectrometry. Tables 6.5-9 show the proteins 
identified for these spots by MS/MS.  
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Figure 6.7:  MS/MS identification of significantly altered spots from polymer-treated 
rats. Reference gel showing significantly altered spots detected by Progenesis Same Spots 
analysis of albumin-depleted pooled-plasma from rats. Spots from all sets of analysis are 
depicted. The blue circle borders spot 426, the yellow circle borders spot 134, the orange circle 
borders spot 151, the purple circle borders spot 125 the red circle borders spot 368. All other 
significantly altered spots are highlighted with a green circle. The arrowhead highlights spot 45 
and arrow highlights spot 274. 
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Table 6.5: Protein identifications for Spot 134. Protein identifications for Spot 134 which showed a 1.8 fold decrease in expression in 
positive control at 22 weeks recovery compared to positive control 9 weeks recovery.  E-Value is statistical representation of the sequence 
coverage of blast search to identified protein. The score is an indication of the sequence similarity of the blast search and the identified 
protein. 
Accession Name Function MW 
(kDa) 
Length Score E Value 
P24090 Alpha-2-HS-
glycoprotein 
Inhibits insulin receptor tyrosine kinase, 
and insulin stimulated receptor auto-
phosphorylation 
38 352 126 6x10
-7 
P05544 Serine protease inhibitor Inhibits serine proteases 68.2 413 175 3x10
-13 
Q5PQU1 Kininogen 1 Thiol protease inhibitor 47.7 430 135 1x10
-8
 
P14046 Alpha-1-inhibitor 3 Wide spectrum protease inhibitor 163 1477 148 3x10
-8 
P17475 Alpha-1-antitrypsin 
precursor 
Inhibits serine proteases, primary target is 
elastase 
45.8 411 205 9x10
-15 
P09006 Serine peptidase 
inhibitor A3N 
Inhibits serine proteases 45.5 418 134 1x10
-6
 
P01015 Angiotensinogen Inhibits serine proteases 51.9 477 91 7x10
-3 
P97569 Kallistatin Inhibits serine type endopeptidases 48.3 423 129 5x10
-6 
Q62930 Complement component 
C9 
Complement cascade 62.2 554 139 4x10
-7 
Q5EBC0 Inter alpha-trypsin 
inhibitor CRA_B 
Inhibits serine type endopeptidases 78.4 933 85 7x10
-2 
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Table 6.6: Protein identification for spot 125. Spot 125 showed a 1.5 fold decrease in expression in positive control 9 and 22 weeks 
recovery compared to negative control 9 and 22 weeks recovery. E-Value is statistical representation of the sequence coverage of blast 
search to identified protein. The score is an indication of the sequence similarity of the blast search and the identified protein. 
Accession Name Function MW 
(kDa) 
length Score E Value 
Q5BJP7 AFM protein  52.6 464 105 3x10
-4
 
Q63041 Alpha-1-macroglobulin Inhibits all classes of proteinases 167 1500 85 7x10
-2
 
Q64268 Heparin cofactor 2 Thrombin inhibitor (serpin d1) 54.5 479 194 9x10
-16
 
P14046 Alpha-1-inhibitor 3 Wide spectrum protease inhibitor 163.7 1477 288 2x10
-24 
P17475 Alpha-1-antitrypsin 
precursor 
Inhibits serine proteases, primary target is 
elastase 
45.8 411 145 2x10
-9 
Q62930 Complement component 
C9 
Complement cascade 62.5 554 108 1x10
-3 
Q5EBC0 Inter alpha-trypsin 
inhibitor CRA_B 
Inhibits serine type endopeptidases 78.4 933 106 1x10
-4 
P01048 T Kininogen-1 Inhibitor of thiol proteases 47.7 430 122 7x10
-7 
P01026 Complement component 
C3 
Complement cascade 186.2 1663 94 5x10
-3 
P20059 Hemopexin precursor Iron transport 51.3 460 110 5x10
-6 
Q99PS8 Histidine rich 
glycoprotein 
Cysteine/thiol protease inhibitor 59 525 122 1x10
-6 
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Table 6.7: Protein identification for Spot 426: Spot 426 showed a 1.9 fold decrease in expression in positive control 22 weeks recovery 
compared to negative control 22 weeks recovery and positive control 9 weeks recovery. E-Value is statistical representation of the sequence 
coverage of blast search to identified protein. The score is an indication of the sequence similarity of the blast search and the identified 
protein. 
Accession Name Function MW 
(kDa) 
Length Score E Value 
Q6IE52 Murinoglobulin 2 Serine type endopeptidase (serpin) 161.5 148 176 2x10
-11 
Q7TMC7 Ab2-417 Iron binding protein 
Acute phase response 
107.3 979 91 1.2x10
-2 
P04276 Vitamin D binding 
protein 
Associates with B&T lymphocytes 53.5 476 96 4x10
-3 
P01026 Complement component 
C3 
Complement cascade 186.2 1663 116 2x10
-4 
P20059 Hemopexin precursor Iron transport 51.3 460 113 1x10
-5 
Q99PS8 Histidine rich 
glycoprotein 
Cysteine/thiol protease inhibitor 59 525 122 1x10
-3 
P17475 Alpha-1-antitrypsin 
precursor 
Inhibits serine proteases, primary target is 
elastase 
45.8 411 109 9x10
-5 
P02767 Transythretin chain A Thyroid hormone binding protein 15.72 147 187 3x10
-15 
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Table 6.8: Protein identification for spot 368. Spot 368 showed a 1.3 fold decrease in expression in positive control 9 weeks recovery 
compared to negative control 9 weeks recovery. E-Value is statistical representation of the sequence coverage of blast search to identified 
protein. The score is an indication of the sequence similarity of the blast search and the identified protein.  
Accession Name Function MW 
(kDa) 
Length Score E Value 
Q4QQR7 DSP Wound healing 69.75 635 83 8.5x10
-2 
P01835 Ig kappa chain C Antigen binding 11.6 106 82 0.12 
Q6POK8 Junction Plakoglobin Cell-cell adhesion 81.8 745 127 5x10
-7 
P23764 Glutathione peroxidase 3 Protects against oxidative damage 25.4 222 105 2x10
-4
 
P17475 Alpha-1-antitrypsin 
precursor 
Inhibits serine proteases, primary target is 
elastase 
45.8 411 109 8x10
-5 
P02767 Transythretin  Thyroid hormone binding protein 15.72 147 190 5x10
-15 
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Table 6.9: Protein identification of spot 151: Spot 151 showed a 1.9fold  decrease in expression in positive control 22 weeks recovery 
compared to positive control 9 week recovery, and PCA group analysis for all doses of 010310. E-Value is statistical representation of the 
sequence coverage of blast search to identified protein. The score is an indication of the sequence similarity of the blast search and the 
identified protein. 
Accession Name Function MW 
(kDa) 
Length Score E Value 
P02651 Apoplipoprotein A IV Lipid transport 44.4 391 298 1x10
-25 
P05545 Serine protease inhibitor 
A3K 
Inhibits serine proteases 45.5 416 121 1x10
-6 
Q5M7T5 Serine peptidase 
inhibitor 
Inhibits serine proteases 49.1 465 144 3x10
-9 
Q6MG90 Complement C4 Complement cascade 
Endopeptidase inhibitor 
192 1737 118 3x10
-9 
Q6IRK9 Plasma glutamate 
carboxy peptidase 
Hydrolysis of circulating peptides 52 472 104 3x10
-4 
P17475 Alpha-1-antitrypsin 
precursor 
Serine protease inhibitor, primary target 
elastase 
45.8 411 118 8x10
-3 
P01048 T Kininogen Thiol protease inhibitor 47.7 430 154 7x10
-9 
P01046 Alpha-1-inhibitor 3 Wide spectrum protease inhibitor 78.8 1477 258 6x10
-21 
P09006 Serine protease inhibitor Serine protease inhibitor 45.5 418 99 7x10
-4 
Q5EBC0 Inter alpha-trypsin 
inhibitor CRA_b 
Serine type endopeptidase inhibitor 78.4 933 140 4x10
-9 
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Q62930 Complement component 
C9 
Complement cascade 62.2 567 158 2x10
-11 
P01015 Angiotensinogen Serine protease inhibitor 51.9 477 89 2.3x10
-2 
P01026 Complement component 
C3 
Complement cascade 186.3 1663 104 3x10
-4 
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6.5: Discussion 
Proteomics, the study of all the proteins within a cell, tissue or physiological fluid at a 
particular time, allows for analysis of expression changes, such as up- or down-
regulation and posttranslational modifications of proteins, which cannot be identified 
with other approaches such as genomics. As proteomics allows for global protein 
changes within a proteome to be observed it has potential to be a powerful tool in 
identification of early biomarkers of disease. In the current study proteomic analysis 
was undertaken on; TiO2, UFTiO2, S2219200, S2218600, S2429901 or control treated 
BEAS-2B cultured at ALI. Proteomics was also undertaken on plasma from 10 week 
old male Wistar rats that had polymer 020310, MM/EM/BA positive control or saline as 
a negative control instilled intratracheally into the lungs, via the oropharynx. Recovery 
periods of either 9 or 22 weeks followed the final treatment.  
 
A previous proteomic study on submerged cultures of BEAS-2B treated with TiO2, has 
shown the pro-inflammatory cytokine macrophage migration-inhibitory factor (MIF) to 
be up-regulated (Cha et al., 2007) indicating the inflammatory potential of TiO2 to the 
airways epithelium.   Proteomic analysis on BEAS-2B cultured at ALI (where the 
morphology of BEAS-2B mimics the airway epithelium in vivo more closely than 
submerged cultures) was undertaken to investigate global protein changes in response 
to both UFTiO2 and TiO2. High electrical resistance, resulting in gel melting, was 
observed during the iso-electric focussing stage of proteomic analysis. Filtration was 
undertaken to remove particles from lysates in a bid to prevent electrical resistance, 
however, during optimisation, protein loss was observed which was not recovered by 
inclusion of detergent and reducing agent DTT. Wang et al., (2005) employed a 
proteomic approach of analysis after diesel exhaust particle (DEP) challenge of BEAS-
2B cells whereby lysates were centrifuged at 23,800xg for 8 minutes to remove 
particles. Centrifugation of lysates from submerged BEAS-2B treated with TiO2 with 
this method failed to remove particles from lysates and electrical resistance was still a 
problem resulting in occurance of gel melting.  
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Adoption of the centrifugation method of Cha et al., (2006) allowed the proteomic 
procedure to be completed, with evidence of melting (areas where there appeared to be 
loss of the the gel on the IPG strip), spots were visible on the gels. To improve spot 
resolution particle-cleared samples were analysed using a narrower pH range. Although 
spots were evident on gels, there were areas where the strips had melted and the 
replication of gels was poor making matching of the gels with Progenesis Same Spots 
software difficult. Indeed, only 1 spot was identified with statistically significant 
differences between treatment groups, the 3-dimensional analysis of the spot shows that 
the reproducibility is poor between the gels. By eye, the spot does not appear to be the 
same in each gel, indicating poor matching. Due to this poor reproducibility and the 
electrical resistance issue, caution is needed in the analysis of this result and protein 
identification of this spot was not pursued.  
 
Cha et al., (2006) observed that 20 protein spots were up- or down-regulated by more 
than 2-fold between control and TiO2 treated groups. These findings were not replicated 
here, possibly because Cha et al., (2006) used 1mg of protein for 2DE whilst in this 
thesis only 50µg of protein was used. It is possible that by using an increased 
concentration of protein, the loss observed here may be overcome, however Transwell
®
 
inserts do not allow for large scale cell culture so it would be difficult to obtain 1mg of 
protein per sample (a typical protein yield for a Transwell
®
 insert with BEAS-2B 
culture conditions outlined in 2.2.1.1 is 0.08mg/well). Further, Cha et al., (2006) used 
the rutile form of TiO2 in their study, whilst in this thesis, the TiO2 used is in the 
anatase form. Anatase TiO2 is not as stable as the rutile from and has more free flowing 
electrons (Murugessan et al., 2007; Sotter et al., 2007) which may also lend explanation 
as to why electrical resistance impeded protein separation and resolution here.  
 
S2219200 and S2218600 are non-cytotoxic and non-inflammatory to BEAS-2B 
cultured at ALI. S2429901 is also non-cytotoxic to BEAS-2B at ALI, but did induce 
increased IL-6 release indicating that this particle is inflammatory to BEAS-2B. Other 
inflammatory proteins may therefore show expression changes in S2429901 treated 
BEAS-2B. Proteomic analysis of lysates from these S2219200, S2218600, S2429901 or 
control cells was undertaken and revealed 1 significantly altered spot in the proteome. 
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However, this spot was in an area containing protein streaking and poor resolution and 
was therefore deemed a false positive. Triplicate gels of each particle treatment 
(containing pooled lysate form 3 individual experiments) were run, however as poor 
protein resolution was observed in some areas of the gels. Increasing the number of 
replicates would increase the confidence in results and may identify additional protein 
spots with expression changes between treatments and control 
  
S2429901 increased the IL-6 secretory response in BEAS-2B, however, no change in 
the cell proteome was observed. Cytokines are rarely detected in 2-DE proteomic 
analysis due to their low abundance (Grant et al., 2011). Supernatants and lysates were 
collected after 24 hour particle exposure, however, increased IL-6 secretion from 
airway epithelial cells can be observed as early as 2 hour post treatment (Carter et al., 
1997). Carter et al., 1997 report that 2 hour challenge with 50µg ROFA induced IL-6 
secretion significantly from submerged cultures of NHBE cells.  Investigation into the 
effect of S2429901 on the BEAS-2B proteome after a shorter incubation may identify 
biomarkers on inflammation.   
 
Histopathological and transcriptomic analyses of polymer 020310 and MM/EM/BA 
treated rats were undertaken by Carthew et al., 2006 and plasma proteomic analysis was 
undertaken here. Polymer treatments were first compared against negative control at 9 
weeks recovery (experiment 1) independently, to investigate the effect of individual 
treatments on the rat plasma proteome. Several proteins were significantly altered by 
particle treatment compared to negative control, after 9 weeks recovery. A total of 5 
protein spots were down--regulated after polymer treatment compared with the negative 
control, after 9 weeks recovery post- polymer instillation (spots; 323, 181, 243, 368 and 
416) with a range in fold expression change of 1.3-3.3. Four spots which showed a 
statistically significant up-regulation in treatment compared to negative control, 9 
weeks recovery (spots; 275, 186, 156, and 274) with a range in fold expression change 
of 1.1-2.7). Spots 125 (1.5 fold change) and 426 (1.9 fold change) were down-regulated 
in MM/EM/BA treated animals at 22 weeks compared to negative control at 22 weeks.  
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To assess the effect of recovery time on rat plasma-proteome after various treatments 
plasma obtained at 9 week recovery were compared to 22 week recovery, i.e. are any 
proteins indicative of chronic effect of exposure up/down-regulated at 22 weeks 
recovery compared to 9 week recovery.  As expected, the MM/EM/BA had the greatest 
effect on the plasma-proteome with 4 proteins being significantly altered (spots; 194, 
134, 151 and 426). These spots were all down regulated (with a range of expression of 
1.4-1.9 fold) in 9 weeks recovery compared to 22 weeks recovery. Carthew et al (2006) 
noted several mRNA species showed increased expression 9 weeks following particle 
020310 exposure, but appeared to be switched off by 22 weeks and these findings are 
consistent with observations reported here. 
 
A limitation of the current study is that many of the spots identified above as potential 
biomarkers of polymer 020310 or MM/EM/BA inhalation are low abundant proteins 
and below the level of detection by mass spectrometry after 50µg total protein loading. 
Flamingo™ fluorescent protein stain was used to visualise protein spots on the 2D-gels, 
and has a linear detection range of 0.5-1000ng. LTQ-orbitrap mass spectrometers have 
a sensitivity of femtomolar (Yates et al., 2009), so the low abundant proteins should be 
detected by ms/ms analysis, indicating that the failure to detect protein spots of low 
abundance maybe due digestion procedure. Inclusion of ProteaseMAX™ Surfactant, 
Trypsin enhancer (Promega) failed to improve protein recovery from the gels. Future 
work would include optimisation of protein recovery techniques, or increasing the 
loading concentration of protein during the 1
st
 dimensional focusing to yield spots with 
higher protein concentrations.  Nevertheless, sensitivity studies were carried out (data 
not shown) from which the following protein spots were selected for protein 
identification by mass spectrometry; 368, 151, 125, 426 and 134.  
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Table 6.10: spots chosen for protein identification. Fold expression changes for each spot are 
given in brackets.  
Spot Analysis Result 
368 (1.3) Negative control 9 week recovery versus 
positive control 9 week recovery 
Decreased expression in 
positive control 
151 (1.9) Negative and positive control 9 week 
recovery versus negative and positive 
control 22 week recovery 
Decreased expression in 
22 week recovery 
125 (1.5) Negative control 9 and 22 weeks recovery 
versus positive control 9 and 22 weeks 
recovery 
Decreased expression with 
positive control 
426 (1.9) Negative control 22 weeks recovery versus 
positive control 22 weeks recovery 
Decreased expression in 
positive control 
134 (1.8) 
& 426 
(1.4) 
Positive control 9 week recovery versus 
positive control 22 week recovery 
Decreased expression in 
22 week recovery 
 
For each spot several potential proteins were identified. Several proteins may occur in 
the same spot for a number of reasons including poor resolution of the proteins or post-
translational modifications to a protein causing a pI shift for example phosphorylation 
of a protein results in a change in pI with a shift in the acidic direction (Zhu et al., 
2005).  
 
Protease inhibitors and serine protease inhibitors (serpins) were identified within spots 
125, and 134 with the highest statistical confidence (Spot 125, Alpha-1-inhibitor 3 
(protease inhibitor) E score of 9x10
-16
, spot 134 Alpha-1-antitrypsin E score of 9x10
-15
) 
and are protein hits with high statistical confidence in spots 134, 368 and 151. These 
results suggest a role for serine proteases in the inflammatory state observed in these 
animals. Carthew et al., (2006) report that MM/ME/BA treated rats exhibited 
granulomas located in the alveoli and interstitium consisting of foamy and occasional 
necrotic alveolar macrophages. Interstitial fibrosis and alveolitis also occurred. There 
was no progression of disease or recovery in the 22 week recovery group compared to 9 
week recovery. Serine proteases are implicated in the pathogenesis of numerous airway 
inflammatory conditions such as COPD (Wang et al., 2006; Zabel et al., 2005) and 
have been shown to induce secretion of the inflammatory mediator IL-8 (Wang et al., 
2006) and induce inflammatory cell recruitment to the site of tissue damage (Zabel et 
al., 2005). Serine proteases themselves are also capable of inducing tissue damage 
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(Barnes et al., 2003). The decrease in serpins identified by 2-DE/ MS proteomics 
suggests a mechanism whereby increased presence of serine proteases allows for 
inflammatory cell migration resulting in macrophage containing granulomas, and tissue 
damage.  Further, transcriptomic analysis conducted on lung tissue (Carthew et al., 
2006) indicated alteration in genes involved in cell adhesion including cadherin II, 
alpha-3-type IV collagen, E-selectin and K-kininogen indicative of tissue damage; a 
kininogen spot was changed (down-regulation) in the rat plasma as determined here by 
proteomics.  
 
Several proteins can exist in a given spot due to protein iso-electric point (pI) shifts 
from post-translational modifications. Further experimental approaches can be 
conducted to identify which of these proteins are responsible for the change in spot 
expression, such a SDS-PAGE and western blotting using antibodies targeted to 
specific proteins, or ELISA. Future work could include investigations into protease 
activity in rat plasma samples by ELISA. Using a data-base approach to identify 
possible candidates for inducing a change in protein intensity, the location of the spots 
here were matched against rat plasma gels obtained by Gianazza et al., (2002) for 
control or inflamed rats. Inflammation was induced in rats exposed to turpentine or 
heat-killed M. tuberculosis, and these gels have been cited by other authors studying rat 
plasma proteomics (Linke et al., 2007). Blast E-value and scores from uniprot.org were 
also considered. Alpha-1-antiproteinase appears in all protein spots chosen for LC-
MS/MS analysis (151, 368, 426, 125 and 134). Alpha-1-antiproteinase is a high 
abundant plasma protein and is often depleted to aid detection of low abundant proteins 
(Linke et al., 2007).  
 
The localisation of the protein in control rat plasma gels obtained by Gianazza et al., 
(2002) is in the position of spot 151 in gels obtained in the current study. Poor 
separation of proteins in the 1
st
 dimensional or pI shifts due to PTM may result in this 
protein focussing to positions near spot 125 and 134, however, its MW (45.8) is smaller 
than that of spot 426 (around 66kDa on the gels) and much greater than that of spot 368 
(which separated in the second dimension in a position near to the 14.4kDa protein 
marker). It is possible that this high abundant protein has contaminated the digest 
216 
 
samples at the LC stage of protein identification. If this were the case the densitometry 
analysis from Progenesis SameSpots would not be due to this protein. 
 
Spot 151 showed a 1.9 fold decrease in expression in negative and positive control 22 
week recovery compared to negative and positive control 9 week recovery, and is 
therefore not a biomarker of MM/EM/BA treatment. As this spot showed decreased 
expression in older animals it is an attractive biomarker for aging. However a protein 
hit with an exceptionally high score and low E-value for this spot was apolipoprotein a-
IV (score 298, E value 1x10
-25
).  Apolipoprotein A-IV displays anti-atherogenic 
properties (Culnan et al., 2008). Atherosclerosis events occur with aging (Walter., 
2009) supporting reduction in plasma apolipoprotein A-IV as a biomarker of aging. 
 
Spot 368 when compared to the reference gels by Gianazza et al., (2002) matches 
transthyretin. By mass spectrometry transthyretin was identified as a protein hit for this 
spot with a high score (190) and low E-value (5x10
-15
) with a 1.3 fold decrease in 
expression in positive control animals with 9 week recovery compared negative control 
9 week recovery. Transythretin is a negative acute phase protein showing decreased 
expression in acute inflammation, (Dickson et al., 1985; Gianazza et al., 2002) 
supporting its identification here. Transthyretin loss is a potential biomarker of 
MM/ME/BA exposure in rats. 
 
Spot 426 showed a 1.9 fold decreased expression in positive control 22 weeks recovery 
compared positive control 9 week recovery and negative control 22 week recovery 
indicating its potential as a biomarker of prolonged inflammation. One of the protein 
hits for this spot was hemopexin precursor (score 113, E value 1x10
-5
), the location of 
this spot matches hemopexin in the reference gels by Gianazza et al., (2002), however, 
they report an increase in this protein during inflammation. The protein hit within spot 
436 with the highest statistical confidence is transthyretin (3x10
-15
). Uniprot reports 
transthyretin as a protein with a molecular mass of 15.72kDa, further the hit for spot 
368 was transthyretin and this spot focused between the molecular weight markers with 
weights of 21.5 and 14.4kDa. Literature reports transthyretin as a 55kDa protein which 
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exists as a heterotetramer Dickson et al., (1985) so a possible explanation is both the 
heterotetramer and individual chains have been separated.  
 
Histidine rich glycoprotein is another protein identified in spot 426 (score 122 E value 
1x10
-3
), this protein was also identified in spot 125 (decreased expression in positive 
control at both 9 and 22 week recovery compared to negative control at both 9 and 22 
weeks recovery) with a score of 122 and E value of 1x10
-6
. Histidine rich glycoprotein 
is structurally related to alpha2-HS glycoprotein a protein which was observed in spot 
134 (decreased expression in positive control 22 week recovery compared to positive 
control 9 weeks recovery, score 126, E value 6x10
-7
). The location of this spot matches 
that in the reference gels by Gianazza et al., (2002) where the expression of this protein 
decreases in inflammation. Histidine rich glycoprotein has a role in opsonisation of 
necrotic cells and inhibition of fibrosis (Jones et al., 2005), similarly alpha2-HS 
glycoprotein aids in removal of necrotic neutrophils by macrophages (Jersmann et al., 
2003). Carthew et al., (2006) report fibrosis and granulomas consisting of necrotic 
macrophages with MM/EM/BA treated rats at both 9 and 22 week recovery supporting 
the result observed here. These results suggest that decreased plasma levels of histidine 
rich glycoprotein and alpha2-HS glycoprotein may be worthy of investigations as 
biomarkers of prolonged lung injury due to inhalation of MM/EM/BA. Hisitidine rich 
glycoprotein undergoes several posttranslational modifications such as glycosylation 
and sulfation (Jahen-Dechant et al., 1994) which may explain how this protein is 
observed in spot 426 as well as 125 which has a more acidic pH and lower molecular 
weight.   
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6.6: Conclusion 
Particles S2219200, S2218600 and S2429901 did not alter the proteome of BEAS-2B at 
ALI after at 24 hour exposure, suggesting that exposure of these particles at the 
concentrations and times used in the current study. However, the following study had 
several limitations including sensitivity imposed by 50µg protein and recovery of 
peptides from gels. Improved separation of proteins in the 1
st
 dimension for these 
samples would provide further confidence in this result. The 2D-separation of cell 
lysates after TiO2 treatment requires further optimization for biomarkers of exposure to 
be identified.  
 
Several potential biomarkers of polymer 020310 exposure have been highlighted as 
being significantly up- or down-regulated in the plasmas obtained from rats after 
recovery from lung instillation with various polymer 020310 doses. Identification of all 
protein spots was limited due to sensitivity. In spite of this, 3 potential biomarkers of 
MM/EM/BA treatment were identified (decreased plasma concentrations of the 
negative acute phase proteins transthyretin, histidine-rich glycoprotein and alpha2-HS 
glycoprotein). Several serpins were also shown to be down-regulated with MM/EM/BA 
treatment. Further work into the expression of these proteins specifically, in 
MM/EM/BA rats is warranted to definitively identify these proteins as biomarkers of 
MM/EM/BA exposure. As complementary gross histological changes were observed in 
MM/EM/BA treated rats (Carthew et al., 2006) these biomarkers have potential use 
screening of new cosmetic compounds for acute lung injury.  
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Chapter 7: Discussion 
 7.1: Discussion 
The objectives of the current study were to develop an in vitro co-culture model of the 
human airways comprising human airway epithelial cells cultured at ALI and human 
pulmonary microvascular endothelial cells. The inflammatory response to model airway 
challenges (LPS and PM) was investigated along with barrier integrity, cell viability 
and GSH status. A proteomic analysis approach was also undertaken to investigate 
identification of potential biomarkers of exposure. Proteomic analysis was also 
undertaken on rat plasma samples to identify biomarkers of polymer exposure.  
The main results of this thesis are:  
 identification of ZO-1 staining indicative of tight junction formation in 
BEAS-2B cultured at ALI (to the authors knowledge, this is the first 
time this result has been shown)  
 BEAS-2B barrier was maintained when co-cultured with HPMEC in 
HPMEC growth media.  
 E. coli LPS treatment of BEAS-2B ALI mono-cultures resulted in 
disrupted ZO-1 localisation, and a directional increase in IL-6 secretion. 
 Increased secretion of IL-6 was observed from acrylate particle 
S2429901-treated BEAS-2B, and a decrease in cellular GSH and 
viability was observed in UFTiO2-treated BEAS-2B. 
 Co-culture of BEAS-2B with HPMEC resulted in a reduction in IL-6 
secretion after LPS and S2429901 particle challenge, and protected 
against loss of cell viability after UFTiO2-treatment.  
 Separately, proteomic analysis undertaken on plasma samples from 
MM/EM/BA polymer treated rats identified a significant down-
regulation in serpins, histidine rich glycoprotein, α2-HS-glycoprotein and 
transthyretin, with treatment compared to saline treated control animals. 
 
If inhaled material such as bacteria breach the airways mucosa, the innate immune 
system mounts an inflammatory response which aims to neutralise and remove the 
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threat (Smith, 1994). Briefly; airway epithelial cells respond to insult by increasing 
secretion of cytokines and chemokines (Bals & Hiemstra, 2004; Polito & Proud, 1998). 
Some of the released inflammatory mediators are sequestered by the ECM in order to 
maintain a chemotactic gradient (Vaday & Lider, 2000), whilst some of the chemokines 
and cytokines activate the airways endothelium. Upon activation, the endothelial cells 
themselves release cytokines to initiate proliferation and differentiation of circulating 
leukocytes and chemokines in order to attract leukocyte migration (Daneese et al., 
2007). Once activated the endothelial cells also up-regulate expression of adhesion 
molecules in order to allow leukocyte diapedesis (Rafiee et al., 2003; Yan et al., 2010). 
Serine proteases are also released which aid in leukocyte migration (Zabel et al., 2005). 
The leukocytes migrate to the site of insult via the chemotactic gradient and 
phagocytose the offending material. If this inflammatory response is not tightly 
regulated tissue damage and airway remodelling may occur. To prevent airways 
damage, the inflammatory response decreases after the threat has been removed 
(Parihar et al., 2010). Cytokines and chemokines are no longer released by epithelial 
and endothelial cells, so there is no activation signal for circulating leukocytes. 
Leukocytes revert back to having short half-lives and their numbers are controlled by 
apoptosis (Parihar et al., 2010). Growth factors sequestered by the ECM are released 
and aid in tissue repair (Schulz & Wyoski, 2009), damaging serine proteases are 
inhibited by serpins, and necrotic and apoptotic leukocytes are removed from sites of 
inflammation (Jersmann et al., 2003; Jones et al., 2005).  
 
Proteomic analysis suggests that there was a failure to resolve the inflammatory 
response mounted after MM/EM/BA treatment in rats. The results obtained show a 1.9 
fold decrease in expression of histidine rich glycoprotein in MM/EM/BA challenged 
rats compared to saline treated rats, after 22 week post treatment recovery (spot 426). A 
1.8 fold decrease in expression of Alpha2-HS-glycoprotein was observed in 
MM/EM/BA polymer-treated rats after 22 weeks recovery compared to MM/EM/BA 
polymer-treated rats after 9 weeks recovery (spot 134). Histidine rich glycoprotein and 
Alpha2-HS-glycoprotein have roles in removal of necrotic cells and inhibition of 
fibroblast proliferation (and therefore may have a role in limiting fibrosis) (Jersman et 
al., 2003; Jones et al., 2005). Proteomic results of MM/EM/BA treated rats also showed 
decreased levels of serine protease inhibitors. Serine proteases induce leukocyte 
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migration (Zabel et al., 2005) and endothelial cell apoptosis (Yang et al., 1996). Gross 
histological changes were observed in these rats, including granulomas and fibrosis in 
the lungs (Carthew et al., 2006).  These results highlight strong support between 
proteomic and histological analysis, and indicate the potential of proteomics for 
identification of biomarkers of lung exposure and response to injury. The proteomic 
results also highlight the mechanisms involved in lung inflammation after toxic 
exposure.  
 
Multi-cell models of the airways that encompass epithelial and endothelial cells, and 
ECM and leukocytes may allow for investigations of these mechanisms in vitro, and 
help to consolidate results from in vivo and in vitro studies.  This study aimed to 
develop a multi-cell model of the airways comprising airway epithelial cells on a 
collagen basement membrane (to represent the ECM) with HPMEC. The first step in 
doing so was the development of a robust airway epithelial monoculture which is 
representative of the airways epithelium in vivo. To this end, BEAS-2B or NHBE were 
cultured at ALI, and their barrier formation investigated by TER, paracellular 
permeability and expression of ZO-1.  
 
Initial studies identified that NHBE failed to form tight junctions, and showed no 
resistance to ion flow (as measured by TER) or solutes (as measured by FITC-dextran 
permeability). The presence of mesenchymal cells, with limited epithelial cells, was 
also identified (by immunhistochemical analysis). As NHBE were not robust in culture 
under the current studies culture conditions, BEAS-2B were used for the remainder of 
the study.  
 
BEAS-2B cultured at ALI contained cytokeratin 5 and 8 positive epithelial cells, which 
are typical of stratified epithelial cells of the trachea (Moll et al., 1982). Measurement 
of tight junction formation by ion and solute conductance is problematic as TER does 
not directly correlate with ion permeability and epithelial cells have different ion 
conducting properties (Tang & Goodenough, 2003). Importantly, BEAS-2B expressed 
the tight junction protein ZO-1 at the sites of cell-cell contact. TER increased during 
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culture at ALI and permeability to 40kDa FITC-dextran decreased indicating the 
presence of a restrictive barrier. Under unstimulated conditions IL-8 secretion in ALI 
cultures is greater than in submerged conditions; submerged total control IL-8 
125.53±38.1pg compared to ALI total control IL-8 368.61±44.75pg (apical 
compartment IL-8 148.71±27.55pg, basolateral compartment IL-8 291.29±58.20pg). 
IL-8 gene expression increases during primary HBEC differentiation (Ross et al., 
2007), the increased expression of IL-8 by BEAS-2B cultured at ALI may therefore be 
favourable and representative of a phenotype similar to that in vivo.   
 
The BEAS-2B ALI monoculture was exposed to LPS or PM to evaluate the 
inflammatory response and viability after challenge. After E. coli LPS-challenge a 
significant increase in IL-8 secretion was observed, along with a directional increase in 
IL-6 towards the basolateral compartment. Leukocyte derived IL-6 induces up-
regulation of endothelial cells adhesion molecules (Zhang et al., 2011). The pro-
inflammatory cytokines TNFα and IL-1β induce up-regulation of human umbilical cord 
endothelial cell (HUVEC) adhesion molecule and cytokine expression in HUVEC via 
NF-κB/p38 MAPK signalling (Kuldo et al., 2005). Further, IL-6 induces up-regulation 
of ICAM-1 expression in intestinal epithelial cells via NF-κB signalling (Wang et al., 
2003). Taken together, it is possible that secretion of IL-6, from LPS-stimulated BEAS-
2B, into the basolateral compartment is physiologically relevant and may induce 
endothelial cell adhesion molecule and cytokine expression via NF-κB signalling. 
Watson et al., (1996), determined that IL-6 treatment of HUVEC resulted in increased 
adhesion of lymphocytes but not leukocytes, however, large experimental variation was 
observed in this study. Further, cytokine secretion profiles vary between LPS- or TNFα-
stimulated HPMEC compared to HUVEC (Beck et al., 1999), as does 
polymorphonuclear cell adhesion during flow conditions and TNFα stimulation (Otto et 
al., 2001), highlighting the importance of using relevant cell lines in in vitro models. 
Further work could investigate the effect of BEAS-2B derived IL-6 (possibly by 
conditioned media treatment with or without IL-6 neutralising antibodies) on HPMEC 
adhesion molecule expression. 
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In vitro studies have identified TiO2, in particular UFTiO2, to be cytotoxic (Gurr et al., 
2005), result in oxidative stress (Gurr et al., 2005) and inflammation in airway 
epithelial cells (Singh et al., 2007). The current study identified a loss of cellular GSH 
and viability in BEAS-2B treated with UFTiO2. The loss of cell viability may be due to 
inflammation induced damage, as observed in vivo during chronic inflammation. Due to 
binding of IL-8 to UFTiO2, measuring the inflammatory response after exposure was 
problematic.  
 
Inclusion of HMPEC cells to the BEAS-2B ALI monolayers resulted in decreased IL-6 
secretion from BEAS-2B after LPS or S2429901-treatment, and decreased the toxicity 
of UFTiO2 to BEAS-2B. E. coli LPS (1000ng/ml for 24 hours) inducing a significant 
1.8 fold increase in IL-6 secretion to the basolateral compartment of BEAS-2B 
monocultures, which was reduced to 1.2 fold (and no-longer significant) in the co-
culture. For S2429901-treatment; the 14 fold increase in IL-6 secretion to the apical 
compartment of BEAS-2B mono-cultures was reduced to 4 fold in co-cultures 
(although the response remains significant). The 2 fold significant increase in IL-6 
secretion to the basolateral compartment of BEAS-2B mono-cultures was reduced to 
1.9 fold in co-cultures and this marginal increase in IL-6 secretion was non-significant. 
UFTiO2-treated of BEAS-2B monocultures resulted in a significant decrease in viability 
to 69.1±8.8% of control. Viability of BEAS-2B from the co-culture model was not 
affected by UFTiO2-treatment (viability was 88.7±5.6% of control).  
 
The protective effect of the endothelial cell layer is suggestive of regulation of the 
inflammatory response to prevent against tissue damage. A possible mode of action 
may be that HPMEC secrete anti-inflammatory mediators which act upon the BEAS-
2B. For example, HGF, which is expressed in lung microvascular endothelial cells 
(Morisako et al., 2010), inhibits the airway inflammatory response of ovalbumin 
sensitised mice (Ito et al., 2005), further HGF as be shown to suppress IL-6 production 
from macrophages (Coudriet et al., 2010). HGF, or other endothelial cell derived anti-
inflammatory mediators, may inhibit epithelial cell IL-6 production. HGF acts as an 
anti-apoptotic mediator in epithelial cells, inhibiting cigarette smoke extract induced 
apoptosis in human primary bronchial epithelial cells (Togo et al., 2010) which could 
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also explain the protection from UFTiO2 cell death (although the mechanism 
responsible for cell death (i.e. necrosis or apoptosis) was not determined).  HGF 
secretion from HPMEC is induced by IL-1β (Morisako et al., 2001), so it is feasible that 
BEAS-2B derived cytokines up-regulate secretion of HGF from the endothelium, which 
in turns regulates the BEAS-2B inflammatory response.  
 
Secretion of pro-survival cytokines such as vascular endothelial cell growth factor 
(VEGF) from endothelial cells may also act to protect the epithelium after insult .VEGF 
has been observed to promote nasal epithelial cells growth and inhibit apoptosis in nasal 
airway epithelial cells in an autocrine manner (Lee et al., 2009). Further work could 
include investigation of HGF and VEGF expression/secretion from in HPMEC in 
mono- and co-culture conditions and the effect of these mediators on BEAS-2B mono-
culture IL-6 secretion and viability after LPS, S2429901 and UFTiO2-treatment. 
 
The differences in physiology and immunology between humans and rodents (for 
example rats and mice do not express IL-8 (Tarrant, 2010)) cannot be overlooked. 
Nikula et al., (2001) compared lung particle burdens and distribution of coal soot in 
exposed rats and humans, and identified differences in particle distribution. Rat 
exposure models (exposed to 0.35mg/m
3
, 3.5mg/m
3
 or 7mg/m
3
 for 7 hours a day, 5 days 
a week for 24 months) were compared to human workplace (coal mine) exposures in 
individuals who were exposed to low ambient dose of particles (≤2mg/m3 for a period 
of 10-20 years), high dose exposure levels (<10mg/m
3
 for a period of 30-50 years) or 
control individuals. The authors identified that in rats, particle burden was mainly in the 
alveolar ducts and lumen, with particles contained in alveolar macrophages (for all 
exposure doses, with increased particle burden correlating to exposure dose). In humans 
however, up to 91% of particles were found within the interstitium (irrespective of 
exposure levels), again with particle burden correlating to exposure (Nikula et al., 
2001).  
 
The differing location of particles in rats and humans highlights the fundamental 
differences between species and the limitations of animal studies. Extrapolation 
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between studies therefore requires caution, for example in the current study S2429901 
induced up-regulation of IL-6 and Gaiser, (2008) identified that this particle was 
inflammatory to rat airways. However Gaiser, (2008) showed that S2219200 and 
S2218600 were more potent inducers of inflammation, whilst in the current study had 
no effect on parameters measured. 
 
Human studies of PM exposure have shown increased levels of IL-8 and GSH (18 hours 
after 2 hour exposure to 100µg/m
3
 DEP PM2.5) in bronchial washings (Behndig et al., 
2006) and increased IL-6 in induced sputum (6 hour exposure to 300µg/m
3
 DEP PM10) 
(Nordenhall et al., 2000). Human studies of LPS inhalation identify increased 
neutrophil and lymphocyte numbers in blood, induced sputum (24 hours after exposure 
to 40µg E. coli 026:B6 LPS (Thorn & Rylander, 1998)) and bronchial lavage (24 hours 
after exposure to 4ng/kg E. coli 0:113 LPS (O’Grady et al., 2001). Increased IL-6 
concentration in bronchial lavage after 2 hour E. coli 0:113 LPS, with levels peaking at 
6 hours post exposure, has also been observed (O’Grady et al., 2001). Importantly the 
results of the current study are in agreement with human in vitro PM and LPS 
exposures where increases inflammatory mediator secretion and oxidative stress are 
observed. Work in this thesis has shown increased IL-6 secretion from LPS-and 
S2429901-challenged mono-cultures and S2429901-challenged co-cultures. 
 
Despite the differences in immunology between rodents and humans, both exhibit 
airway inflammation after airways exposure to noxious material (Behndig et al., 2006; 
Bermudez et al., 2004; Carthew et al., 2006; Nordenhall et al., 2000; Thorn & 
Rylander, 1998). Notably, proteomic biomarker results obtained in the current study 
from plasmas collected from MM/EM/BA exposed rats identified a down-regulation of 
α2-HS-glycoprotein and the serpin α1-antitrypsin. Histologically, airway inflammation 
and fibrosis was observed in these animals (Carthew et al., 2006). Bowler et al., (2009) 
identified a decrease in expression of α2-HS-glycoprotein and α1-antitrypsin in BAL 
fluid (using proteomic analysis) from LPS challenged humans. As the serpin α1-
antitrypsin can be produced by lung epithelial cells (Wang et al., 2007) the potential for 
BEAS-2B to show altered secretion of these proteins in response to challenge should be 
studied.  The agreement between results obtained from the BEAS-2B ALI model 
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compared to human in vivo studies, and the regulation of inflammation by HPMEC 
which suggests crosstalk between the two cell types as observed in vivo, highlights the 
significance of the model developed in this thesis. 
 
7.2: Conclusion 
BEAS-2B mono-cultured cultured at ALI produce tight junctions, with ZO-1 
localisation to the site of cell-cell contact, with low TER. To the author’s knowledge 
this is the first time this result has been identified in BEAS-2B cultured at ALI. Tight 
junctions in epithelial cells in vivo function to maintain cellular homeostasis and 
provide a protective barrier against invading pathogens and inhaled toxicants, the 
presence of tight junctions in BEAS-2B ALI cultures provides evidence that these cells 
have a morphology resembling in vivo airway epithelial cell cultures. LPS and 
S2429901 induced IL-6 secretion from BEAS-2B mono-culture at ALI without 
compromising cell viability. LPS-stimulation of BEAS-2B ALI mono-cultures resulted 
in disruption of ZO-1 localisation, which may be the initiation of tight junction 
disruption. The presence of HPMEC resulted in a reduction of the BEAS-2B 
inflammatory response after LPS and S2429901 challenge, and HPMEC also protected 
against UFTiO2 cytotoxicity in BEAS-2B. Importantly in vitro findings reported here, 
are in agreement with human in vivo studies. These results emphasise the importance 
for use of multi-cell in vitro models of the airways to investigate the inflammatory and 
toxicity potential of particulates and pathogens in vivo.  
 
Analysis of TiO2 induced inflammation, and identification of biomarkers or response to 
exposure was inconclusive due to assay interference. Identification of biomarkers of 
response to exposure with polymer 020310 or MM/EM/BA was limited due to lack of 
protein recovery from tryptic digests, however, 4 potential response biomarker of 
MM/EM/BA exposure in rats (where gross histopathological changes were also 
observed, Carthew et al., (2006)) were identified; serpins/ α1-antitrypsin, transthyretin, 
histidine rich glycoprotein and alpha2-HS glycoprotein. Specific analysis of expression 
for these proteins in rat plasma samples is required to confirm these as biomarkers of 
response to inhalation toxicity. However, down-regulation of expression of alpha2-HS 
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glycoprotein and the serpin α1-antitrypsin has been identified in BAL from LPS 
challenged humans, again highlighting how results of the current study on airways 
inflammation in rats, and human cell in vitro studies, may be used to understand human 
in vivo inflammatory critical pathways and for identification of biomarkers or response.  
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Chapter 8: Future Work 
The overall aim of this thesis is to develop a co-culture of the human airways for 
toxicity testing and identification of novel biomarkers of response to particles, with 
specific objectives including;  
1) Characterisation of BEAS-2B morphology at ALI compared to NHBE 
2) Development of an epithelial/endothelial co-culture model 
3) Investigations into inflammatory mediator secretions from this model after 
challenge with LPS or PM 
4) Determination of GSH oxidation and cell viability after LPS/PM challenge 
5) Identification of biomarkers of response using proteomics and LC-MS/MS 
 
The above objectives were carried out; however, several small investigations are 
required to clarify results of the current study. For example; do BEAS-2B cultured at 
ALI form cilia and express the tight junction protein claudin. BEAS-2B cultured at ALI 
should be challenged with increasing doses of LPS from the respiratory pathogens P. 
aeruginosa 5ODR and B. cepacia to investigate the hypothesis that airway epithelial 
cells do not produce and inflammatory response after challenge with low respiratory 
LPS concentrations, probably as a protective mechanism. Of importance is further 
investigation into the IL-8 response of TiO2 and UFTiO2 challenged BEAS-2B. Since 
UFTiO2 interferes with IL-8 detection by ELISA, a functional assay (the neutrophil 
respiratory burst assay) was conducted for investigations into IL-8.  However, it is 
unknown as to whether cells respond to UFTiO2 challenge by up-regulation of IL-8. 
Investigations into IL-8 mRNA levels would give insight into the IL-8 response of 
UFTiO2 challenge. In vitro models allow translation of results from animal toxicity 
studies to human diseases. Clarification of the results obtained in the current study 
would allow for further comparisons of the model to validated in vivo animal models.    
 
Biomarkers of toxicity were not identified in the current study due to assay interference. 
Future work would focus on optimisation of the iso-electric focussing method for 
samples from TiO2-treated cells. Carthew et al., (2006) identified gross histological 
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changes in the lungs of MM/EM/BA treated rats, whilst the proteomic work undertaken 
in the current study on plasma samples from these rats identified changes in expression 
of the following proteins;  α1-antitrypsin, transthyretin, histidine rich glycoprotein and 
α2-HS glycoprotein. Transthyretin, histidine rich glycoprotein and α2-HS glycoprotein 
are produced in the liver, so investigations into the expression of these proteins in the 
model developed in the current study cannot be undertaken. Protein identification in the 
rat plasma proteomic studies was limited due to poor recovery of peptides form trypsin-
digests, an improved digestion method would allow for identification of these lower-
abundant significantly altered spots, some of which may be epithelium or endothelium 
derived. Future work would therefore also include LC-MS/MS identification of the 
lower abundant-significantly altered spots identified in plasma from MM/EM/BA 
treated rats. The serpin α1-antitrypsin is secreted by the epithelium, investigation into 
the expression of this protein in PM treated BEAS-2B should also be considered to 
along with investigations into α1-antitrypsin, transthyretin, histidine rich glycoprotein 
and α2-HS glycoprotein mRNA levels and protein expression levels directly (by ELISA 
for example) in plasmas from MM/EM/BA  treated rats. These studies would give 
insight into the potential of these proteins as biomarkers of response to inhalation 
exposure of toxic PM.  
 
Optimisation of NHBE culture at ALI and proteomic analysis of TiO2 and UFTiO2 
challenged BEAS-2B should also be undertaken to allow for identification of 
biomarkers of exposure and development of an airways epithelial-endothelial co-culture 
consisting of primary cells only. Primary cells have not undergone transformation and 
are taken from “normal” tissue and therefore more representative of in vivo cells.  
 
A valuable line of enquiry would be to investigate monocyte adhesion to the endothelial 
cells after LPS or PM challenge of the co-culture, compared to stimulation of 
endothelial cells directly. This would give insight as to whether epithelial cell derived 
cytokine (with increased secretion after challenge) up regulate leukocyte adhesion to 
the endothelium, as observed in vivo. Philips et al., (2003) investigate monocyte (U937) 
adhesion to LPS activated endothelium (HUVEC monolayers) by labelling the 
monocytes the fluorescent dye 2’-7’ bis-2-carboxy-5-(6)-carboxyfluorescein-
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acetoxymethylester ( BCECF-AM).  Labelled monocytes are added to LPS activated 
HUVEC cells for 30 minutes at 37°C.  After incubation non-adhered cells are removed 
by washing, and adhered cells are lysed. The fluorescence of the resultant lysate is 
measured (Ex 485nm, Em 535nm) to give a measure of monocyte adherence.   
 
This could be carried out after challenge of the co-culture with LPS or PM by removal 
of the Transwell
®
 insert and addition of monocytes to the endothelial cell monolayer. 
Controls should include addition of challenge/control to the apical surface of a blank-
collagen-coated Transwell® insert (Figure 8.1) as a control for non-direct stimulation of 
endothelial cells in the absence of epithelial cells. Endothelial cells should also be 
directly stimulated with LPS or PM. These controls will allow investigations into 
whether challenged epithelial cells respond by signalling up-regulation of endothelial 
cell adhesion molecules, whether enhanced adhesion is due to challenge of endothelial 
cells by particle translocation (by comparing adhesion of monocytes in the co-culture 
system to the blank-collagen-coated Transwell
®
 insert) and whether the presence of an 
epithelial cells layer enhances monocyte adhesion to endothelium.  
 
However, as the inflammatory response in vivo involves multiple cell types including 
leukocytes, fibroblasts and mast cells, further development of the current model would 
concentrate on inclusion of these cells into the model.  
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Figure 8.1 : Schematic diagram of proposed adhesion assay. 1) represents the co-culture model. 2) the co-culture treated with control (media alone). 
3) the co-culture treated with LPS or PM. 4) Treatment in the absence of epithelial cells. Treatment given apical on a blank-collagen-coated Transwell® 
Insert as a control for in-direct exposure. 5) monocyte adhesion in the absence of eptithelial cells or stimulus, 6) monocyte adhesion in the absence of 
epithelial cells, with direct stimulus of endothelial cells. 
control control 
control 
PM/LPS PM/LPS 
PM/LPS 
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Chapter 10:  
 
10.1: Appendix one: Immunohistochemistry: method development and controls 
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10.1.1: Optimisation of Cytokeratin staining methods  
 
BEAS-2B seeded onto human placental type IV collagen-coated (10µg/cm
2
) 4-well 
slides at 5x10
4
 cells/ml in 200µl airway epithelial cell medium and cultured until 
confluent, or on Transwell
®
 inserts as described above. Immunohistochemical staining 
on Transwell
®
 inserts was undertaken when a differentiated monolayer was formed as 
indicated by TER measurements (when a TER of >45 Ω x cm2 was reached). Cells on 
Transwell
®
 inserts and 4 well slides were fixed with 100µl 100% methanol (pre-cooled) 
for 20 minutes at -20°C and washed 3 times with 200µl PBS. Cells were then 
permeabilised with 100µl 0.1% (v/v) Triton X-100 in PBS for 30 minutes at room 
temperature followed by 3 washes with 200µl PBS. Cells were then blocked with 100µl 
1% (v/v) normal goat serum in PBS for 1 hour at room temperature followed by an 
additional 3 washes with 200µl PBS. Cells were incubated with 100µl primary mouse 
monoclonal anti-cytokeratin antibodies, mouse monoclonal anti-fibroblast surface 
antigen, mouse monoclonal anti-muc5AC, mouse monoclonal anti-vimentin, mouse 
monoclonal anti-ZO-1 or isotype-matched control in 1% BSA (w/v) in PBS or 1% BSA 
in PBS alone overnight at 4
°
C. Cells were then washed 3 times with 200µl PBS and 
incubated with 100µl goat anti-mouse FITC-conjugated secondary antibody diluted 
1:100 in 1% BSA in PBS for 1 hour at 4°C. Cells were washed a final 3 times with 
200µl PBS and mounted with hard set mounting medium containing DAPI (1 
drop/well/insert) and left to set for 48 hours at 4°C in the dark. Images were taken on a 
Zeiss Axiovert 200M fluorescent microscope using objective 63 with a DAPI filter 
(exposures of 5-20ms) and a FITC filter (exposures of 50-150ms). ZO-1 images were 
taken at the most apical surface of cells. 
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10.1.2: Results 
 
In order to determine the optimum conditions for immunohistochemical detection of 
cytokeratin in BEAS-2B and NHBE grown on Transwell
®
 inserts, experiments were 
first conducted using different fixing and blocking conditions and a range of antibody 
concentrations (1:50, 1:100 and 1:250) on a basal, i.e. undifferentiated, BEAS-2B 
population in submerged culture. BEAS-2B cells were used for the initial method 
development as primary cells are expensive and have limited passage doublings.   
 
  10.1.2.1: Optimising antibody dilutions  
 
In order to determine the optimum primary antibody concentration for cytokeratin 5 
staining, BEAS-2B were seeded on uncoated glass coverslips and antibody dilutions of 
1:50, 1:100 and 1:250 were tested.  Cytokeratin 5 was detected in basal epithelial cells 
grown on glass coverslips at all antibody dilutions used (Figure 10.1A-C), however, 
there was noticeable cell loss from the coverslips (arrow head Figure 10.1A and C) in 
the majority of cases. Further experiments were conducted with primary cytokeratin 
antibody concentrations of 1:250 as this was sufficient to detect cytokeratin 5 (Figure 
10.1C, arrows indicate clear staining of cytokeratin filaments). Further cytokeratin 
staining experiments on basal populations of BEAS-2B cells were conducted on 
collagen coated 4 well slides as these more closely replicate conditions used to culture 
cells at ALI and are easier to handle and therefore help to reduce cell loss. 
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A)          B) 
                         
 
C)  
  
 
Figure 10.1: Cytokeratin 5 filaments are detected with an antibody dilution of 1:250. 
BEAS-2B were seeded on glass coverslips at a density of 1x10
5
 cells/ml (200µl/well) and 
grown to confluence for 3 days. Cells were fixed with 200µl pre-cooled methanol at -20
°
C, 
blocked with 1% (v/v) normal goat serum in PBS and permeabilised with 0.1% (v/v) Triton-X-
100 in PBS.  Cells were then incubated with mouse-monoclonal anti-cytokeratin 5 antibody 
diluted 1:50 (A), 1:100 (B) or 1:250 (C) in 1% (w/v) BSA in PBS, overnight at 4
°
C. Cells were 
then washed and incubated with FITC-conjugated goat anti-mouse secondary antibody (1:100 
in 1% (w/v) BSA in PBS) for 1 hour at room temperature. Cells were mounted in DAPI and 
images taken using a Zeiss Axiovert 200M fluorescent microscope, results are from a single 
experiment representative of 2 wells per antibody dilution. Scale bar indicates 31µm. 
Arrowheads indicate areas of cell loss and arrows indicate cytokeratin filaments. 
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 10.1.2.2: Optimising fixing and blocking conditions  
 
In order to further optimise the cytokeratin staining method, a comparison was made 
between BSA and goat serum as blocking agents.  In addition, fixing steps with 
methanol or paraformaldehyde were compared to define a protocol that produced 
minimal cell loss. 
 
Cells were grown on collagen coated 4 well slides.  The results show that following 
methanol fixation, cell loss was minimal and blocking with goat serum yielded a more 
defined cytokeratin staining pattern (Figure 10.2A, arrow) than BSA blocking (Figure 
10.2B). Cells that had undergone paraformaldehyde PFA fixation appeared to have lost 
their cobblestone morphology and had a rounded appearance (Figure 10.2C and D 
arrowheads). With paraformaldehyde as a fixative there was little difference between 
goat serum block (Figure 10.2C) and BSA blocked (Figure 10.2D) experiments.  
 
For further experiments methanol fixative and goat serum block were used as these 
conditions produced the clearest cytokeratin 5 staining with minimal cell loss.  
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A)  Goat serum block   B) BSA block 
 
            
 
C)  Goat serum block   D) BSA block 
                      
 
 
Figure 10.2: Optimising fixing and blocking conditions BEAS-2B epithelial cells were 
seeded on collagen coated 4 well slides at a density of 1x10
5
 cells/ml (200µl/well) and grown to 
confluence for 3 days. Cells were fixed with 200µl pre-cooled methanol at -20
°
C (A and B) or 
4% (v/v) paraformaldehyde at room temperature (C and D), blocked with 1% (v/v) normal goat 
serum in PBS (A and C) or 1% BSA in PBS (B and D) and permeabilised with 0.1% (v/v) 
Triton-X-100 in PBS.  Cells were then incubated with mouse-monoclonal anti-cytokeratin 5 
antibodies diluted 1:250 in 1% (w/v) BSA in PBS, overnight at 4
°
C. Cells were washed and 
incubated with FITC conjugated goat anti-mouse secondary antibody (1:100 in 1% BSA in 
PBS) for 1 hour at room temperature. Cells were mounted in DAPI and images taken using 
Zeiss Axiovert 200M fluorescent microscope, images are from a 2 separate experiments. Scale 
bar indicates 31µm, arrow indicates cytokeratin filaments and arrow heads highlight cells with a 
rounded appearance.  
Methanol fix 
PFA fix 
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10.1.2.3: Determining the specificity of the immunocytochemical method  
 
In order to determine whether the staining is observed is specific for detection of bound 
primary antibodies, BEAS-2B cells were grown on collagen coated 4 well slides and 
incubated with either primary antibodies alone, no antibody, or isotype control (IgG1). 
Collagen coated slides without cells were also incubated with primary and secondary 
antibody to ascertain whether the primary antibody binds to the collagen.  The cellular 
staining patterns observed with anti-cytokeratin 5 and cytokeratin 8 antibody (Figure 
10.3A and B respectively) were not observed with either isotype control (Figure 10.3C) 
or with no primary antibody (Figure 10.3D).  No staining was observed when collagen-
coated slides in the absence of cells were incubated with antibodies to cytokeratin 5 
(Figure 10.3E) of cytokeratin 8 (Figure 10.3F).   
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A)              B) 
                          
C)             D) 
                      
E)             F) 
                                       
 
Figure 10.3: Determining the specificity of the immunocytochemical method. BEAS-2B 
epithelial cells were seeded on collagen coated 4 well slides at a density of 5x10
4
cells/ml 
(200µl/well) cell culture media alone (E and F) and cultured until slides with cells on had 
confluent cell populations. Slides were incubated with fix ( 200µl pre-cooled methanol at -20
°
C) 
and block (1% (v/v) normal goat serum in PBS) followed by permeabilising solution  (0.1% 
(v/v) Triton X-100 in PBS). Slides were then  incubated with mouse-monoclonal antibody to 
cytokeratin 5 (A and D), cytoekratin 8 (B and F), isotype control IgG1 (C) diluted 1:250 in 1% 
(v/v) BSA in PBS, or 1% (v/v) BSA in PBS alone (D) overnight at 4
°
C. Slides were then 
washed and incubated with FITC-conjugated goat anti-mouse secondary antibody (1:100 in 1% 
(v/v) BSA in PBS) for 1 hour at room temperature. Cells were mounted in DAPI and images 
taken using Zeiss Axiovert 200M fluorescent microscope, images are representative of 4 
separate experiments. Scale bar indicates 31µm. 
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10.2: Appendix two: Development of a mucin dot blot 
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10.2.1: Mucin dot blot optimisation method 
10.2.2: Results 
Increased expression and secretion of the airways mucin muc5AC has been observed in 
ROFA PM (100µ/ml for 24 hours) challenged pulmonary mucoepidermoid carcinoma 
cells NCI-H292 (Longphre et al., 200) In order to investigate mucous secretion from 
PM challenged NHBE and BEAS-2B a method to detect mucin using dot blots was 
developed. 
10.2.2.1: Heat denaturing or deglycosylation is not required for muc5AC 
detection by dot blot 
 
The anti-Muc5AC antibody recognises the peptide core of the muc5AC protein. Since 
mucins are heavily glycosylated (oligosaccharides account for 65-50% of mucins 
molecular weight (Rose, 1992) the antibody may not be able to bind its target. 
Investigations were carried out to determine whether Muc5AC detection via the mouse 
monoclonal anti-Muc5AC primary antibody requires mucin to be denatured and/or 
deglycosylated. To this end, a dot blot of standard porcine mucin (which contains 
Muc5AC, Nordman et al., 2002) under denaturing or deglycosylated conditions was 
compared to that of native mucin. Denaturing of the mucin may be required mucin is 
heavily glycosylated (~80%) which may prevent the anti-muc5AC antibody binding its 
target, the peptide core of mucin. BSA was used as a control for mucin detection via the 
anti-Muc5AC antibody.  
 
The results indicate that the anti-muc5AC antibody detects mucin in its native form at 
concentrations of 5µg/well (Figure 10.4A5 and B5) and 1.25µg/well (Figure 10.4A6 
and B6) but not at 0.6µg/well (Figure 10.4A7 and B7).   Chemical and/or heat 
denaturation of the mucin standard did not prevent detection by the antibody (Figure 
10.4 dots labelled A1, 2, B1, 2, show heat and chemical denatured samples and dots C1, 
2, D1, 2, indicate heat denatured only).  BSA was not detected by the anti-Muc5AC 
antibody at any of the concentrations tested (Figure 10.4C and D, 5-7). 
 
To investigate whether the presence of lysis buffer (Triton X-100) affects mucin 
detection by anti-muc5AC, mucin (5µg/well) was applied to the membrane in different 
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concentrations of lysis buffer. The results (Figure 10.4) show that none of the 
concentrations of Triton X-100 used (Figure 10.4 1% A9 A10, 0.1% B9 B10, 0.5% C9 
C10) affected mucin detection, and that lysis buffer alone was not detected by anti-
muc5AC antibody at the concentrations tested (1% A11, 12,.(0.1% Figure 10.4 B11,12 
0.5% B11,12).  However, the results also show that there is some cross-reaction with 
serum-free airway epithelial medium (QAEM, shown in C8 and D8).   
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  1 2 3 4 5 6 7 8 9 10 11 12 
A 
5µg M 
 D+ H+ 
1.25µg M 
D+ H+ 
0.6µg M 
 D+ H+ PBS D+H+ 
5µg M 
 D- H- 
1.25µg M 
D- H- 
0.6µg M 
D- H- PBS D-H- 
5µg M 
 1%T 
5µg M 
 1%T 1% T 1% T 
B 
5µg M 
D+ H+ 
1.25µg M 
 D+ H+ 
0.6µg M 
 D+ H+ PBS D+H+ 
5µg M 
 D- H- 
1.25µg M 
D- H- 
0.6µg M 
D- H- PBS D-H- 
5µg M 
  0.1%T 
5µg M 
 0.1%T 0.1% T 0.1% T 
C  
5µg M 
 D- H+ 
1.25µg M 
 D- H+ 
0.6µg M 
 D- H+ PBS D-H+ 
5µg 
 BSA 
1.25µg 
BSA  
0.6µg 
BSA  QAEM  
5µg M 
  0.5%T 
5µg M 
 0.5%T 0.5% T 0.5% T 
D 
5µg M 
D- H+ 
1.25µg M 
 D- H+ 
0.6µg M 
 D- H+ PBS D-H+ 
5 µg 
 BSA 
1.25µg 
BSA  
0.6µg 
BSA  QAEM  AEM 5%T AEM 5%T     
 
 
 
Figure 10.4: Heat denaturing or deglycoslation is not required for muc5AC detection by dot blot. Standard porcine gastric mucin (M) and BSA (5μg 1.25μg, 
0.6μg) in 50μl PBS were either denatured by boiling at 100°C for 10 minutes (H+), denatured by treatment with 2% octyl β-D-glucopyranoxidase with 100mM 2-
mercaptoethanol and boiled at 100
0
C for 10 minutes (D+), or with no treatment(H-D-). PBS samples were also denatured in the above manner as controls. Airway 
epithelial medium with 5% serum (AEM) or serum free (QAEM) along with mucin (5μg) in Triton X-100 (percentage of Triton indicated in the table) or Triton X-100 
alone were also analysed The samples were blotted onto nitrocellulose membrane under vacuum. The membrane was subsequently blocked and stained with primary 
mouse monoclonal anti-muc5AC antibody diluted 1:500, washed and treated with HRP-conjugated sheep anti-mouse antibody at 1: 1000.  The scanned image is 
representative of two independent experiments.  
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10.2.2.2: HRP-conjugated sheep anti-mouse secondary antibody at a dilution of 
1:1000 cross reacts with serum free airway epithelial cell medium. 
 
In order to identify whether the mouse monoclonal anti-muc5AC antibody or HRP-
conjugated sheep anti-mouse) cross-react with complete and serum-free airway 
epithelial cell medium (QAEM), a series of control dot blots were carried out (Figure 
10.5). These results confirm that the HRP-conjugated sheep anti-mouse secondary 
antibody was cross reacting with serum free medium (Figure 10.5 blot 3 C2, 3 and 4).  
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Blot Mouse monoclonal anti-
Muc5AC dilution 
HRP-conjugated sheep 
anti-mouse antibody 
dilution 
1 1:500 1:1000 
2 1:500 No antibody 
3 No antibody 1:1000 
4 No antibody No antibody 
 
Figure 10.5: HRP-conjugated sheep anti-mouse secondary antibody at a dilution of 1:1000 
cross reacts with serum free airway epithelial cell medium. Mucin standard and BSA (5μg 
in 50μl PBS) along with PBS or serum free airway epithelial cell medium (QAEM) were 
blotted onto nitrocellulose membrane. The membrane was subsequently blocked and treated 
with primary mouse monoclonal anti-muc5AC antibody diluted 1:500 (1 and 2) or with no 
antibody (3 and 4) washed and treated with horseradish peroxidase linked sheep anti-mouse 
antibody at 1: 1000 (1 and 3) or no secondary antibody (2 and 4). 
  
Blot 
1 &2 
1 2 3 4 
A mucin mucin mucin PBS 
B BSA BSA BSA PBS 
C QAEM QAEM QAEM PBS 
Blot  
3 & 4 
1 2 3 4 
A PBS mucin mucin mucin 
B PBS BSA BSA BSA 
C PBS QAEM QAEM QAEM 
       1      2       3       4  
Blot 1         A 
B 
C 
Blot 2         A 
B 
C 
Blot 4         A 
B 
C 
Blot 3         A 
B 
C 
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10.2.2.3: HRP-conjugated sheep anti-mouse secondary antibody diluted 1:5000 
shows minimal cross reaction with serum free airway epithelial cell medium 
 
In order to determine a HRP sheep anti-mouse secondary antibody concentration that 
allows for specific muc5AC detection but does not cross react with serum free airway 
epithelial cell medium a series of antibody titrations was conducted.  Results show that, 
secondary antibody concentrations of 1:1000 (Figure 10.6 blot 2) and 1:2500 (Figure 
10.6 blot 4) show cross-reactivity with quiescent airway epithelial cell medium. A 
secondary antibody concentration of 1:5000 allows for muc5AC detection (Figure 10.6 
blot 5) with minimal quiescent AEM cross reactivity (Figure 10.6 blot 6). No muc5AC 
was detected in either of the controls (Figure 10.6 blot 7; mouse monoclonal anti-
muc5AC primary antibody without HRP-conjugated sheep anti-mouse secondary 
antibody, and blot 8, no antibodies).   
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Figure 10.6: HRP-conjugated sheep anti-mouse secondary antibody diluted 1:5000 
shows minimal cross reaction with serum free airway epithelial cell medium 
(QAEM). Mucin standard and BSA (5μg in 50μl PBS) along with PBS or QAEM were 
blotted onto nitrocellulose membrane. The membrane was subsequently blocked and 
treated with primary mouse monoclonal anti-muc5AC antibody at 1:500 or with no 
antibody, washed and treated with HRP-conjugated sheep anti-mouse antibody at the 
stated dilutions or without secondary antibody n=1. 
  
Blot 
 
Mouse monoclonal 
anti-muc5Ac antibody 
dilution 
HRP-conjugated sheep 
anti-mouse antibody 
dilution 
1 1:500 1:1000 
2 No antibody 1:1000 
3 1:500 1:2500 
4 No antibody 1:2500 
5 1:500 1:5000 
6 No antibody 1:5000 
7 1:500 No antibody 
8 No antibody No antibody 
 1 2 3 4 
A PBS PBS PBS QAEM 
B mucin mucin mucin QAEM 
C BSA BSA BSA QAEM 
    1      2       3       4         1      2       3       4  
Blot 1         A 
B 
C 
Blot 3         A 
B 
C 
Blot 7         A 
B 
C 
Blot 5         A 
B 
C 
A       Blot 2 
B 
C 
A       Blot 4 
B 
C 
A       Blot 6 
B 
C 
A       Blot 8 
B 
C 
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10.2.2.4: HRP-conjugated sheep anti-mouse secondary antibody diluted 1:5000 
allows for detection of 1.25µg muc5AC 
 
Once conditions were defined that allowed specific detection of muc5AC, a dot blot 
was carried out with a range of standard porcine mucin concentrations. The results 
show that with a secondary antibody concentration of 1:5000 (Figure 10.7 blot 1) mucin 
was detected at the lowest concentration tested (1.25µg/well; Figure 10.7, blot 1 row F). 
However, with this secondary antibody concentration there is still cross-reaction with 
serum-free medium (Figure 10.7 rows A and L).  
 
In an attempt to reduce cross reactivity whilst keeping the assay sensitivity, the dot blot 
was repeated with a secondary antibody dilution of 1:10,000. The results (Figure 10.7) 
show that the serum-free airway epithelial cell medium cross reactivity was nearly 
abolished (Figure 10.7, blot 2 rows column A and L) however the assay sensitivity was 
markedly reduced, with the lowest mucin concentration detected being 5µg/ml (Figure 
10.7; Blot 2, row D). For further studies a dilution of 1:5000 for HRP-conjugated sheep 
anti-mouse secondary antibody was used to maintain assay sensitivity.  
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Figure 10.7: HRP-conjugated sheep anti-mouse secondary antibody diluted 1:5000 
allows for detection of 1.25µg muc5AC.  Standard porcine mucin and BSA (10μg- 
1.25μg in 50μl PBS) along with PBS or serum free airway epithelial cell medium 
(QAEM) were blotted onto nitrocellulose membrane. The membrane was subsequently 
blocked and treated primary mouse monoclonal anti-muc5AC antibody at 1:500, 
washed and treated with HRP-linked sheep anti-mouse antibody at 1:5000 (blot 1) or 
1:10,000 (blot 2), n=1. 
  
Well sample 
A QAEM 
B  10µg mucin 
C 7.5µg mucin 
D 5µg mucin 
E 2.5µg mucin 
F 1.25µg mucin 
G PBS 
H 10µg BSA 
I 7.5µg BSA 
J 5µg BSA 
K 1.25µg BSA 
L QAEM 
A 
F 
E 
D 
C 
B 
G 
L 
K 
J 
I 
H 
Blot 1            Blot 2 
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10.3: Appendix three: Particle method controls  
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10.3.1: Methods 
 
10.3.1.1: IL-8/IL-6 ELISA 
Standards IL-8/IL-6 was incubated with 100µg/ml particles at 37°C for 24hours. 
Samples were cleared by centrifugation at 295xg for 2 minutes. IL-8/IL-6 ELISA’s 
were carried out as described in section 2.2.5.  
 
10.3.1.2: CellTiter-Blue
®
 viability assay 
Un-converted CellTiter-Blue
®
 reagent was incubated with 100µg/ml particles at 37°C 
for 4 hours, after which fluorescence was determined as described in section 2.2.6. 
 
10.3.1.3: TER acquisition 
TER was taken of a collagen coated Transwell
®
 insert in the absence of cells with 600µl 
AEM in the basolateral compartment and 300µl AEM with or without 100µg/ml 
particles as described in 2.2.2. 
 
10.3.1.4: Respiratory burst assay 
Human recombinant IL-8 (10ng) was incubated with 100µg/ml particles at 37°C for 24 
hours. Following incubation the respiratory burst assay was conducted in the absence of 
neutrophils as described in section 5.3.10. 
 
10.3.1.5: GSH-Glo™ assay 
GSH-Glo™ assay was conducted in the presence of 100µg/ml particles and absence of 
cells, as described in 5.3.12.  
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10.3.2: Results 
10.3.2.1: UFTiO2 treated IL-8 is not detected by IL-8 ELISA 
IL-8 has been reported to adsorb onto DEP particle surface (Segrave 2008). To test for 
adsorption of IL-8 onto test particles IL-8 standards were incubated at 37°C for 24 
hours with or without TiO2, UFTiO2 or S2219200, S2218600 and S2429901, and the 
IL-8 ELISA carried out. Figure 10.8A indicates that UFTiO2 results in a loss of IL-8 
detection but other particles did not interfere with IL-8 analysis using ELISA (Figure 
10.8B). 
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Figure 10.8: UFTiO2 treated IL-8 is not detected by IL-8 ELISA. IL-8 ELISA standards 
were incubated for 24 hours at 37°C with 100µg/ml particles and analysed by ELISA. Results 
are expressed as mean ± SD of inter-assay duplicates and are representative of 3 individual 
experiments 
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10.3.2.2: PM/polymer-treated IL-6 is detected by IL-6 ELISA 
 
To test for adsorption of IL-6 onto particles, IL-6 standards were incubated at 37°C for 
24 hours with or without PM (100µg/ml).  Samples were cleared by centrifugation at 
295xg for 2 minutes. IL-6 ELISA was carried out with cleared IL-6 standards as above. 
Figure 10.9A and 10.9B indicate that particles treatment of standards does not result in 
a loss of IL-6 detection. 
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Figure 10.9: Particles -treated IL-6 is detected by IL-6 ELISA. IL-6 ELISA standards were 
incubated for 24 hours at 37°C with 100µg/ml particles and analysed by ELISA. Results are 
expressed as mean ± SD of inter-assay duplicates and are representative of 3 individual 
experiments. 
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10.3.2.3: S2218600 and S2429901 reduce the CellTiter-Blue
®
 viability assay signal 
significantly.   
 
In order to investigate interference of particles with CellTiter-Blue®, un-converted 
reagent was incubated for 4 hours with 100µg/ml PM in airway epithelial cell media 
and endothelial cell culture media, after which fluorescence was measured as above.  
S2218600 and S2429901 result in a slight, but significant reduction in fluorescence in 
airway epithelial cell media (Figure 10.10B).  
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Figure 10.10: S2218600 and S2429901 reduce the CellTiter-Blue
®
 signal significantly. 
CellTiter-Blue reagent was incubated with particles or 1% (v/v) Triton X-100 in the absence of 
cells in airway epithelial cell media (A and B) or endothelial cell culture media (C and D). After 
incubation fluorescence was measured at excitation 560nm emission 590nm. Results are 
expresses as mean ± SEM, n=3, *=P<0.05 compared to control, **P<0.001 compared to 
control. 
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10.3.2.4: The presence of particles do not affect TER acquisition 
 
Westmoreland et al., (1999) observed that sodium carbonate as a positive control for 
airway damage induced a significant time dependent reduction in TER, which 
correlated to loss of viability using MTT. TER was therefore used in the current study 
to investigate the effects of particles or LPS on the airways epithelium barrier. Triton 
X-100 was used as a positive control. To test for interference of particles on TER, TER 
of empty collagen coated Transwell
®
 insert with 600µl airway epithelial cell media in 
the basolateral compartment and 100µg/ml particles in 300µl airway epithelial cell 
media, 1% (v/v) Triton X-100 in 300µl airway epithelial cell media or epithelial cell 
media alone in the apical compartment. TER was measured as above. Figure 10.11 
shows that TER was unaffected by the presence of particles.     
 
 281 
A) 
C
on
tr
ol 2
Ti
O 2
U
FT
iO
1%
 T
ri
to
n 
X
-1
00
0
20
40
60
80
T
E
R
 (

 x
 c
m
2
)
 
B)  
C
on
tr
ol
S
22
19
20
0
S
22
18
60
0
S
24
29
90
1
1%
 T
ri
to
n 
X
-1
00
0
20
40
60
80
T
E
R
 (

 x
 c
m
2
)
 
Figure 10.11: The presence of particles do not affect TER acquisition. TER of serum free 
airway epithelial cell media with or without 100µg/ml PM or 1% (v/v) Triton X-100 was taken 
using an empty collagen coated Transwell
®
 insert. Results are expressed as mean ± SEM, n=3 
**.  
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10.3.2.5: The lucigenin signal is not affected by particles.  
 
Control experiments were conducted to test for particle interference with the lucigenin 
signal. Figure 10.12 shows that there was no interference in luminescence with any of 
the test PM. 
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Figure 10.12:The lucigenin signal is not effected by particles. Lucigenin was incubated with 
particle bound IL-8 for 15 minutes during which time baseline luminescence was measured.  
Results are expressed as mean ± SEM, n=3. 
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10.3.2.6: Effect of particles on the  GSH-Glo™ assay  
 
The ability of particles to induce oxidative damage in BEAS-2B and HPMEC was 
investigated with the GSH-GLO™ assay. To test for possible interference in signal by 
particles, the assay reagents were incubated with 100µg/ml particles in the absence of 
cells. Figure 10.13 shows that there was no interference with the assay by particles. 
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Figure 10.13: Effect of particles treatment on GSH-Glo™ GSH assay. GSH-Glo™ was 
conducted in a cell free system in the presence of 100µg/ml particles. Results are expressed as 
mean ± SEM n=3. 
